Simple and Practical Mental Health

The BEST resource for mental health clinicians

  • REVIEWS
  • MENUS
  • RESOURCES
    • Side effect handouts
    • Patient handouts: Main page
    • How to find treatment resources
    • Rating scales and questionnaires for mental health clinicians
    • BEST books
    • BEST apps/ websites
  • NEWS
  • QUESTIONS?
  • DAILY EMAILS
  • FAQ
  • LOG IN
  • JOIN

Daily emails

Included in Membership of this website is a feature that has greatly benefited thousands of your colleagues—daily emails providing high-yield tips on an advanced topic in mental health. Every day,  365 days a year! These tips are sent directly in an email to you and can be read in less than 5 minutes each.

Do you want to be a truly Expert Psychopharmacologist? Do you wish you could get brief, clear, but authoritative answers to your clinical questions? Do you want a source of reliable information rather than having to rely only on the internet? If you are willing to spend 3 to 5 minutes a day, we do all the rest of the work for you!


“Every day, incredibly useful clinical pearls. After 30 years of practice, I am amazed how much I didn’t know! Best CME $ ever spent!” — Mark Komrad, MD (Baltimore, Maryland, USA). http://www.komradmd.com/


“After 24 years practicing psychiatry, I have tried many types of CME, Updates, Newsletters, etc and I receive the most consistent knowledge from your website and emails.” — John Justice, MD (West Virginia University School of Medicine, Poca, West Virginia).


“It is a very useful website that is unlike any other resource that I have seen. Great, great stuff.” — Kari Groff, MD (Private Practice, New York, USA).


“Dr. Mago, I just want to say “thank you!” This is truly the best money I’ve spent on educational material.” — Mo Dattu, MD (Private Practice, Pennsylvania, USA).


***Read more reviews of Membership in Simple and Practical Mental Health***


***Click here to become a Member!***


Here are the clinical summaries that have been sent out so far:

1. How to reduce risk of priapism due to trazodone

2. What is the best single test for checking the body’s iron stores?

3. Which psychiatric medications MUST be taken with food?

4. You may be giving the wrong dose of stimulant (discussion of equivalent doses of stimulants)

5. Which antibiotics could cause serious problems in your patients?

6. Important detail when prescribing temazepam (some practical tips regarding hypnotics)

7. This blood test is very helpful in patients on buprenorphine

8. Lithium and antihypertensives: Be careful!

9. Correct dose and duration of l-methylfolate

10. These are the patients in whom we should consider lithium

11. Mirtazapine and renal transplant

12. When patients demand a sleeping pill

13. List of options for hypnotics with lower addiction potential

14. What to do about fatigue/somnolence

15. Can you solve this clinical puzzle?

16. Will buprenorphine show up in a urine drug screen?

17. One website to inform them all

18. Oxcarbazepine versus Carbamazepine: Three Pros and One Con

19. How to identify hyponatremia due to psychotropic medications

20. How should we manage hyponatremia?

21. Your patient may be taking a psychiatric medication by another brand name

22. Extended-release preparations come in many forms

23. Some extended-release capsules are OK to open and some are not

24. Warning: Hydroxyzine (Vistaril, Atarax) can be dangerous

25. Should we routinely prefer extended-release preparations? (Part 1)

26. Should we routinely prefer extended-release preparations? (Part 2)

27. Which MAOI should I pick?

28. An easy way to significantly reduce discontinuation of medications

29. Does vortioxetine work for GAD?

30. What to do about antidepressants in persons with renal disease?

31. What are the side effects, doctor?

32. Watch out for dry mouth

33. How to manage dry mouth: level one (the simplest measures)

34. How to manage dry mouth–Level 2 and 3 measures

35. What to do about rash/itching with transdermal selegiline?

36. Oral contraceptives and lamotrigine (Part 1)

37. Oral contraceptives and lamotrigine (Part 2)

38. A case of tardive dyskinesia on an antidepressant (Part 1)

39. A case of tardive dyskinesia on an antidepressant (Part 2)

40. When to measure serum levels of mood stabilizers (Part 1)

41. When to measure serum levels of mood stabilizers (Part 2)

42. Which psychotropic medication should be taken WITHOUT food?

43. Managing loss of appetite due to stimulant medications (Part 1)

44. Managing loss of appetite due to stimulant medications (Part 2)

45. Brain zaps-Part 1 (Clinical features)

46. Brain zaps-Part 2 (Assessment and Management)

47. Which CYP 450 isoenzyme metabolizes which medication?

48. Drug holidays for sexual dysfunction

49. How to know if the BUN and creatinine are elevated due to dehydration

50. 365 Advanced Topics in Psychopharmacology (Quiz no. 1)

51. Should we prescribe medications for weight loss?

52. Some issues about phentermine-topiramate (Qsymia) for weight loss

53. How does bariatric surgery affect the dissolution of psychotropic medications?

54. Bariatric surgery and extended-release preparations

55. Can hypnotics be used in persons with sleep apnea?

56. Is your patient taking a psychotropic drug with another brand name?

57. Vortioxetine and sexual dysfunction: How to read a clinical trial

58. Finding out the price, comparing prices, and getting a lower price

59. What do the es-, the levo-, and the dex- mean in drug names?

60. Serum folate is not the right test to order

61. What if lamotrigine is missed for three or more days?

62. Lithium: in how many doses per day and at what time?

63. Let’s not miss orthostatic hypotension

64. How to correctly measure and interpret orthostatic blood pressure and pulse

65. Simple tips to manage orthostatic hypotension

66. Should we prescribe dexmethylphenidate (Focalin®) rather than methylphenidate (Ritalin®)?

67. What are the advantages of dexmethylphenidate XR (Focalin XR®)?

68. Pros and cons of dexmethylphenidate XR versus methylphenidate ER

69. Is it true that mirtazapine (Remeron®) can cause agranulocytosis?

70. Should we use gabapentin for bipolar disorder or not?

71. Which omega-3 fatty acids to recommend (Part 1)

72. Exactly which omega-3 product to recommend

73. Are the clozapine-norclozapine ratio and norclozapine level useful?

74. Doesn’t escitalopram cause QTc prolongation?

75. Which psychotropic medications to continue or stop during surgery?

76. How to systematically examine a person with akathisia

77. Watch out for herbal-psychotropic drug interactions

78. Drug interactions with St. John’s Wort

79. How to tell if a rash is benign or possible Stevens-Johnson Syndrome

80. How is high-dose vitamin C important in prescribing medications?

81. We often don’t identify rapid cycling but should

82. Essential facts about bupropion and seizures

83. Bupropion versus bupropion: Seizure risk with different preparations and doses

84. Should we prescribe Forfivo XL 450 mg?

85. HLA testing in psychopharmacology (Part 1)

86. HLA testing in psychopharmacology (Part 2)

87. Oxcarbazepine? Lamotrigine? HLA testing and psychopharmacology (Part 3)

88 How likely is your patient to carry higher-risk HLA antigens?

89. Tips on using gabapentin for anxiety disorders

90. 7 things to know about divalproex and hair loss

91. Gabapentin (Neurontin®) versus pregabalin (Lyrica®): potential for misuse

92. Be careful with medications that have a long half-life

93. TEN psychotropic medications with a long half-life

94. Higher than usual doses of SSRIs for OCD?

95. For which medications do you ALWAYS do an ECG?

96. Six medications for which big changes are needed in CYP poor metabolizers

97. One exit door or many?

98. Are antidepressants addictive?

99. Management of antidepressant discontinuation (withdrawal) syndrome (Part 1)

100. Management of antidepressant discontinuation (withdrawal) syndrome (Part 2)

101. How exactly to add fluoxetine to manage antidepressant discontinuation (withdrawal) syndrome

102. How to really slowly taper an antidepressant (Part 1)

103. How to look up whether a drug can cause QTc prolongation or torsades

104. A puzzling case of acute dyskinesia

105. Don’t cause unplanned pregnancy

106. Hepatic function tests: Part 1—Overview

107. Four strange things about levels of AST and ALT

108. Remember: L is for Liver

109. Is the elevated plasma ammonia a false positive?

110. What is pramipexole and why should we care?

111. Should we consider pramipexole for treating mood disorders?

112. Tips on using pramipexole (Part 1)

113. Tips on using pramipexole (Part 2)

114. Potential adverse effects of pramipexole

115. Should clomipramine be a first-line treatment for OCD?

116. Six tips about using SSRIs for OCD

117. OCD: If the initial medication does not work?

118. How to do a drug interaction search in one minute

119. Antipsychotics for OCD: What and for whom

120. Antipsychotics for OCD: How much and for how long

121. Don’t miss bruxism in your patients

122. How to manage antidepressant-induced bruxism

123. An antidote to treat antidepressant-induced bruxism

124. CYP450 update about newer medications

125. Are lower doses of lithium helpful?

126. Do you regularly prescribe metformin for metabolic adverse effects?

127. Metformin: Who are the best candidates?

128. Potential adverse effects of metformin (Part 1)

129. Metformin can cause B12 deficiency (Part 2)

130. A potentially fatal adverse effect of metformin

131. Tips on prescribing metformin

132. Warning-this could happen if we are not careful (Restarting lamotrigine)

133. What dose should you switch to?

134. Antipsychotic dose equivalents: The Table

135. 365 Advanced Topics in Psychopharmacology (Quiz no. 2)

136. Pros and cons of the two extended-release injections of aripiprazole

137. Warning–the patient may faint after the very first dose

138. How to minimize risk of syncope with prazosin

139. How to choose a cholinesterase inhibitor

140. How to manage MAO-inhibitor-induced insomnia

141. The bottom line on medications for Alzheimer’s disease

142. What about vascular dementia?

143. What about other dementias?

144. Are you specifying these?

145. What is “anxious distress” and why does it matter?

146. VMAT2 inhibitor? What’s that?

147. Which VMAT2 inhibitor should we prefer?

148. In older adults, avoid medications with anticholinergic activity

149. Which medications have significant anticholinergic activity?

150. How exactly to evaluate anticholinergic burden

151. Can lamotrigine levels predict adverse effects? 

152. How to get the benefits of split treatment

153. Tips for managing split treatment

154. Three commonly held fallacies about the AIMS

155. How to reduce risk in split treatment

156. How often should the AIMS examination be done?

157. THREE activating procedures in AIMS and what to look for

158. Should we combine methylphenidate and guanfacine? 

159. Do side effects of methylphenidate and guanfacine cancel each other out?

160. Tips on using clonazepam orally disintegrating tablets (ODTs)

161. Six differences between guanfacine and clonidine (Part 1)

162. Six differences between guanfacine and clonidine (Part 2)

163. When NOT to use antidepressants in bipolar depression

164. Which antidepressants have greater or lesser risk in bipolar depression?

165. Dose equivalents for antidepressants

166. What is excoriation (skin-picking) disorder?

167. Key clinical features of excoriation (skin-picking) disorder

168. How to treat excoriation (skin-picking) disorder (Part 1)

169. How to treat excoriation (skin-picking) disorder (Part 2) (pharmacological treatments; psychological treatments)

170. Clozapine-induced hypersalivation is a big deal

171. Treatment of medication-induced hypersalivation (Part 1)

172. Treatment of medication-induced hypersalivation (Part 2)

173. Treatment of medication-induced hypersalivation (Part 3)

174. 365 Advanced Topics in Psychopharmacology (Quiz no. 3)

175. Don’t do it (about the dangers of abruptly switching from one MAOI to another)

176. Pharmacogenetics (Part 1): 5-HTTLPR

177. Pharmacogenetics (Part 2): 5-HTTLPR polymorphisms

178. Can 5-HTTLPR polymorphisms predict if an SSRI will work?

179. 5-HTTLPR polymorphisms and antidepressant efficacy (Part 2)

180. 5-HTTLPR polymorphisms do predict side effects with SSRIs

181. Significance of 5-HTTLPR polymorphisms: A summary

182. Serotonin 2A receptor gene polymorphisms predict antidepressant side effects

183. HTR2C polymorphisms and weight gain (Part 1)

184. HTR2C polymorphisms and weight gain (Part 2)

185. What is P-glycoprotein (ABCB1 transporter)?

186. Antidepressants and P-glycoprotein

187. ABCB1 predicts adverse effects with SSRIs

188. Understanding lithium-induced polyuria and diabetes insipidus

189. Evaluating the patient with polyuria (Part 1)

190. Evaluating the patient with polyuria (Part 2)

191. Evaluating the patient with polyuria (Part 3)

192. How to manage lithium-induced polyuria/ diabetes insipidus (Part 1)

193. How to manage lithium-induced polyuria/ diabetes insipidus (Part 2)

194. How to manage lithium-induced polyuria/ diabetes insipidus (Part 3)

195. Are we missing Body Dysmorphic Disorder?

196. Body Dysmorphic Disorder: Pharmacological treatment (Part 1)

197. Body Dysmorphic Disorder: Pharmacological treatment (Part 2)

198. Body Dysmorphic Disorder: Pharmacological treatment (Part 3)

199. My genetic testing showed I need a high dose of a stimulant (Part 1)

200. My genetic testing showed I need a high dose of a stimulant (Part 2)

201. How to measure serum prolactin

202. If prolactin is elevated, ask these questions

203. Elevated prolactin: Next steps

204. Is the extended-release preparation of lithium carbonate better?

205. Pimavanserin (Nuplazid®): A new antipsychotic (Part 1)

206. Pimavanserin (Nuplazid®): A new antipsychotic (Part 2) (A)

         Pimavanserin (Nuplazid®): A new antipsychotic (Part 2) (B)

207.  Pimavanserin (Nuplazid) Part three: Potential serious adverse effects

208.  Pimavanserin (Nuplazid) Part four: The how to

209. What does Transcranial Magnetic Stimulation (TMS) work for?

210. What percentage of patients with MDD responds to TMS?

211. Who is more likely to respond to TMS?

212. How much is the risk of a seizure with TMS?

213. Lithium and psoriasis

214. Which TCA should we recommend first?

215. Tips on thyroid function testing (Part 1)

216. Tips on thyroid function testing (Part 2)

217. Tips on thyroid function testing (Part 3)

218. Orally disintegrating tablets (ODTs) can be useful 

219. Psychotropic medications are sometimes given sublingually

220. Important instructions to give for sublingual medications

221. Complementary and alternative medicines (CAM) for depressive disorders

222. Complementary and Alternative Medications for MDD: Summary

223. S-adenosylmethionine (SAMe) for depressive disorders (Part 1)

224. S-adenosylmethionine (SAMe) for depressive disorders (Part 2)

225. S-adenosylmethionine (SAMe) for depressive disorders (Part 3)

226. MAO inhibitors can affect vitamin B6 (Part 1)

227. MAO inhibitors can affect vitamin B6 (Part 2)

228. Ketamine infusions for major depression (Part 1)

229. Ketamine infusions for major depression (Part 2)

230. Ketamine infusions for major depression (Part 3)

231. Ketamine infusions for major depression (Part 4)

232. Lithium-induced benign tremor: Introduction

233. Lithium-induced benign tremor: Evaluation

234. How to treat lithium-induced benign tremor

235. Which beta blockers to use for lithium-induced benign tremors

236. Is lamotrigine safe for use in pregnancy? (Part 1)

237. Is lamotrigine safe for use in pregnancy? (Part 2)

238. Is lamotrigine safe for use in pregnancy? (Part 3)

239. Is lamotrigine safe for use in pregnancy? (Part 4)

240. Don’t ignore atomoxetine for ADHD in adults

241. Does atomoxetine improve executive functioning?

242. Eight advantages of prescribing atomoxetine

243. How to prescribe atomoxetine for ADHD in adults

244. Atomoxetine: Are we giving enough and for long enough?

245. How to add valproate to lamotrigine

246. Important interactions when using two medications for ADHD

247. 365 Advanced Topics in Psychopharmacology (Quiz no. 4)

248. What is antidepressant-induced mania or hypomania?

249. Do you prescribe bupropion for ADHD in adults?

250. Is it important to taper gabapentin?

251. Cardiovascular Risk Screening Form

252. Smoking can seriously affect some psychotropic medications

253. Smoking and psychotropic medications (Part 2)

254. Smoking and psychotropic medications (Part 3)

255. Can we use topiramate to treat medication-induced weight gain?

256. Is TD less likely with second-generation (“atypical”) antipsychotics?

257. We have to choose one of two types of TCAs

258. Two types of tricyclic antidepressants (TCAs) (Part 2)

259. Management of tardive dyskinesia: First-line options

260. Systematic management of tardive dyskinesia (Part 2)

261. Systematic management of tardive dyskinesia (Part 3)

262. Systematic management of tardive dyskinesia (Part 4)

263. Is lurasidone useful for longer-term treatment of bipolar disorder?

264. Bipolar disorder with comorbid panic disorder (Part 1)

265: Bipolar disorder with comorbid panic disorder (Part 2)

266: Bipolar disorder with comorbid panic disorder (Part 3)

267. False positive urine drug screens (Part 1)

268. The urine drug screen is positive but the patient denies using the substance

269. Next step to rule out a false positive

270. Dose adjustment for second-generation antipsychotics based on drug interactions

271. Check for this before prescribing an antidepressant for bipolar depression

272. The dose of quetiapine is NOT the same for each disorder

273. How to not delay treatment of acute mania

274. Does loading dose of valproate have pros and (usually) no cons?

275. Order genetic testing for a patient on atomoxetine?

276. Do CYP2D6 PM’s have more side effects on atomoxetine?

277. When and how to check the clomipramine level

278. Changing between the different forms of long-acting injectable aripiprazole

279. An alert from a colleague (psychotropic medication induced glaucoma)

280. Psychotropic medication and glaucoma (Part 1)

281. Keep an “eye” out for these high risk patients

282. 365 Advanced Topics in Psychopharmacology (Quiz no. 5)

283. Once-a-day preparation of mixed amphetamine salts

284. A triple-bead preparation of mixed amphetamine salts

285. Potential disadvantages of the triple-bead preparation of mixed amphetamine salts

286. Conclusions and verdict about the triple-bead preparation of mixed amphetamine salts (Mydayis®)

287. Should we give high-dose SSRI for panic disorder?

288. We need to learn more about difficult-to-treat panic disorder

289. One of our Member’s urine was positive for PCP

290. Would you ever use bupropion to treat panic disorder?

291. Do you prescribe beta blockers for panic disorder?

292. Which beta blocker and for how long?

293. How common is ADHD in persons with bipolar disorder?

294. How to treat ADHD in persons with bipolar disorder

295. Best books about adult ADHD for patients and/or families

        Best books on adult ADHD for clinicians

296. How to assess outcome in panic disorder and not leave the patient only partially treated

297. Who is at higher risk of bleeding with antidepressants?

298. Antidepressants and bleeding: When do we need to ask additional questions?

299. Antidepressants and bleeding: What should we ask?

300. Should we recommend ultrabrief pulse ECT?

301. The final verdict on ultrabrief pulse ECT

302. Insomnia? Ask about medications

303. Pros and cons of ramelteon (Rozerem) as a hypnotic

304. Pros and cons of ramelteon (Rozerem) as a hypnotic: Part two

305. Best medicines for sleep in elderly patients?

306. Which brand and preparation of melatonin to recommend?

307. Best medicines for sleep in elderly patients? Part two

308. Best medicines for sleep in elderly patients? Part three

309. Best medicines for sleep in elderly patients? Part four

310. Sleep medications to avoid in older adults

311. 365 Advanced Topics in Psychopharmacology (Quiz no. 6)

312. Does oxcarbazepine work for bipolar disorder?

313. My opinion about using oxcarbazepine for bipolar disorder

314. How to start, titrate, and dose oxcarbazepine (Trileptal®)

315. How to diagnose Premenstrual Dysphoric Disorder (PMDD): Part one

316. How to diagnose Premenstrual Dysphoric Disorder (PMDD): Part two

317. How to treat Premenstrual Dysphoric Disorder (PMDD): Part one

318. How to treat Premenstrual Dysphoric Disorder (PMDD): Part two

319. Five ways in which an SSRI can be given for PMDD

320. Next steps in the management of premenstrual dysphoric disorder (PMDD)

321. Management of premenstrual dysphoric disorder: third-line options 

322. Equivalence of risperidone oral and long-acting injection (RLAI; Risperdal Consta®)

323. Have you ever prescribed or recommended disulfiram?

324. How does disulfiram work?

325. In what situations could disulfiram be particularly helpful?

326. What exactly happens if alcohol is used by a person on disulfiram?

327. Instructions for patients who are prescribed disulfiram (Antabuse)

328. Disulfiram (Antabuse): How much and for how long?

329. Whom is disulfiram (Antabuse) contraindicated for?

330. What are the potential side effects of disulfiram?

331. Cannabis or cannabinoids for PTSD? 

332. What happened to polysubstance dependence?

333. Can a simple intervention reduce risk of delirium in our elderly patients?

334. Does melatonin work for reducing the risk of delirium in our elderly patients?

335. Melatonin to reduce risk of delirium: For whom and exactly how?

336. Tips on using lithium for bipolar disorder during pregnancy: Part one

337. Teratogenic risk with lithium — how much, which malformations, dose-dependent?

338. Other (non-teratogenic) risks of using lithium during pregnancy

339. How to manage dosing of lithium during pregnancy

340. How should lithium dosing be managed at the time of delivery and postpartum?

341. Three characteristics of a seasonal pattern: Part one

342. Three characteristics of a seasonal pattern: Part two

343. Summary of key facts about clozapine and seizures: Part one

344. Summary of key facts about clozapine and seizures: Part two

345. Summary of key facts about clozapine and seizures: Part three

346. 365 Advanced Topics in Psychopharmacology (Quiz no. 7)

347. Choosing the right device for bright light therapy: Part one

348. What kind of light?

349. Final suggestions about bright light therapy devices

350. How our patients should do bright light therapy

351. At what time of the day should bright light therapy be done?

352.  Important details about how exactly to do bright light therapy

353. Citalopram for agitation in Alzheimer’s disease

354. Citalopram for agitation in Alzheimer’s disease: Part two

355. Citalopram for agitation in Alzheimer’s disease: Part three

356. Citalopram for agitation in Alzheimer’s disease: Part four

357. What to do with meds if a person is on TMS

358. How to examine a person with tremor: Part one

359. How to examine a person with tremor: Part two

360. How to examine a person with tremor: Part three

361. Tips on how to rule out other causes of tremors

362. 365 Advanced Topics in Psychopharmacology (Quiz no. 8)

363. Where to look up information on meds and lactation

364. We should be able to identify POTS in our patients

365. Important clinical features of POTS and how to diagnose it

366. Differential diagnosis and management of POTS

367. High blood pressure has been redefined in 2017

368. Blood pressure measurements vary. What should we do?

369. Which iron supplement should we recommend? Part one

370. Which iron supplement should we recommend? Part two

371. How to improve the tolerability of an iron supplement

372. How to improve the absorption of iron

373. 365 Advanced Topics in Psychopharmacology (Quiz no. 9)

374. Another very serious side effect of clozapine that we should know about

375. How should we screen for clozapine-induced myocarditis?

376. Diagnosing clozapine-induced myocarditis and what to do next

377. Why mental health clinicians need to learn about Polycystic Ovarian Syndrome PCOS

378. Clinical features of PCOS: Part one

379. Clinical features of PCOS: Part two

380. Clinical features of PCOS: Part three. Hyperandrogenism

381. Clinical features of PCOS: Part four

382. Polycystic Ovarian Syndrome (PCOS): Diagnostic evaluation: Part one

383. Polycystic Ovarian Syndrome (PCOS): Diagnostic evaluation: Part two

384. Management of PCOS

385. Misleading interpretation of pharmacogenomic testing results: Part one

386. Misleading interpretation of pharmacogenomic testing results: Part two

387. 365 Advanced Topics in Psychopharmacology (Quiz no. 10)

388. A greatly underutilized treatment option for bipolar depression that we should all know about

389. How to do bright light therapy differently for bipolar depression

390. What all these terms mean: Cannabis, marijuana, hemp, THC, CBD, dronabinol, and so on

391. What if you refuse an early refill of a stimulant medication?

392. What to look for in stimulant withdrawal (including a physical sign that is little known)

393. Acne is a potential side effect of lithium

394. How to know that the acne may be due to the lithium

395. What to do about caffeine

396. How much caffeine is too much?

397. Let’s educate ourselves about the caffeine content of different beverages

398. How much caffeine do coffee and tea contain?

399. Which three soft drinks have ZERO caffeine?

400. Are your patients drinking so-called “energy” drinks?

401. What do you call a cow that has been sterilized?

402. Some cases of unexpected side effects related to stimulants and antipsychotics

403. Be careful if a person is on both a stimulant and an antipsychotic

404. A perfect storm

405. What could happen when changing from an antipsychotic to a stimulant?

406. Going from an antipsychotic to a stimulant

407. Can persons on psychotropic medications donate blood?

408. It is very important for learning to intermittently test yourself (Quiz no. 11)

409. What is “Mild Neurocognitive Disorder”? Part one

410. What is “Mild Neurocognitive Disorder”? Part two

411. What is “Mild Neurocognitive Disorder”? Part three

412. Seizure risk if atomoxetine and bupropion are used together?

413. Why use the MoCA instead of other tests?

414. An overview of the items on the MoCA: Part one

415. An overview of the items on the MoCA: Part two

416. How exactly to administer the MoCA: Part one

417. How exactly to administer the MoCA: Part two

418. How to score the MoCA

419. Six arguments against the Mini-Mental State Exam

420. Antidepressants can injure the liver, some more than others

421. Antidepressant-induced liver injury: Part two

422. Antidepressant-induced liver injury: Part three

423. Antidepressant-induced liver injury: What should we do (part one)

424. Antidepressant-induced liver injury: What should we do (part two)

425. True or False? (Quiz no. 12)

426. When treating major depression, follow these three steps

427. S is for Sleep

428. Does improving sleep improve depression too?

429. A is for Anxiety

430. Should we consider a benzodiazepine for persons with major depressive disorder?

431. Benzodiazapine for persons with major depressive disorder?

432. How to do relapse prevention in bipolar disorder: Part one

433. How to do relapse prevention in bipolar disorder: Part two

434. Five websites for information about psychotropic medications and pregnancy

435. Tips on getting the most out of attending live meetings (conferences, congresses)

436. Tips on meeting people at conferences

437. Tips on attending the sessions and for after the meeting

438. Are you using a questionnaire to assess sexual functioning?

439. Which questionnaire should we use to assess sexual functioning?

440. Important instructions while giving the CSFQ to the patient: Part one

441. Important instructions while giving the CSFQ to the patient: Part two

442. How to score the CSFQ

443. How to interpret the CSFQ total and subscale scores

444. How common are benign and serious rashes with lamotrigine?

445. Do you recommend dermatological precautions when starting lamotrigine?

446. Valproate-induced pancreatitis: Part one

447. Valproate-induced pancreatitis: Part two

448. Valproate-induced pancreatitis: Part three

449. Correct answers in just ONE OR TWO SENTENCES each (Quiz no. 13)

450. Hypnotic if waking up in the middle of the night? Part one

451. Hypnotic if waking up in the middle of the night? Part two

452. Hypnotic if waking up in the middle of the night? Part three

453. Pros and cons of dextroamphetamine versus levoamphetamine. Part one

454. Pros and cons of dextroamphetamine versus levoamphetamine. Part two

455. Can we combine metformin and topiramate to produce weight loss? Part one

456. Can we combine metformin and topiramate to produce weight loss? Part two

457. Three quick questions with short answers (Quiz no. 14)

458. Tips on using naltrexone for alcohol use disorder: Part one

459. Tips on using naltrexone for alcohol use disorder: Part two

460. Tips on using naltrexone for alcohol use disorder: Part three

461. What is cannabidiol (CBD)? Part one

462. What is cannabidiol (CBD)? Part two

463. Can melatonin increase blood sugar? Part one

464. Can melatonin increase blood sugar? Part two

465. Cannabidiol (CBD): Clinical experience. Part one

466. Cannabidiol (CBD): Clinical experience. Part two

467. Laws about prescriptions for psychostimulants. Part one

468. Laws about prescriptions for psychostimulants. Part two

469. Laws about prescriptions for psychostimulants. Part three

470. Why neuropsychiatric symptoms in dementia are important

471. Should we prescribe valproate for neuropsychiatric symptoms in persons with dementia?

472. Carbamazepine for neuropsychiatric symptoms in persons with dementia? Part one

473. Carbamazepine for neuropsychiatric symptoms in persons with dementia? Part two

474. Gabapentin for neuropsychiatric symptoms of dementia? Part one

475. Gabapentin for neuropsychiatric symptoms of dementia? Part two

476. What are the BEST books for adults with ADHD and their loved ones?

477. Do psychotropic medications affect intrauterine devices (IUDs)? Part one

 478. Do psychotropic medications affect intrauterine devices (IUDs)? Part two

479. Why I don’t usually prescribe paroxetine. Part one

480. Why I don’t usually prescribe paroxetine. Part two

481. Why I don’t usually prescribe paroxetine. Part three

482. How to assess persons who are “sensitive to medications.” Part one

483. How to assess persons who are “sensitive to medications.” Part two

484. How to manage a person who is “sensitive to medications”

485. How to start patients on “ridiculously” low doses

486. Final tips on managing patients who are “sensitive to medications”

487. For how long are substances detected in a urine drug screen (UDS)? Part one

488. For how long are substances detected in a urine drug screen (UDS)? Part two

489. What is estimated GFR (eGFR)?

490. Which medications are mostly excreted unchanged and why is this important? Part one

491. Which medications are mostly excreted unchanged and why is this important? Part two

492. We must do more to treat obesity

493. An overview of medications for the treatment of obesity

494. Some issues regarding medications for weight loss

495. Medications for the treatment of obesity: For how long and next steps

496. Be very careful when switching from one MAO inhibitor to another

497. Two types of MAO and of MAO inhibitors: Part one

498. Two types of MAO and of MAO inhibitors: Part two

499. Two types of MAO and of MAO inhibitors: Part three

500. Can I have cheese or pizza?

501. How about some Chinese food?

502. Tips about the MAO inhibitor diet: Part one

503. Tips about the MAO inhibitor diet: Part two: General principles

504. Tips about the MAO inhibitor diet: Part three: Patient handouts

505. Tips about the MAO inhibitor diet: Part four: Educating patients about the MAOI diet

506. Important instructions regarding MAO inhibitors and other medications

507. What do the stages of chronic kidney disease mean?

508. Bupropion in persons with renal impairment: Part one

509. Bupropion in persons with renal impairment: Part two

510. Tips on Premenstrual Dysphoric Disorder: Part one

511. Tips on Premenstrual Dysphoric Disorder: Part two

512. Tips on Premenstrual Dysphoric Disorder: Part three

513.  Tips on Premenstrual Dysphoric Disorder: Part four

514.  Tips on Premenstrual Dysphoric Disorder: Part five

515. Correct answers given in 2 to 3 sentences only (Quiz no. 15)

516. Tips on dealing with “slips” in recovery: Part one

517. Tips on dealing with “slips” in recovery: Part two

518. Tips on using acamprosate for alcohol use disorder: Part one

519. Tips on using acamprosate for alcohol use disorder: Part two

520. Tips on using acamprosate for alcohol use disorder: Part three

521. Tips on using acamprosate for alcohol use disorder: Part four

522. Can oral contraceptives cause or worsen depression? Part one

523. Can oral contraceptives cause or worsen depression? Part two

524. Can oral contraceptives cause or worsen depression? Part three

525. Omega-3 fatty acids for vegetarian and vegan patients: Part one

526. Omega-3 fatty acids for vegetarian and vegan patients: Part two

527. Which psychotropic medications does cannabis affect? Part one

528. Which psychotropic medications does cannabis affect? Part two

529. Medications from Canadian pharmacies? Part one

530. Medications from Canadian pharmacies? Part two

531. Medications from Canadian pharmacies? Part three

532. Stimulant medications and irritability in children with ADHD: Part one

533. Stimulant medications and irritability in children with ADHD: Part two

534. THREE-question quiz with correct answers in THREE sentences or less (Quiz no. 16)

535. Transdermal testosterone for hypoactive sexual desire disorder in postmenopausal women: Part one

536. Transdermal testosterone for hypoactive sexual desire disorder in postmenopausal women: Part two

537. Transdermal testosterone for hypoactive sexual desire disorder in postmenopausal women: Part three

538. Which laboratory tests in men with erectile dysfunction?

539. How to reduce the risk of erectile dysfunction–Part one

540. How to reduce the risk of erectile dysfunction–Part two

541. Which PDE-5 inhibitor for erectile dysfunction? Part one

542. Which PDE-5 inhibitor for erectile dysfunction? Part two

543. Which PDE-5 inhibitor for erectile dysfunction? Part three

544. Which PDE-5 inhibitor for erectile dysfunction? Part four

545. Which laboratory tests for persons taking valproate? Part one

546. Which laboratory tests for persons taking valproate? Part two

547. Different preparations of valproate–Part one

548. Different preparations of valproate–Part two

549. Different preparations of valproate–Part three

550. How to differentiate between bipolar I and II, mania and hypomania

551. How to treat bipolar II depression

552. How to treat bipolar disorder with comorbid anxiety

553. How to treat bipolar disorder with comorbid ADHD

554. What to do when a person on lamotrigine develops a rash

555. Carbamazepine/oxcarbazepine for maintenance therapy in bipolar disorders?

556. Second-generation antipsychotics as first-line treatment for bipolar disorders?

557. Long-acting injectable antipsychotics for bipolar disorder?

558. Some options for refractory bipolar depression

559. Tips on managing perimenopausal symptoms. Part one

560. Tips on managing perimenopausal symptoms. Part two

561. Tips on managing perimenopausal symptoms. Part three

562. Tips on managing perimenopausal symptoms. Part four

563. Three quick questions (Quiz no. 17)

564. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part one

565. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part two

566. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part three

567. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part four

568. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part five

569. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part six

570. Are varenicline (Chantix) and bupropion safe for smoking cessation in persons with mental disorders? Part seven

571. How to refer your patient for TMS. Part one

572. How to refer your patient for TMS. Part two

573. How to refer your patient for TMS. Part three

574. How to refer your patient for TMS. Part four

575. How to identify bipolar disorder. Part one

576. How to identify bipolar disorder. Part two

577. How to identify bipolar disorder. Part three

578. How to identify bipolar disorder. Part four

579. Cognitive domains that we need to evaluate: Complex attention. Part one

580. Cognitive domains that we need to evaluate: Complex attention. Part two

581. Cognitive domains that we need to evaluate: Complex attention. Part three

582. Cognitive domains that we need to evaluate: Complex attention. Part four

583. Cognitive domains: Executive function. Part one

584. Cognitive domains: Executive function. Part two

585. Cognitive domains: Executive function. Part three

586. Cognitive domains: Executive function. Part four

587. How exactly to add aripiprazole for hyperprolactinemia

588. Cognitive domains: Learning and memory. Part one

589. Cognitive domains: Learning and memory. Part two

590. Cognitive domains: Learning and memory. Part three

591. Cognitive domains: Learning and memory. Part four

592. Cognitive domains: Learning and memory. Part five

593. Cognitive domains: Learning and memory. Part six

594. Cognitive domains: Learning and memory. Part seven

595. Cognitive domains: Learning and memory. Part eight

596. Cognitive domains: Learning and memory. Part nine

597. Amphetamine stopped working after keto diet started. Part one

598. Amphetamine stopped working after keto diet started. Part two

599. Clinicians’ guide to screening tests in mental health. Part one

600. Clinicians’ guide to screening tests in mental health. Part two

601. Clinicians’ guide to screening tests in mental health. Part three

602. Clinicians’ guide to screening tests in mental health. Part four

603. Clinicians’ guide to screening tests in mental health. Part five

604. Clinicians’ guide to screening tests in mental health. Part six

605. Clinicians’ guide to screening tests in mental health. Part seven

606. The patient who “demands” TWO antipsychotics

607. Why cut-off scores on screening tests matter to clinicians. Part one

608. Why cut-off scores on screening tests matter to clinicians. Part two

609. Why cut-off scores on screening tests matter to clinicians. Part three

610. Why cut-off scores on screening tests matter to clinicians. Part four

611. The Mood Disorders Questionnaire is being used inappropriately. Part one

612. The Mood Disorders Questionnaire is being used inappropriately. Part two

613. Don’t use screening questionnaires for bipolar disorder

614. Is mirtazapine LESS sedating at higher doses? Part one

615. Is mirtazapine LESS sedating at higher doses? Part two

616. Avoid these three antipsychotics in women with breast cancer

617. Is a beta blocker causing erectile dysfunction in your patient?

618. A beta blocker that may even *improve* erectile dysfunction

619. The pros and cons of the beta blocker nebivolol

620. Should we prescribe emergency medication for hypertensive urgency with MAO inhibitors? Part one

621. Should we prescribe emergency medication for hypertensive urgency with MAO inhibitors? Part two

622. Should we prescribe emergency medication for hypertensive urgency with MAO inhibitors? Part three

623. Should we prescribe emergency medication for hypertensive urgency with MAO inhibitors? Part four

624. Cognitive domains: Language. Part one

625. Cognitive domains: Language. Part two

626. Cognitive domains: Language. Part three

627. Cognitive domains: Language. Part four: Testing Fluency in the MoCA

628. Two types of verbal fluency and how to evaluate them

629. Understanding abnormalities of language: Aphasias

630. Advanced tips on evaluating verbal fluency clinically. Part one

631. When should we consider letter and semantic fluency to be impaired?

632. More tips about evaluating verbal fluency

633. Do you assess semantic advantage in your patients?

634. A phonemic “advantage” is not an advantage–it is a bad sign

635. Why is borderline personality disorder often missed?

636. Why has it been difficult to screen for borderline personality disorder?

637. What would it take to quickly screen for borderline personality disorder?

638. One criterion to screen them all, One criterion to find them

639. How exactly to ask about affective instability

640. What the presence of affective instability does NOT mean

641. In whom is screening for borderline personality disorder most useful?

642. Which diagnoses suggest that we should screen for borderline personality disorder?

643. What is pregabalin (Lyrica) and what does it do?

644. Does pregabalin work for generalized anxiety disorder (GAD)?

645. How well does pregabalin work for GAD and how does it compare to other medications?

646. Can pregabalin (Lyrica) be added to a serotonergic antidepressant after partial response?

647. What dose of pregabalin should we titrate to for GAD?

648. Which contraceptive after oral-contraceptive-associated depression? Part one

649. Which contraceptive after oral-contraceptive-associated depression? Part two

650. How to judge the quality of a journal. Part one

651. How to judge the quality of a journal. Part two

652. How to judge the quality of a journal. Part three: Journal Impact Factor

653. Three quick questions for you about screening tests (Quiz no. 18)

654. What is N-acetylcysteine (NAC)?

655. N-acetylcysteine (NAC) for trichotillomania? Part one

656. N-acetylcysteine (NAC) for trichotillomania? Part two

657. N-acetylcysteine (NAC) for Excoriation (skin picking) disorder?

658. Before we recommend NAC, we should know this

659. Tips on how exactly to prescribe NAC

660. Tips on how exactly to prescribe NAC. Part two

661. This is the problem with nicotine replacement treatment

662. Are e-cigarettes effective for smoking cessation?

663. Can e-cigarettes be a stepping stone to quitting cigarettes in the future?

664. Are e-cigarettes recommended for treating tobacco use disorder?

665. Are e-cigarettes recommended for treating tobacco use disorder? Part two

666. What are electronic cigarettes (e-cigarettes)?

667. Three generations of electronic cigarettes (e-cigarettes)

669. More about e-cigarettes and related products

669. Switching to e-cigarettes may increase medication levels. Part one

670. Switching to e-cigarettes may increase medication levels. Part two

671. Thyroid hormones for psychopharmacologists: What’s what

672. Pros and Cons of T3 and T4. Part one

673. Pros and Cons of T3 and T4. Part two

674. No reliable evidence for the addition of thyroid hormone to an SSRI

675. What is a failed study?

676. Why do clinical trials sometimes have both a placebo and an active control arm?

677. Summing up: Positive, negative, and failed studies

678. Liothyronine (T3) with an antidepressant: How much? Part one

679. Liothyronine (T3) with an antidepressant: How much? Part two

680. Liothyronine (T3) with an antidepressant: For how long?

681. Can mirtazapine be started at 30 mg per day?

682. Bipolar disorder with rapid cycling: In what percentage of your patients?

683. Who is more likely to develop rapid cycling?

684. Risk factors for rapid cycling: Caveats and what we can do

685. What to do if a patient has bipolar disorder with rapid cycling

686. Which medications for bipolar disorder with rapid cycling?

687. More on what we don’t know about treatment of rapid cycling in bipolar disorder

688. Summing up rapid cycling

689. Why isn’t bupropion the most frequently prescribed antidepressant?

690. Lamotrigine: No additional benefit at 400 mg per day?

691. Is lamotrigine 400 mg per day no more effective than 200 mg per day?

692. Should we consider amantadine for antipsychotic-induced parkinsonism?

693. Advantages and disadvantages of amantadine

694. Some key things about the pharmacology of amantadine

695. How to test for B vitamins in patients with cognitive impairment

696. How to interpret vitamin B12 level and serum methylmalonic acid levels

697. Testing serum or RBC folate levels in patients with cognitive impairment

698. Why homocysteine is important and should be measured

699. Just three quick questions with brief answers (Quiz no. 19)

700. Shocking data on weight gain and metabolic side effects in adolescents on olanzapine

701. The bottom line on metabolic side effects of olanzapine in adolescents

702. Does weight gain with second-generation antipsychotics continue even after six months?

703. A psychopharmyth about weight gain with second-generation antipsychotics

704. Sundowning in patients with dementia is important!

705. Sundowning or Delirium?

706. Does melatonin work for sundowning in dementia?

707. Lithium-induced hypercalcemia and hyperparathyroidism are common

708. Clinical features of hyperparathyroidism

709. How to screen for lithium-induced hyperparathyroidism

710. Measuring serum calcium and calculating corrected serum calcium

711. How to calculate the corrected serum calcium: a real-life example

712. Corrected serum calcium: The bottom line

713. Summing up: What labs to do and when to screen for lithium-induced hyperparathyroidism

714. Monitoring for metabolic side effects in children and adolescents on a second-generation (atypical) antipsychotic

715. Is measuring BMI at four weeks useful?

716. A simple, free questionnaire for Adult Autism Spectrum Disorder

717. How to score and interpret the Adult Autism Spectrum Quotient (AQ)

718. How to screen adults for autism spectrum disorder

719. Is vortioxetine more efficacious than other antidepressants?

720. Should patients with celiac disease worry about gluten in medications?

721. Part 2: Should patients with celiac disease worry about gluten in medications?

722. What else can cause Steven-Johnson Syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN)?

723. Do past infections increase the risk of Stevens-Johnson Syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN)?

724. Vitamin B6 for lithium-induced benign tremor?

725. Vitamin B6 for lithium-induced benign tremor? Part two

726. How common is liver toxicity with disulfiram and when does it occur?

727. When and how often should hepatic function tests be done in patients on disulfiram?

728. Prescription Drug Monitoring Programs (PDMPs)

729. Tips on using the Prescription Drug Monitoring Program

730. L-theanine for anxiety or stress?

731. How is L-theanine used for anxiety and stress responses?

732. What is a “standard” drink?

733. How much alcohol intake is “normal”?

734. What are Binge drinking and Heavy drinking?

735. Summarizing: More than low risk, Binge, and Heavy drinking

736. We should screen every patient for possible alcohol use disorder

737. How exactly to screen patients for possible alcohol use disorder. Part one

738. How exactly to screen patients for possible alcohol use disorder. Part two

739. A mnemonic to help diagnose Restless Legs Syndrome

740. Advanced tips about the urges to move in RLS

741. Important details about Rest, Getting up, and Evenings in RLS

742. E and S: Advanced tips on the diagnostic clinical features of restless legs syndrome (RLS)

743. DSM-5 criteria for restless legs syndrome (RLS): A simple explanation and mnemonic. Part one

744. DSM-5 criteria for restless legs syndrome (RLS): A simple explanation and mnemonic. Part two

745. What is vitamin D? Part one

746. What is vitamin D? Part two

747. Which test to order for vitamin D status

748. How should we define vitamin D insufficiency or deficiency?

749. When and how to treat vitamin D insufficiency or deficiency

750. Quick! Are these statements True or False? (Quiz no. 20)

751. What is Lewy body dementia?

752. How is neurocognitive disorder with Lewy bodies different from that due to Parkinson’s disease?

753. Why we must be able to recognize Neurocognitive disorder with Lewy bodies

754. Diagnostic criteria for Neurocognitive disorder with Lewy bodies explained

755. How to identify fluctuating cognition

756. How variability in NCD with Lewy bodies differs from that in Alzheimer’s disease

757. We need to differentiate between Neurocognitive disorder with Lewy bodies and delirium

758. How to differentiate NCD with Lewy bodies from delirium

759. NCD with Lewy bodies versus delirium

760. What kinds of psychotic symptoms are present in neurocognitive disorder with Lewy bodies?

761. Explaining spontaneous parkinsonism in Neurocognitive disorder with Lewy bodies

762. REM sleep behavior disorder is important in diagnosing NCD with Lewy bodies

763. How to identify REM sleep behavior disorder in our patients with dementia

764. Marked sensitivity to side effects of antipsychotics in NCD with Lewy bodies

765. What to do about marked sensitivity to side effects of antipsychotics in NCD with Lewy bodies

766. Three benzodiazepines are safer in the elderly and in liver disease

767. Which benzodiazepines for alcohol withdrawal syndrome (AWS)?

768. Three different approaches to using benzodiazepines for alcohol withdrawal

769. Use the CIWA-Ar to monitor the severity of alcohol withdrawal and to guide treatment

770. How to do symptom-triggered treatment for alcohol withdrawal

771. Fixed-dose regimens for alcohol withdrawal and their advantages

772. Fixed-dose regimens for alcohol withdrawal: Disadvantages and examples

773. A table with key facts about commonly used benzodiazepines

774. We are missing most cases of sleep apnea

775. The STOP-Bang questionnaire and where to get it for free

776. How to monitor for metabolic side effects in adults on second-generation antipsychotics

777. Important points about monitoring for metabolic side effects of second-generation antipsychotics

778. Elevated vitamin B12 levels are common and could be very serious

779. What serious illnesses may be causing an elevated vitamin B12

780. Functional vitamin B12 deficiency can occur even with a high vitamin B12 level

781. How common are the different types of thyroid problems that lithium can cause? (a) Introduction

       How common are the different types of thyroid problems that lithium can cause? (b) Incidence

782. How should lithium-induced hypothyroidism be evaluated?

783. When and how to check antithyroid antibodies in a patient on lithium

784. How to manage lithium-induced hypothyroidism. Part one

785. How to manage lithium-induced hypothyroidism. Part two

786. Past ECT treatment should not be assumed to have been adequate

787. Which factors related to ECT technique are important for adequate treatment?

788. Which factors related to ECT technique are important for adequate treatment? Part two

789. More about adequacy of ECT treatment

790. Mirtazapine is a treatment option for antipsychotic-induced akathisia

791. Mirtazapine for treating akathisia: Two possible clinically-important points

792. Mirtazapine may also CAUSE akathisia

793. True or False? (Quiz no. 21)

794. What is melatonin and what does it do?

795. Melatonin for insomnia–advantages, efficacy, effects, and a mind-blowing statistic

796. What dose of melatonin to start with and where to get low dose preparations (a)

       What dose of melatonin to start with and where to get low dose preparations (b)

797. Beyond insomnia and sleep apnea: Another type of sleep disorder

798. Many patients with insomnia actually have Delayed Sleep Phase Disorder

799. Pull from both ends to treat Delayed Sleep Phase Disorder

800. Pulling at the other end: Bright light therapy in the morning

801. More on how exactly to treat Delayed Sleep Phase Disorder

802. Next steps in treating Delayed Sleep Phase Disorder

803. How to diagnose SIADH

804. What is BEN and why does it matter to mental health clinicians?

805. E-cigarettes or conventional nicotine-replacement products? Which is more effective?

806. More on e-cigarettes, “smoking replacement,” and “harm reduction”

807. Five reasons why many clinicians sometimes combine a stimulant and atomoxetine

808. Cyproheptadine as-needed to reverse antidepressant-induced sexual dysfunction?

809. How exactly to use cyproheptadine for antidepressant-induced sexual dysfunction

810. Will mirtazapine increase the risk of QT prolongation? (Member’s case)

811. Can mirtazapine cause QT prolongation and ventricular arrhythmias?

812. Bottom line regarding mirtazapine and QT prolongation

813. Do you give thiamine routinely for the prevention of Wernicke-Korsakoff syndrome?

814. Problems regarding how thiamine is being prescribed

815. Thiamine for prevention: How much? By what route? How many times a day?

816. THIS is exactly how we should prescribe thiamine to prevent Wernicke-Korsakoff syndrome

817. Can I drink while on the antidepressant?

818. It is not a problem but don’t do it???

819. Six types of abnormal reactions to alcohol that may occur in persons taking an antidepressant

820. Two cases where stopping estrogen led to worsening of psychosis

821. Starting or stopping an oral contraceptive (or other estrogen) in a patient on clozapine

822. How is clozapine metabolized?

823. Estrogen and estrogen-containing oral contraceptives affect clozapine levels

824. What does estrogen have to do with schizophrenia??

825. Adjunctive estrogen for schizophrenia?

826. Should we not insist on fasting before getting labs for metabolic monitoring?

827. Should we go ahead and get a non-fasting lipid profile?

828. Easily find patient assistance programs for patients who can’t afford a particular medication

829. Stimulants for ADHD with a history of a substance use disorder?

830. Does this person really have ADHD?

831. History of ADHD: Learn more about what we are looking for

832. Neuropsychological testing for diagnosing ADHD?

833. What is the (limited) role of neuropsychological testing in ADHD or suspected ADHD?

834. Other possible uses of neuropsychological testing in ADHD

835. Can medication X cause side effect Y?

836. “Not a known and common side effect”

837. The Prescribing Information has useful information for prescribers

838. Can buspirone cause dyskinesia or parkinsonism?

839. How to search PubMed efficiently for possible adverse effects

840. How to search PubMed efficiently for possible adverse effects–Part 2

841. I didn’t know about this, did you?

842. Clinical features of cannabinoid hyperemesis syndrome

843. More clinical features of cannabinoid hyperemesis syndrome

844. An ingredient from hot peppers is used as a treatment for cannabinoid hyperemesis syndrome

845. How exactly to use capsaicin for cannabinoid hyperemesis syndrome

846. Acute treatment of cannabinoid hyperemesis syndrome: General measures

847. Acute treatment of cannabinoid hyperemesis syndrome: Specific measures

848. Final words on cannabinoid hyperemesis syndrome

849. How often should we check an ECG? Part one

850. How often should we check an ECG? Part two

851. How often should we check an ECG? Part three

852. How often should we check an ECG? Part four

853. True or False? (Quiz no. 22)

854. What is the optimal serum valproic acid (valproate) level? Part one

855. What is the optimal serum valproic acid (valproate) level? Part two

856. Bupropion for cocaine use disorder? What’s the evidence?

857. Bupropion for cocaine use disorder? What’s the bottom-line?

858. Agitation in Alzheimer’s disease: First, assess for modifiable causes

859. Valproate or quetiapine for agitation in Alzheimer’s disease: Yes or No?

860. Medications for agitation in Alzheimer’s disease: Part one

861. Antipsychotic in a patient with tardive dyskinesia?

862. FDA-cleared is not the same as FDA-approved

863. The FDA has a class system for medical devices

864. Are TMS and Alpha-Stim FDA “approved” or FDA “cleared”?

865. Initial steps in managing lithium-induced hypercalcemia/ hyperparathyroidism

866. Surgery for lithium-induced hyperparathyroidism

867. There is a medication for treating lithium-induced hyperparathyroidism

868. How psychotropic medications cause blurred vision: Part one

869. How psychotropic medications cause blurred vision: Part two

870. How to evaluate blurred vision apparently due to a psychotropic medication

871. Managing diarrhea due to mood stabilizers

872. How to find a cognitive therapist

873. How to measure neck circumference

874. Why do we need an “Apnea-Hypopnea Index”?

875. Apnea-Hypopnea Index for diagnosing obstructive sleep apnea and rating its severity

876. Understanding the proper place of Apnea-Hypopnea Index

877. Does dose reduction work for neuroleptic-induced parkinsonism?

878. Can isotretinoin cause depression or suicidality?

879. Why we can’t easily dismiss the risk of depression or suicidality with isotretinoin

880. What exactly is a “therapeutic window” for nortriptyline?

881. Nortriptyline level: At what dose and after how many days?

882. The timing of nortriptyline trough levels

883. What to do with the nortriptyline level

884. True or False?

885. Do you think that valproate causes PCOS?

886. Valproate and PCOS: What should we do before starting valproate

887. Valproate and PCOS: What we should do during treatment

888. How to find a facility that provides TMS

889. Nausea due to psychotropic medications is more important than we might think

890. Two simple strategies to reduce the risk of nausea

891. It makes a big difference—atomoxetine once a day or twice a day?

892. What dose of aripiprazole as an adjunct for OCD?

893. How to dose aripiprazole as an adjunct for OCD

894. Elevated alkaline phosphatase with normal AST and ALT

895. Metformin for antipsychotic-induced weight gain in children and adolescents?

896. Important tips on using metformin in children and adolescents

897. When and what to do about clozapine and olanzapine after smoking cessation

898. Add clomipramine to an SSRI for OCD?

899. Could it have been a type II error?

900. Adding clomipramine to an SSRI for OCD: Were the treatments adequate?

901. Concerns about combining clomipramine and SSRIs

902. If combining with clomipramine, which SSRIs should we worry the most about?

903. How exactly to add clomipramine to an SSRI

904. What monitoring should be done if clomipramine is added to an SSRI?

905. How to make sleep hygiene interventions more efficient and effective

906. The ONE most effective part of CBT-I that all of us should learn to implement

907. How exactly to do sleep restriction therapy. Part one

908. How exactly to do sleep restriction therapy. Part two

909. How exactly to do sleep restriction therapy. Part three

910. How exactly to do sleep restriction therapy. Part four

911. Can adding buspirone to a serotonergic antidepressant cause serotonin syndrome?

912. Be especially careful when combining buspirone with these two antidepressants

913. Does intermittent use of an antidepressant work for premature ejaculation?

914. Is as-needed treatment of premature ejaculation with a serotonergic antidepressant as effective and as acceptable?

915. Important factors for deciding on as-needed antidepressant for premature ejaculation

916. How do antidepressants increase the risk of bleeding?

917. Which antidepressants in persons at increased risk of bleeding?

918. True or False? (Quiz no. 24)

919. Dose equivalents for long-acting injectable second-generation antipsychotics

920. How dose equivalents for LAI second-generation antipsychotics were calculated

921. Dose equivalents of LAI second-generation antipsychotics

922. How to diagnose atypical features

923. Four things to look for if atypical features are present

924. A mnemonic for medications metabolized by CYP3A4

925. Important inhibitors of CYP3A4

926. Are oral, irreversible MAOIs the first-line treatment for major depression with atypical features?

927. Atypical depression: Oral irreversible MAOIs or SSRIs?

928. Bupropion first-line for major depressive disorder with atypical features?

929. Stimulants in a patient receiving ketamine/ esketamine?

930. What to do about stimulants during ketamine/esketamine treatment

931. What to do about stimulants after ketamine/esketamine treatment

932. Why is migraine important for mental health clinicians?

933. The four phases of migraine

934. Prodromal phase of migraine

935. Clinical features of the migraine aura

936. The mechanism of migraine aura explains its clinical features

937. Common characteristics of migraine headache

938. Associated symptoms during the headache phase of migraine (a)

       Associated symptoms during the headache phase of migraine (b)

939. Diagnostic criteria for migraine

940. Diagnostic subtypes of migraine

941. Three simple questions help to PIN the diagnosis of migraine

942. Recommend an “aura diary”

943. Where can patients get kosher vitamins and supplements?

944. Complementary and alternative medicines (CAM): Specific kosher products

945. Vitamins and minerals: Specific kosher products

946. Naltrexone-bupropion in a patient on clomipramine?

947. Links to 5 free templates for sleep diaries

948. Some tips on using sleep diaries

949. True or False? (Quiz no. 25)

950. How to change from gabapentin (Neurontin®) to pregabalin (Lyrica®)

951. Switching between gabapentin and pregabalin: Potential side effects and an illustrative case

952. “Fingerprint” metabolites that uniquely identify substances in a urine drug screen

953. Which TCAs are the most effective ones for MDD?

954. TCA versus TCA for MDD: How BIG were the differences?

955. Which TCAs to consider as first-line options

956. Are any of your patients on topiramate?

957. How to monitor serum bicarbonate for possible metabolic acidosis

958. What is the anion gap and how can we easily calculate it from the lab results?

959. How we can easily calculate the anion gap

960. Important clinical tips on using the anion gap

961. Two types of metabolic acidosis: Examples

962. Some antidepressants may have clinically important interactions with tramadol (Ultram®)

963. Serious problems that can occur when an antidepressant is combined with tramadol

964. More clinical tips on tramadol and antidepressants

965. Is fluvoxamine more effective for OCD than other SSRIs?

966. What did other sources find about fluvoxamine versus other SSRIs for OCD?

967. Another one bites the dust!

968. Clinical tips on managing Parkinson’s disease psychosis: Part one

969. Clinical tips on managing Parkinson’s disease psychosis: Part two

970. Clinical tips on managing Parkinson’s disease psychosis: Part three

971. Is tardive dyskinesia reversible if the antipsychotic is stopped?

972. Is tardive dyskinesia reversible? Part two

973. Final conclusions on “Is tardive dyskinesia reversible?”

974. Does bupropion treat antidepressant-induced sexual dysfunction? Part one

975. Does bupropion treat antidepressant-induced sexual dysfunction? Part two

976. Does bupropion treat antidepressant-induced sexual dysfunction? Part three

977. Does bupropion treat antidepressant-induced sexual dysfunction? Part four

978. How often does antidepressant-induced sexual dysfunction resolve spontaneously?

979. MAO inhibitors (MAOIs) and contraindicated medications: How long do we have to wait?

980. How long do we have to wait? Part 2

981. Combination therapy (mood stabilizer plus antipsychotic) for acute mania? Part one

982. Combination therapy (mood stabilizer plus antipsychotic) for acute mania? Part two

983. Combination therapy (mood stabilizer plus antipsychotic) for acute mania? Part three

984. Our advice on combination therapy (mood stabilizer plus antipsychotic) for acute mania

985. Why is dextromethorphan combined with a CYP 2D6 inhibitor?

986. Does new-onset psychosis late in life predict the onset of dementia?

987. Alzheimer’s disease often travels in “mixed company” for acute mania?

988. Behavioral symptoms in dementia that are unlikely to improve with an antipsychotic

989. Avoid these mistakes in using antipsychotics for psychosis in dementia

990. Minimizing caffeine may be helpful in bipolar disorder

991. Four issues about caffeine and bipolar disorder

992. Serious dangers to avoid if it is essential to physically restrain a pregnant woman

993. What to do if it is essential to physically restrain a pregnant woman

994. True or False? (Quiz no. 26)

995. Why we must identify and characterize psychotic features in manic episodes. Part one

996. Two types of psychotic symptoms in mania

997. Do psychotic symptoms in mania affect the prognosis?

998. Psychotic symptoms in mania affect the treatment plan

999. What to do about cognitive complaints in brief outpatient visits

1000. First, which cognitive domains are impaired and to what extent?

1001. In difficult-to-treat patients, always focus on more evaluation before more treatment trials

1002. Unusually severe difficulties tolerating an antidepressant?

1003. Quetiapine monotherapy for generalized anxiety disorder (GAD)?

1004. How well does quetiapine XR monotherapy for GAD work?

1005. Bottom line on quetiapine monotherapy for GAD

1006. Elevated triglycerides are common in mental health patients

1007. Non-medication management of elevated triglycerides

1008. Do you recommend omega-3 fatty acids for hypertriglyceridemia?

1009. Omega-3 fatty acids to lower serum triglycerides can make a HUGE difference

1010. How to elicit what our patients really think about their diagnosis

1011. How to discuss relapse prevention strategies to improve outcomes in bipolar disorder

1012: Specific strategies for relapse prevention in bipolar disorders

1013. A key strategy for for preventing relapse and aborting manic episodes: Part one

1014. A key strategy for for preventing relapse and aborting manic episodes: Part two

1015. Does divalproex (valproate) work for bipolar depression? Part one

1016. Bottom line on the efficacy of divalproex for bipolar depression

1017. Important tips on using divalproex for bipolar depression

1018. Tranylcypromine: Third-line for bipolar depression

1019. True or False? (Quiz no. 27)

1020. Clock drawing: A simple, brief, but very useful clinical test

1021. How to administer the Clock Drawing Test

1022. More things the Clock Drawing Test can tell us

1023. Stimulus-bound behavior and semantic processing difficulty identified by the Clock Drawing Test

1024. How visual field defects may be identified on the clock drawing test

1025. What errors to look for in the Clock Drawing Test

1026. Final conclusions about the Clock Drawing Test

1027. Do you try to avoid SNRIs in bipolar depression?

1028. Greater risk of switching to mania/hypomania with SNRIs?

1029. Essential details about the Increased risk of switching with SNRIs

1030. Bottom line and Action items regarding SNRIs in bipolar depression

1031. Is ondansetron (brand name Zofran) associated with an increased risk of QT prolongation?

1032. Useful information and guidance about QT prolongation with ondansetron

1033. What if ondansetron is combined with a psychotropic medication?

1034. Final recommendations regarding ondansetron and QT prolongation

1035. How to switch from oral or transdermal selegiline to another MAO inhibitor

1036. What is khat and why is it important in mental health?

1037. Why it is important for all of us to screen for eating disorders

1038. A simple 5-item screen for eating disorders is nothing to SCOFF at

1039. How well does the SCOFF do in screening for eating disorders?

1040. SCOFF: Verbally or in writing? In other languages?

1041. Important additional tips on screening for eating disorders

1042. Here’s a screening questionnaire specifically for binge-eating disorder

1043. How to convert from alprazolam immediate-release to extended-release

1044. Potential advantages of alprazolam extended-release

1045. Does alprazolam extended-release have a lower addictive/ abuse potential?

1046. My recommendations regarding alprazolam extended-release

1047. Does hydroxyzine have advantages over diphenhydramine?

1048. Hydoxyzine versus diphenhydramine: Bottomline and Clinical Recommendations

1049. Bradycardia in a patient with bipolar disorder

1050. Lithium can cause certain benign changes in the ECG, but…

1051. Lithium and ECG changes: What to look for

1052. Six general principles about lithium’s effects on the ECG

1053. Clinical recommendations regarding lithium and ECGs

1054. True or False? (Quiz no. 28)

1055. Is sertraline safe to use during breastfeeding?

1056. Tips on psychotropic medications during breastfeeding

1057. Tips on breastfeeding while on a psychotropic medication

1058. Strategies to reduce the infant’s medication exposure during breastfeeding

1059. How to monitor a newborn being breastfed by a mother on a psychotropic medication

1060. Can I take my medication with me when I travel to another country?

1061. Can I take my medication with me when I travel to another country? Part two

1062. Headache DURING sex. Really?

1063. Headache during sexual activity? Could be serious!

1064. More clinical features of primary headaches associated with sexual activity

1065. Are we identifying comorbid diagnoses in bipolar disorders?

1066. How common is comorbid OCD in bipolar disorders?

1067. Which patients with bipolar disorders are more likely to also have comorbid OCD?

1068. Serotonergic antidepressants for comorbid OCD in bipolar disorder?

1069. Other options for OCD comorbid with bipolar disorder

1070. Clinical recommendations for OCD comorbid with bipolar disorder: Part one

1071. Clinical recommendations for OCD comorbid with bipolar disorder: Part two

1072. Cannabidiol (CBD) for schizophrenia or other psychotic disorders? Part one

1073. Cannabidiol in schizophrenia? What did randomized, double-blind clinical trials find?

1074. Clinical trials of cannabidiol for schizophrenia: What to make of them (part one)

1075. Clinical trials of cannabidiol for schizophrenia: What to make of them (part two)

1076. With cannabidiol, keep possible drug interactions in mind

1077. Bottom line on cannabidiol in schizophrenia

1078. How to find treatment facilities for substance use disorders (addictions)

1079. True or False? (Quiz no. 29)

1080. Is this medication “weight-neutral”?

1081. How to identify potentially significant side effects hidden behind “misleading means”

1082. Another case of “misleading means”

1083. Two more tips on what to look at in evaluating risks with a medication

1084. General approach to treating women during pregnancy and lactation

1085. Two general principles and three models of treatment during pregnancy and lactation

1086. Some questions to ask in evaluating a patient with blurred vision

1087. Questions to ask to try to rule out some other causes of blurred vision

1088. Does quetiapine work for insomnia?

1089. How quetiapine saved the day

1090. When might we consider quetiapine for insomnia?

1091. Addressing two concerns about off-label use of quetiapine for insomnia

1092. Even low-dose quetiapine carries some risks

1093. Quetiapine for insomnia? Bottom line and Clinical recommmendations

1094. BOTH a bipolar disorder AND a substance use disorder: More common that we may realize

1095. Comorbid bipolar disorder and substance use disorder: What, who, and so what

1096. Bipolar disorder or substance use? Tips on clarifying the diagnosis

1097. Bipolar disorder or substance use? More tips on clarifying the diagnosis

1098. Tips on treating comorbid bipolar disorder and substance use disorder. Part one

1099. General tips on treating comorbid bipolar disorder and substance use disorder. Part two

1100. Tips on treating alcohol use disorder in persons with a bipolar disorder. Part one

1101. Tips on treating alcohol use disorder in persons with a bipolar disorder. Part two

1102. Clinical recommendations on treating alcohol use disorder in persons with a bipolar disorder

1103. A systematic evaluation of bright light therapy devices. Part one

1104. A systematic evaluation of bright light therapy devices. Part two

1105. Bright light therapy devices that passed the test

1106. Which large light box to recommend. Part one

1107. Which large light box to recommend. Part two

1108. Consider smaller light boxes? If so, which one? Part one

1109. Consider smaller light boxes? If so, which one? Part two

1110. How to easily search for drug interactions with cannabidiol

1111. True or False? (Quiz no. 30)

1112. What is performance anxiety (“stage fright”) and why is it important?

1113. Why consider a beta-blocker for performance anxiety?

1114. When and when not to consider a beta-blocker for performance anxiety

1115. Which beta-blocker for disabling performance anxiety with physical/autonomic symptoms?

1116. Final tips about beta-blockers for physical symptoms in performance anxiety

1117. When and how to prescribe lithium citrate oral solution

1118. Some interesting facts about boxed warnings (so-called “black box warnings”)

1119. What to do about boxed warnings. Part one

1120. What to do about boxed warnings. Part two

1121. SSRIs for OCD: How high can we go?

1122. Reducing the cost of medications by using higher strength pills. Part one

1123. Reducing the cost of medications by using higher strength pills. Part two

1124. Using a Canadian pharmacy can reduce the cost of some medications

1125. A simple way to significantly reduce the cost of l-methylfolate (Deplin®)

1126. Online resources for complementary and alternative medicines or products

1127. Elevated serum creatinine in young man on lithium

1128. Can creatine supplementation lead to elevated serum creatinine?

1129. Creatine supplementation: What happened with my patient

1130. Two types of creatine supplements 

1131. Clinical recommendations about creatine supplements and serum creatinine

1132. What serum creatinine is and why it is important

1133. Factors that can affect serum creatinine. Part one

1134. Factors that can affect serum creatinine. Part two

1135. Factors that can affect serum creatinine. Part three

1136. True or False? (Quiz no. 31)

1137. Patients on high doses of controlled substances

1138. General tips on engaging patients in dose reduction

1139. Tips on reducing patients’ anxiety about medication dose reduction

1140. How to frame the need for reduction in the dose of a controlled substance

1141. Valproate-induced hyperammonemia

1142. Evaluation of hyperammonemia in patients on valproate

1143. How to manage valproate-induced hyperammonemia: Part one

1144. How to manage valproate-induced hyperammonemia: Part two

1145. Key points to know about L-carnitine

1146. Levels of seriousness in drug interaction search results

1147. Drug interaction search (checker) tools: Free options (Part one)

1148. Drug interaction search (checker) tools: Free options (Part two)

1149. Which antidepressants in patients with a history of, or at higher risk for, bleeding? Part one

1150. Which antidepressants in patients with a history of, or at higher risk for, bleeding? Part two

1151. Stimulant “holidays” (breaks) in adults with ADHD? Part one: Tolerance

1152. Stimulant “holidays” (breaks) in adults with ADHD? Part two

1153. Stimulant “holidays” (breaks) in adults with ADHD? Part three

1154. How significant are interactions between lithium and antihypertensives?

1155. Factors affecting the severity of the interaction between antihypertensives and lithium

1156. Clinical recommendations on thiazide diuretics in persons on lithium

1157. What does “treatment-resistant depression” in the indication for esketamine (Spravato®) mean? Part one

1158. What does “treatment-resistant depression” in the indication for esketamine (Spravato®) mean? Part two

1159. How well does esketamine work for treatment-resistant depression? Part one

1160. How well does esketamine work for treatment-resistant depression? Part two

1161. Does esketamine work rapidly as intravenous ketamine does?

1162. Does esketamine work rapidly as intravenous ketamine does? Part two

1163. True or False? (Quiz no. 32)

1164. Common and other side effects of esketamine nasal spray (Spravato®)

1165. Dissociative and perceptual changes are esketamine’s commonest psychological side effects

1166. What exactly are “dissociative or perceptual changes” that may occur with esketamine?

1167. How serious are the dissociative and perceptual side effects of esketamine?

1168. What do WE need to be do about dissociative and perceptual changes?

1169. Are we identifying and treating anxiety disorders in persons with bipolar disorders?

1170. Pharmacological treatment of anxiety disorders in persons with bipolar disorders. Part one

1171. Pharmacological treatment of anxiety disorders in persons with bipolar disorders. Part two

1172. Are you using a self-rated scale in persons with OCD?

1173. Use this self-rating scale for OCD

1174. The Obsessive-Compulsive Inventory-Revised (OCI-R)

1175. There are many ways in which we can use the OCI-R

1176. How to score and interpret the OCI-R

1177. How to use the OCI-R for screening

1178. “Rescue measures” for orthostatic hypotension

1179. Abdominal binders: Simple but effective for orthostatic hypotension

1180. How exactly to use an abdominal binder

1181. How exactly to recommend increased salt intake for orthostatic hypotension

1182. Grapefruit or its juice can interact with psychotropic medications

1183. More tips on the interaction between grapefruit and psychotropic medications

1184. Can grapefruit be entered into an interaction checker?

1185. Does paliperidone HAVE to be taken with food?

1186. Medications to be taken consistently either with or without food

1187. Caffeine can significantly change serum clozapine levels

1188. More on caffeine’s effect on clozapine levels

1189. We need to warn patients on fluvoxamine about caffeine

1190. When cigarette smokers stop smoking…

1191. Why we need ICD-10 codes other than those for mental disorders

1192. ICD-10 codes for mental health clinicians

1193. True or False? (Quiz no. 33)

1194. Ropinirole off-label for treatment-resistant depression?

1195. When to consider off-label ropinirole for “treatment-resistant depression”

1196. Ropinirole can have some serious side effects

1197. Potential drug interactions with ropinirole

1198. How is bipolar depression different from unipolar depression?

1199. How is bipolar depression different from unipolar depression? Part two

1200. How is bipolar depression different from unipolar depression? three

1201. Do stimulant medications work for major depressive disorder?

1202. The bottom line on stimulants for treatment-resistant depression

1203. Should we use automated blood pressure instruments?

1204. Automated blood pressure measurement can be BETTER

1205. How to correctly measure blood pressure. Part one

1206. How to correctly measure blood pressure. Part two

1207. How to correctly measure blood pressure. Part three

1208. How to correctly measure blood pressure. Part four

1209. How to correctly measure blood pressure. Part five

1210. When should we consider ECT for major depressive disorder?

1211. How well does ECT work for major depressive disorder?

1212. Comparing different types of ECT

1213. What type of ECT should patients receive and how often?

1214. Some issues in the practice of ECT for major depressive disorder

1215. An alarm that makes you PROVE that you are really awake!

1216. Clozapine-induced constipation can be very serious

1217. Evaluation and management of clozapine-induced constipation

1218. Basic (level 1) strategies for clozapine-induced constipation

1219. Intermediate (level 2) strategies for clozapine-induced constipation

1220. Advanced (level 3) strategies for clozapine-induced constipation: Part one

1221. Advanced (level 3) strategies for clozapine-induced constipation: Part two

1222. FDA’s warning about clozapine-induced constipation

1223. Why warfarin is important for psychopharmacologists

1224. Best and worse choices of psychotropic medications in a patient on warfarin

1225. Best antidepressants for a patient on warfarin

1226. Clinical recommendations for psychotropic medications in patients on warfarin

1227. Generic medications lead to HUGE savings

1228. Do you worry about generic medications?

1229. Generic medications: When should we be more concerned?

1230. Clinical recommendations about generics

1231. The educational story of generic bupropion extended-release. Part one

1232. The educational story of generic bupropion extended-release. Part two

1233. The educational story of generic bupropion extended-release. Part three

1234. The educational story of generic bupropion extended-release:Bottom line

1235. Should trazodone be taken with food or without food?

1236. True or False? (Quiz no. 34)

1237. Bipolar depression: Factors affecting treatment selection and outcomes. Part one

1238. Bipolar depression: Factors affecting treatment selection and outcomes. Part two

1239. Bipolar depression: Factors affecting treatment selection and outcomes. Part three

1240. Bipolar depression: Factors affecting treatment selection and outcomes. Part four

1241. More on interpreting thyroid function tests. Part one

1242. More on interpreting thyroid function tests. Part two

1243. More on interpreting thyroid function tests. Part three

1244. Serum TSH level is NORMAL but T4 level is low

1245. What causes central hypothyroidism (and can our meds cause it)?

1246. How to find patient assistance programs: An example

1247. Why do some people take lithium orotate?

1248. Does lithium orotate work?

1249. Lithium orotate or lithium carbonate?

1250. In what strengths is lithium orotate available?

1251. Lithium orotate: Clinical recommendations

1252. How common is new-onset hyponatremia during antidepressant treatment?

1253. How common is new-onset hyponatremia during antidepressant treatment? Part two

1254. How should carbamazepine be discontinued? Part one

1255. How should carbamazepine be discontinued? Part two

1256. Dopamine agonist withdrawal syndrome (DAWS)

1257. Two cases of major depression after stopping a dopamine agonist

1258. DAWS is common but very variable

1259. DAWS: Risk factors and Diagnosis

1260. How to prevent DAWS

1261. How to treat DAWS

1262. Can medication A cause side effect X? An example (Part one)

1263. Can medication A cause side effect X? An example (Part two)

1264. How EXACTLY to screen for tardive dyskinesia

1265. How EXACTLY to screen for tardive dyskinesia: Part two

1266. What are MAO-B inhibitors?

1267. What’s the possible serious interaction between MAO-B inhibitors and antidepressants?

1268. What do we know about using an antidepressant with an MAO-B inhibitor?

1269. Bottom line and clinical recommendations on using antidepressants along with MAO-B inhibitors

1270. True or False? (Quiz no. 35)

1271. Warning! Some antipsychotics can be dangerous in catatonia

1272. Which antipsychotics to prefer in patients with catatonia

1273. What are 504 plans?

1274. How is imipramine palmoate (Tofranil-PM) different from imipramine hydrochloride (Tofranil)?

1275. What to do if renal impairment develops while on lithium. Part one

1276. What to do if renal impairment develops while on lithium. Part two

1277. How often do kidney stones occur on topiramate?

1278. Laboratory findings related to stone formation in patients on topiramate

1279. Factors that increase the risk of urinary stones with topiramate

1280. Atypical sensory processing is common and clinically important

1281. Three types of symptoms of atypical sensory processing

1282. How sensory oversensitivity presents clinically

1283. Sensory under-responsivity and unusual fascination with sensory stimuli

1284. Look for sensory dysregulation in your patients with migraine

1285. What symptoms of sensory dysregulation in persons with migraines?

1286. How long till the glucose levels decrease?

1287. Case reports of antipsychotic-induced severe hyperglycemia

1288. Two patterns of antipsychotic-associated hyperglycemia: Clinical implilcations

1289. After switching to aripiprazole, will the blood sugar improve?

1290. What to do about hyperglycemia if switched to aripiprazole

1291. When are drug interactions with TCAs more serious?

1292. Not all TCAs are created equal

1293. Have any of your patients complained of tinnitus?

1294. Why tinnitus is important for mental health clinicians to learn about

1295. Key things to ask about if a patient complains of tinnitus

1296. Tinnitus in patients on bupropion?

1297. Tinnitus and antidepressants

1298. True or False? (Quiz no. 36)

1299. Generic alternative to naltrexone/bupropion (Contrave®)?

1300. Does guanfacine work for ADHD in adults?

1301. How well does guanfacine work for adults with ADHD?

1302. The bottomline on guanfacine for ADHD in adults

1303. Metformin for weight gain or obesity unrelated to antipsychotic medications?

1304. More on weight gain unrelated to antipsychotic medications

1305. Certain herbal products can cause mania/ hypomania/ mixed states

1306. Clinical recommendations: herbal products and substance/medication-induced bipolar disorder

1307. Which antidepressant in a patient on multiple non-psychiatric medications?

1308. A brief introduction to directly-acting oral anticoagulants

1309. Potential interactions between DOACs and psychotropic medications

1310. Which serotonin reuptake inhibitors may have a lower risk of bleeding?

1311. An example of misleading means (averages)

1312. Are you over-diagnosing PTSD?

1313. What kind of trauma can lead to PTSD?

1314. Many ways of experiencing trauma that can lead to PTSD

1315. TCAs other than clomipramine for OCD?

1316. Should we recommend vitamin B12 supplements?

1317. What causes vitamin B12 deficiency in our patients?

1318. Tips on understanding the clinical features of vitamin B12 deficiency

1319. Don’t miss the symptoms and signs of vitamin B12 deficiency

1320. Tips on checking and interpreting vitamin B12 levels

1321. How to confirm vitamin B12 deficiency

1322. Does vitamin E work for tardive dyskinesia? Yes and No

1323. The bottom line on vitamin E for tardive dyskinesia

1324. How much vitamin E do we need?

1325. Warning! High doses of vitamin E can be harmful

1326. Perimenopausal depression may be a special situation

1327. Tips on choosing medication(s) for perimenopausal depression

1328. Add estrogen to an antidepressant after partial/ non-response?

1329. Safety considerations in using estrogen for perimenopausal depression

1330. True or False? (Quiz no. 37)

1331. Important! Motor threshold in TMS may be affected by medications

1332. Medications that may LOWER the motor threshold in TMS

1333. Order an MRI of brain in first-episode psychosis?

1334. How useful is a brain MRI in first-episode psychosis?

1335. When is a brain MRI indicated in first-episode psychosis?

1336. Does lamotrigine decrease the effectiveness of oral contraceptives?

1337. Clinical recommendations regarding the effect of lamotrigine on oral contraceptive

1338. Converting from OROS methylphenidate to amphetamine is a two-step process

1339. Pilocarpine “mouthwash” to treat medication-induced dry mouth?

1340. How to make pilocarpine mouthwash to treat dry mouth

1341. How to use the topical pilocarpine (mouthwash) for medication-induced dry mouth

1342. Folic acid may counteract the benefit of lamotrigine

1343. How lamotrigine affects folate metabolism

1344. Possible alternatives to folic acid for patients on lamotrigine

1345. Can 5ARIs cause depression or suicidality?

1346. 5ARIs, sexual dysfunction, and depression

1347. 5ARIs, sexual dysfunction, and depression: Bottom line and Clinical recommendations

1348. Diagnose PTSD only if all four categories of symptoms are present

1349. PTSD: Examples of symptoms in the four categories

1350. Ultraviolet A and B: Implications for vitamin D production

1351. Ultraviolet A (UVA) versus ultraviolet B (UVB): Implications for sunscreen use

1352. Lorazepam for catatonia: How much? How long?

1353. Lorazepam for catatonia: How much? How long? (Part 2)

1354. Lorazepam for catatonia: How much? How long? (Part 3)

1355. Lorazepam Challenge Test in catatonia: Part one

1356. Lorazepam Challenge Test in catatonia: Part two

1357. How is ECT used for catatonia? Part one

1358. How is ECT used for catatonia? Part two

1359. A patient with a low vitamin B12 level

1360. Can patients on bupropion drink alcohol? Part one

1361. Can patients on bupropion drink alcohol? Part two

1362. True or False? (Quiz no. 38)

1363. Two patients where opening medication capsules was helpful

1364. Should we encourage patients to use independent pharmacies?

1365. FDA-approved Medication Guides for patients

1366. QT prolongation with hydroxyzine and diphenhydramine. Part one

1367. QT prolongation with hydroxyzine and diphenhydramine. Part two

1368. Let’s not get mixed up about “mixed features”

1369. Important! Mixed features consist of “non-overlapping” symptoms

1370. Four things to check for before adding the mixed features specifier

1371. Can lamotrigine CAUSE depression?

1372. Lamotrigine can also cause other psychiatric side effects

1373. Are doxepin’s anticholinergic effects dose-dependent?

1374. Why (HIPAA-compliant) emails with patients are invaluable

1375. What kind of email for communicating with patients?

1376. Risk management concerns regarding email with patients

1377. Should we be using gabapentin for alcohol use disorder?

1378. In whom is gabapentin more likely to work for alcohol use disorder?

1379. What dose of gabapentin for alcohol use disorder?

1380. Do modafinil/ armodafinil increase cardiovascular risk?

1381. Recommendations for cardiovascular monitoring with modafinil/ armodafinil

1382. Do benzodiazepines reduce the response to TMS treatment?

1383. Should we reduce or stop benzodiazepines before TMS treatment?

1384. What do you think about these results of iron studies?

1385. What are “iron studies” and why should we care?

1386. Serum ferritin: the best single test for iron deficiency

1387. Could the serum ferritin be normal even if iron deficiency is present?

1388. What cut-off to use for serum ferritin

1389. Pros and cons of other iron studies

1390. Which iron studies to order and exactly how to order them

1391. Case examples: Interpreting iron studies

1392. Instructions to patients

1393. How to interpret the results of iron studies

1394. Are psychiatric medications safe AFTER laser iridotomy for narrow-angle glaucoma?

1395. Conclusion on whether psychiatric medications are safe AFTER laser iridotomy for narrow-angle glaucoma

1396. What is lactose intolerance and what are its symptoms?

1397. Tips on identifying lactose intolerance

1398. Can lactose in pills cause lactose intolerance?

1399. Lactose in medication pills: Clinical recommendations

1400. When a patient has difficulty getting off venlafaxine. Part one

1401. When a patient has difficulty getting off venlafaxine. Part two

1402. All three phases of treatment are very important in major depressive disorder

1403. Continuation treatment of MDD is very important!

1404. Who should get continuation treatment and what should they get?

1405. Continuation treatment for MDD: How much?

1406. How long should continuation treatment for MDD last?

1407. Many patients need PREVENTIVE treatment but most don’t receive it

1408. The main reasons for longer-term preventive treatment in MDD

1409. Other factors suggesting that preventive treatment of MDD is needed

1410. Obstructive sleep apnea is common and massively underdiagnosed (Part 1)

1411. Obstructive sleep apnea is common and massively underdiagnosed (Part 2)

1412. Are we missing the diagnosis of OSAH in our patients with major depressive disorder?

1413. More evidence that obstructive sleep apnea is frequently going undiagnosed

1414. Just screen everyone for OSAH, Ok?

1415. True or False? (Quiz no. 39)

1416. A mnemonic for symptoms of antidepressant discontinuation syndrome

1417. An expanded mnemonic for all common symptoms of antidepressant discontinuation syndrome

1418. What is medication-induced excessive yawning and why does it matter?

1419. Which medications can cause excessive yawning?

1420. Management of antidepressant-induced excessive yawning

1421. Add aripiprazole to treat clozapine-induced weight gain?

1422. The possible benefits of adding aripiprazole to clozapine

1423. More on aripiprazole to produce weight loss in patients on clozapine or olanzapine

1424. Why C-reactive protein matters to us

1425. Why are there two different tests for C-reactive protein?

1426. Can high sensitivity C-reactive protein help us choose antidepressant treatment?

1427. C-reactive protein: Bottom line and Clinical recommendations

1428. Treating ADHD in persons with stimulant (including cocaine) use disorder. Part one

1429. Treating ADHD in persons with stimulant (including cocaine) use disorder. Part two

1430. Treating ADHD in persons with stimulant (including cocaine) use disorder. Part three

1431. Treating ADHD in persons with stimulant (including cocaine) use disorder. Part four

1432. Treating ADHD in persons with stimulant (including cocaine) use disorder. Part five

1433. Is “low dose” lithium sufficient for antidepressant augmentation in MDD?

1434. The problem of inadequate serum lithium levels in major depressive disorder

1435. Clinical recommendations: How much lithium for augmentation in major depressive disorder?

1436. How long should a trial of lithium augmentation last? Part one

1437. How long should a trial of lithium augmentation last? Part two

1438. For how long should lithium augmentation be continued?

1439. Lamotrigine monotherapy for maintenance treatment in bipolar I disorder? Part one

1440. Lamotrigine monotherapy for maintenance treatment in bipolar I disorder? Part two

1441. Lamotrigine monotherapy for maintenance treatment in bipolar I disorder? Part three

1442. What is kratom and why is it important to know about?

1443. How is kratom used and what are its effects?

1444. What are the potential harms of kratom?

1445. Kratom withdrawal and toxicity

1446. How are kratom withdrawal, dependence, and overdose treated?

1447. Medication prices on Costco.com versus on Goodrx.com

1448. Does exercise work as a treatment for depressive disorders?

1449. For depressive symptoms, aerobic exercise or resistance training?

1450. How MUCH exercise for treating depressive symptoms?

1451. Final tips on exercise as a treatment for depressive symptoms

1452. What is nightmare disorder and why is it important?

1453. Five ways in which nightmares are very different from sleep terrors

1454. Nightmares versus “bad dreams”

1455. Suggestion: We should specifically ask about nightmares when we ask about sleep

1456. When should we separately diagnose nightmare disorder?

1457. PTSD-associated nightmares: Menu of treatment options

1458. Major practice guidelines have downgraded prazosin for PTSD

1459. What did studies of prazosin for PTSD find? And, what changed?

1460. What may have gone wrong

1461. Bottom line: Does prazosin work for PTSD-associated nightmares or not?

1462. Who might respond better to prazosin?

1463. What is the maximum dose of prazosin for PTSD?

1464. How is the dose of prazosin divided and titrated up?

1465. Atomoxetine can cause EITHER insomnia or somnolence/sedation

1466. Could the serum levels of atomoxetine be too high?

1467. Atomoxetine at bedtime or in split doses?

1468. What else can we do for somnolence/ sedation on atomoxetine?

1469. Does modafinil work for ADHD?

1470. Modafinil for ADHD? Bottom line and Clinical recommendations

1471. Non-selective versus “cardioselective” beta-blockers

1472. Beta-blockers in a person with asthma? Part 1

1473. Beta-blockers in a person with asthma? Part 2

1474. Which beta-blockers in persons with diabetes?

1475. Viewpoint: Has the pendulum swung from too far against the use of benzodiazepines? Part one

1476. Viewpoint: Has the pendulum swung from too far against the use of benzodiazepines? Part two

1477. 365 Advanced Topics in Psychopharmacology (Quiz no. 40)

1478. How to identify clinical versus subclinical hypothyroidism or hyperthyroidism

1479. Thyroid function tests: The four commonest combinations

1480. Thyroid function in acute psychiatric conditions

1481. What do you make of these thyroid function test results?

1482. My thoughts on the patients with abnormal thyroid function tests. Part one

1483. A patient with low TSH AND low free T4

1484. What to do about medications in a patient who is NPO

1485. What if a tremor is either unilateral or asymmetrical? Part one

1486. What if a tremor is either unilateral or asymmetrical? Part two

1487. What is the tremor in Parkinson’s disease like?

1488. More on recognizing Parkinson’s disease tremor

1489. How can response to intravenous ketamine be maintained? Part one

1490. How can response to intravenous ketamine be maintained? Part two

1491. How can response to intravenous ketamine be maintained? Part three

1492. How can response to intravenous ketamine be maintained? Part four

1493. Are we missing iron deficiency without anemia?

1494. What symptoms may suggest non-anemic iron deficiency (NAID)?

1495. Let’s ask about heavy menstrual bleeding

1496. Drug interactions with an herbal product like ashwagandha

1497. Can psychostimulant medications cause Raynaud’s syndrome?

1498. Clinical features of Raynaud’s phenomenon

1499. Important facts about stimulant-induced Raynaud’s phenomenon

1500. Clinical recommendations Raynaud’s syndrome associated with stimulants

1501. What is the maximum dose of mixed amphetamine salts? Part one

1502. What is the maximum dose of mixed amphetamine salts? Part two

1503. What is the maximum dose of mixed amphetamine salts? Part three

1504. What exactly do tics look like?

1505. Four qualities of tics that can help to differentiate them from other movements

1506. How high can we go with naltrexone for alcohol use disorder? Part one

1507. How high can we go with naltrexone for alcohol use disorder? Part two

1508. How high can we go with naltrexone for alcohol use disorder? Part three

1509. How high can we go with naltrexone for alcohol use disorder? Part four

1510. Which laboratory tests in persons with first-episode psychosis? Part one

1511. Which laboratory tests in persons with first-episode psychosis? Part two

1512. Which laboratory tests in persons with first-episode psychosis? Part three

1513. Understanding sleep study results in obstructive sleep apnea

1514. In a sleep study result, what is the Respiratory Disturbance (Distress) Index (RDI)?

1515. 365 Advanced Topics in Psychopharmacology (Quiz no. 41)

1516. What are the alternatives to the oral route? Part one

1517. Tips on giving antidepressants through a feeding tube

1518. Antidepressants: What are the alternatives to the oral route? Part three

1519. Sometimes, a medication may be given rectally

1520. Can antidepressants be given rectally if needed?

1521. Bottom line on antidepressants in patients who are NPO

1522. Clinical case: New onset of acute anxiety and physical symptoms

1523. How does toxicity from anticholinergic medications present clinically?

1524. Clinically-important differences between the various SNRIs? Part one

1525. Reasons to prefer desvenlafaxine (Pristiq®) over venlafaxine (Effexor XR®)

1526. (More) Reasons to prefer desvenlafaxine (Pristiq®) over venlafaxine (Effexor XR®)

1527. How exactly should desvenlafaxine be stopped?

1528. SNRIs differ in the extent of norepinephrine reuptake inhibition

1529. How high do we have to go to get significant norepinephrine reuptake inhibition?

1530. Pros and cons of venlafaxine versus duloxetine. Part one

1531. Pros and cons of venlafaxine versus duloxetine. Part two

1532. How to manage lithium treatment before and after bariatric surgery: Part one

1533. How to manage lithium treatment before and after bariatric surgery: Part two

1534. What are the potential side effects of melatonin? Part one

1535. What are the potential side effects of melatonin? Part two

1536. Can melatonin have negative effects on puberty?

1537. (Relative) contraindications to prazosin for PTSD-associated nightmares

1538. Case: Rising serum creatinine in a patient on lithium. Part one

1539. Case: Rising serum creatinine in a patient on lithium. Part two

1540. Case: Rising serum creatinine in a patient on lithium. Part three

1541. Case: Elevated serum creatinine that remained stable for many years

1542. Which urine drug screen do most workplaces require?

1543. A specific example of a DOT-5-compliant urine drug screen panel

1544. More on workplace urine drug screening

1545. Urinary hesitancy or retention due to atomoxetine is not rare

1546. The “Who” and “When” of atomoxetine-induced urinary hesitancy/ retention

1547. How to manage medication-induced urinary hesitancy/retention. Part one

1548. How to manage medication-induced urinary hesitancy/retention. Part two

1549. How to manage medication-induced urinary hesitancy/retention. Part three

1550. Hypomania or mania? Why do we care?

1551. Ways in which manic and hypomanic episodes are and are not different

1552. Was it really hypomania?

1553. Evaluating for hypomania: How to ask

1554. Tip on documenting a hypomanic episode

1555. A safeguard to reduce overdiagnosis of bipolar II disorder

1556. How to “sell” sleep restriction therapy to persons with insomnia

1557. How exactly to restrict in sleep restriction therapy

1558. How to manage a stimulant “crash” in the evening

1559. Many ways to add up to 15 hours

1560. Lisdexamfetamine (Vyvanse®) for binge-eating disorder

1561. 365 Advanced Topics in Psychopharmacology (Quiz no. 42)

1562. Pros and cons of short-acting preparations of psychostimulants

1563. Expert commentary: Lamotrigine monotherapy for bipolar I disorder?

1564. Why depression in persons with Parkinson’s disease is important

1565. Tips on diagnosing depression in persons with Parkinson’s disease

1566. How to treat depression in persons with Parkinson’s disease. Part one

1567. How to treat depression in persons with Parkinson’s disease. Part two

1568. How to treat depression in persons with Parkinson’s disease. Part three

1569. How long before sexual activity should PDE-5 inhibitors be taken?

1570. Can antidepressants cause urinary incontinence?

1571. Antidepressant-induced urinary incontinence: Clinical features and management

1572. L-methylfolate can sometimes precipitate irritability, agitation, insomnia, or aggressiveness

1573. Key facts about increased blood pressure on venlafaxine

1574. Could extended-release naltrexone injection work even if oral naltrexone did not?

1575. Abstinence from alcohol can be monitored by a urine screening test

1576. Recent alcohol use can be detected by a urine screening and confirmation test

1577. Is urine screening for alcohol metabolites really useful?

1578. Special situations in which urine screening for alcohol metabolites is particularly useful

1579. A strategy for patients who decline every medication option

1580. A strategy for patients who decline every medication option (Part two)

1581. Medication-induced priapism of the clitoris

1582. Management of medication-induced priapism of the clitoris

1583. Can beta-blockers cause depression or is this a myth?

1584. Bottom line on beta-blockers and depression

1585. Watch out for cholinergic rebound syndrome

1586. Cholinergic rebound syndrome: Clinical features and prevention

1587. Anticholinergic to prevent or treat cholinergic rebound

1588. Lithium-induced hair loss

1589. Answers to two key questions about lithium-induced hair loss

1590. How to evaluate suspected medication-induced hair loss

1591. What can be done about lithium-induced hair loss?

1592. It is important to review what we have learned! (Quiz no. 43)

1593. Is it risky to stop lithium abruptly or rapidly?

1594. Let’s not stop lithium abruptly or rapidly

1595. Excessive daytime sleepiness after remission of major depression

1596. Understanding the diagnostic criteria for autism spectrum disorder

1597. Deficits in social communication and social interaction

1598. Restricted, repetitive patterns of behavior, interests, or activities in autism spectrum disorder

1599. Tips on diagnosing autism spectrum disorder

1600. What is NOT autism spectrum disorder

1601. With or Without? Two big factors in autism spectrum disorder

1602. Does medication-induced hyponatremia change lithium blood levels?

1603. How can duloxetine can be tapered very slowly? Part 1

1604. How can duloxetine can be tapered very slowly? Part 2

1605. How can duloxetine can be tapered very slowly? Part 3

1606. What if a patient on naltrexone is in acute pain? Part 1

1607. What if a patient on naltrexone is in acute pain? Part 2

1608. What if a patient on naltrexone is in acute pain? Part 3

1609. Why is it important to check clozapine levels?

1610. Exactly when to check clozapine levels

1611. What clozapine levels should we aim for?

1612. What clozapine levels should we aim for? Part 2

1613. No to two creative ideas from our Members

1614. Can aripiprazole *worsen* psychosis?

1615. When is aripiprazole more likely to cause worsening of psychosis?

1616. More on possible worsening of psychosis after adding or switching to aripiprazole

1617. Factors to consider in switching from one antidepressant to another. Part 1

1618. Factors to consider in switching from one antidepressant to another. Part 2

1619. Factors to consider in switching from one antidepressant to another. Part 3

1620. Factors to consider in switching from one antidepressant to another. Part 4

1621. Switching antidepressants: Lessons from a difficult case. Part 1

1622. Switching antidepressants: Lessons from a difficult case. Part 2

1623. Switching antidepressants: Lessons from a difficult case. Part 3

1624. Switching antidepressants: Lessons from a difficult case. Part 4

1625. Three quick questions to review some of what we have learned (Quiz no. 44)

1626. Why we should more often consider splitting tablets

1627. When it is or isn’t OK to split tablets

1628. When it is or isn’t OK to split tablets. Part 2

1629. Tips on how to correctly split tablets and take them

1630. Can a dopamine agonist (pramipexole, ropinirole) and a stimulant be combined? Part 1

1631. Can a dopamine agonist (pramipexole, ropinirole) and a stimulant be combined? Part 2

1632. Is brain imaging useful in catatonia?

1633. Functional brain imaging in catatonia and the bottom line

1634. Are stimulants useful after traumatic brain injury?

1635. Tips on using stimulants for post-TBI deficits

1636. Isn’t it risky to prescribe a stimulant after TBI?

1637. Does any atypical antipsychotic have a lower risk of tardive dyskinesia?

1638. Lower risk of TD with quetiapine?

1639. What chronic fatigue syndrome is and what it is not

1640. Chronic fatigue syndrome: A lot more than just fatigue

1641. Diagnostic criteria for chronic fatigue syndrome/ myalgic encephalomyelitis

1642. ME/ CFS is a very serious illness!

1643. General approach to the treatment of ME/ CFS

1644. Stimulants/ wakefulness-promoting agents for ME/ CFS?

1645. Other medications often used in ME/ CFS

1646. ME/ CFS: Understanding their illness and “Activity Pacing”

1647. GET and CBT for ME/ CFS?

1648. Instructions for WHEN and HOW to take iron supplements. Part 1

1649. Instructions for WHEN and HOW to take iron supplements. Part 2

1650. Clinicians are “uninformed, misinformed, and misinforming patients” about gun laws

1651. Federal law about when firearms cannot be sold to someone with mental illness

1652. How involuntary psychiatric hospitalization affects gun ownership

1653. State laws regarding mental illness and gun rights

1654. “Relief from firearm disability”: How patients can get their gun rights back

1655. Answer 3 quick questions to reinforce your learning! (Quiz no. 45)

1656. What type of suicidal ideation does this patient have?

1657. “Pre-suicidal” and “Passive suicidal” ideation

1658. Three factors to look for in evaluating active suicidal ideation

1659. Dissecting active suicidal ideation into categories

1660. Some medications have a low “therapeutic index”. What’ exactly is that?

1661. More on the therapeutic index and window

1662. Some important points about lithium toxicity

1663. Tips that will help reduce errors related to lithium toxicity

1664. Three simple principles about ECG changes in lithium toxicity

1665. Risks of second-generation (atypical) antipsychotics in pregnancy

1666. Do atypical antipsychotics increase the risk of congenital malformations? Part 1

1667. Conclusions about whether atypical antipsychotics increase the risk of congenital malformations

1668. Gestational diabetes: Do atypical antipsychotics increase the risk? Part 1

1669. Gestational diabetes: Do atypical antipsychotics increase the risk? Part 2

1670. Atypical antipsychotics and various other pregnancy outcomes

1671. Clinical recommendations regarding using antipsychotics during pregnancy. Part 1

1672. Clinical recommendations regarding using antipsychotics during pregnancy. Part 2

1673. Bupropion with a history of seizures in early childhood? Part 1

1674. Bupropion with a history of seizures in early childhood? Part 2

1675. Skin rash on a SSRI can sometimes be serious

1676. SSRI-induced rash that we are more likely to see

1677. Treatment options for SSRI-induced rash

1678. Which preparation of lithium is less likely to harm the kidneys? Part 1

1679. Which preparation of lithium is less likely to harm the kidneys? Part 2

1680. Who’s job is it to check for drug interactions?

1681. Watch out for this new class of diabetes medications!

1682. Anticholinergic medication for antidepressant discontinuation syndrome?

1683. What to do about the risk of arrhythmias with lamotrigine. Part 1

1684. What to do about the risk of arrhythmias with lamotrigine. Part 2

1685. What to do about the risk of arrhythmias with lamotrigine. Part 3

1686. What to do about the risk of arrhythmias with lamotrigine. Part 4

1687. Recommend this medication reminder app to ALL your patients!

1688. Some cool and useful options in the Medisafe app

1689. A few more cool, helpful features in Medisafe

1690. Why we sometimes specifically order a “CBC with differential”

1691. A primer on the Absolute Neutrophil Count (ANC)

1692. Why don’t we routinely prescribe lamotrigine extended-release (Lamictal XR)?

1693. Acute effects of cannabis that we should warn patients about

1694. Potential physical and psychological adverse effects of longer-term cannabis use

1695. What to look for to identify a higher risk of problems with cannabis use

1696. Which medications work for cannabis use disorder? Part 1

1697. Which medications work for cannabis use disorder? Part 2

1698. Does gabapentin work for cannabis use disorder?

1699. Downsides of considering gabapentin for cannabis use disorder

1700. Cannabinoid receptor agonists for cannabis use disorder?

1701. Medications that MAY work for cannabis use disorder

1702. Medications for cannabis use disorder: Bottom line and Clinical recommendations

1703. True or False? (Quiz no. 46)

1704. The FDA versus NAC

1705. Where can patients still get N-acetylcysteine (NAC)?

1706. How to recognize caffeine withdrawal in our patients

1707. Some tips on understanding caffeine withdrawal

1708. How to prevent and treat caffeine withdrawal

1709. Key facts about ADHD and cannabis use (and their practical implications)

1710. Clinical recommendations for ADHD with cannabis use

1711. Two possible mistakes we may make in treating ADHD with cannabis use

1712. We MUST address the problems for which persons with ADHD use cannabis

1713. How is beta-thalassemia minor relevant to mental health clinicians?

1714. How beta-thalassemia minor affects the complete blood count

1715. How to manage patients with increased bruising on a serotonin reuptake inhibitor

1716. “Telewear”: What to wear when seeing patients virtually

1717. Telehealth: What’s your background?

1718. Managing antidepressant-induced mania or hypomania. Part 1

1719. Managing antidepressant-induced mania or hypomania. Part 2

1720. Managing antidepressant-induced mania or hypomania. Part 3

1721. In antipsychotic-induced hyperprolactinemia, systematically look for potential harms

1722. In males with hyperprolactinemia, ask about these potential harms

1723. In females with hyperprolactinemia, ask about these potential harms

1724. When do we say that amenorrhea or oligomenorrhea are present?

1725. Antidepressant-induced excessive sweating is common and bothersome

1726. Antidepressant-induced sweating is not like other sweating

1727. Management of antidepressant-induced excessive sweating (ADIES). Part 1

1728. Management of antidepressant-induced excessive sweating (ADIES). Part 2

1729. Glycopyrrolate: Management of antidepressant-induced excessive sweating (ADIES). Part 3

1730. Potential side effects of glycopyrrolate

1731. Terazosin for antidepressant-induced excessive sweating (ADIES)

1732. Other potential treatment options for ADIES?

1733. More on the management of antidepressant-induced excessive sweating (Part 7)

1734. How to time lisdexamfetamine (Vyvanse®) for maximum effect

1735. Important warning regarding gabapentin and pregabalin in renal failure

1736. How to use gabapentin and pregabalin in renal impairment and hemodialysis

1737. The terms “blunted affect” and “flat affect” are often used inappropriately

1738. How to identify blunted or flat affect

1739. Not only schizophrenia: Blunted or flat affect can occur in many different conditions

1740. Standard urine drug screens can be false-negative for some benzodiazepines

1741. Clinical recommendations regarding urine testing for benzodiazepines

1742. The FDA has published a “Table of Pharmacogenetic Associations”

1743. The most important list from the FDA’s “Table of Pharmacogenetic Associations”

1744. The other 3 lists based on the FDA’s “Table of Pharmacogenetic Associations”

1745. What the FDA says about HLA gene alleles and the risk of serious skin reactions

1746. Clinical recommendations about HLA testing and carbamazepine/ oxcarbazepine

1747. Digesting this question about pharmacogenetics from a Member can be a good learning exercise

1748. Do 5-HTTLPR polymorphisms predict the risk of antidepressant-induced mania/ hypomania?

1749. How to convert from oral to long-acting injectable (LAI) aripiprazole. Part 1

1750. How to convert from oral to long-acting injectable (LAI) aripiprazole. Part 2

1751. How to convert from oral to long-acting injectable (LAI) aripiprazole. Part 3

1752. What symptoms might suggest topiramate-induced metabolic acidosis?

1753. Watch out for these risk factors and longer-term risks of topiramate-induced metabolic acidosis

1754. Should benzodiazepines ALWAYS be avoided in older adults?

1755. Practical strategies for reducing the risks of benzodiazepines

1756. How common are CYP2D6 poor metabolizers in different racial/ ethnic groups?

1757. Which psychiatric medications are leading causes of falls in older adults?

1758. To reduce falls in the elderly, look for these THREE side effects of their medications

1759. Many different medications have anticholinergic activity and can increase the risk of falls

1760. Watch out for medications that can increase the risk of falls by causing hypotension

1761. Which antidepressants increase the risk of falls in the elderly?

1762. Some antipsychotics, other medications, and polypharmacy increase the risk of falls in the elderly

1763. Can ECT be stopped after the catatonia has resolved?

1764. Continuation ECT after catatonia has resolved?

1765. Longer-term (maintenance) ECT for catatonia?

1766. Tips on correctly diagnosing mixed features. Part one

1767. Tips on correctly diagnosing mixed features. Part two

1768. Tips on correctly diagnosing mixed features. Part three

1769. True or False? (Quiz no. 47)

1770. What to do about antidepressants in bipolar disorder episodes with mixed features

1771. Should we prefer divalproex over lithium for acute mania with mixed features?

1772. Second-generation antipsychotics for bipolar disorder episodes with mixed features?

1773. Other options for bipolar disorder episodes with mixed features?

1774. Clinical recommendations for bipolar disorder episodes with mixed features

1775. Some psychotropic medications can cause testicular pain

1776. Think twice before adding topiramate to valproate

1777. If valproate and topiramate are used together

1778. Are you evaluating and treating tobacco use disorder in your patients?

1779. Quick, high-yield questions to ask of patients who use tobacco

1780. A simple questionnaire to help guide tobacco cessation treatment

1781. How to score and interpret the Fagerström Test for Nicotine Dependence

1782. Instructions for and troubleshooting the Fagerström Test for Nicotine Dependence

1783. Overview of treatment options for tobacco use disorder

1784. Two key things to improve the outcomes of tobacco cessation treatment

1785. Helpful motivational messages for tobacco (smoking) cessation

1786. How to use varenicline (Chantix®) for tobacco cessation. Part 1

1787. How to use varenicline (Chantix®) for tobacco cessation. Part 2

1788. What are the common side effects that can occur with varenicline?

1789. How to choose a nicotine replacement product

1790. Tips on using nicotine replacement therapy (NRT) effectively

1791. Answers to some more questions about nicotine replacement therapy

1792. How exactly should nicotine patches be used?

1793. How exactly should nicotine gum be used?

1794. How exactly should nicotine lozenges be used?

1795. How exactly should nicotine oral inhalers be used?

1796. How exactly should nicotine nasal spray be used?

1797. How to dose valbenazine (Ingrezza®) for antipsychotic-induced tardive dyskinesia

1798. How to dose deutetrabenazine (Austedo®) for tardive dyskinesia

1799. Is bupropion a good choice in persons with heart disease? Part one

1800. Is bupropion a good choice in persons with heart disease? Part two

1801. True or False? (Quiz no. 48)

1802. How to recognize serotonin toxicity (syndrome)

1803. How to make the diagnosis of serotonin toxicity (syndrome)

1804. Can psychedelics cause serotonin toxicity (syndrome)?

1805. Warning! MDMA can cause serotonin toxicity

1806. How to distinguish between serotonin toxicity and NMS

1807. How is serotonin toxicity managed?

1808. How to know if our patients snore—even if they live alone

1809. How NOT to talk about suicide

1810. Consider a separate diagnosis of ADHD in children and adults with epilepsy

1811. Can we use methylphenidate if there is a history of seizures?

1812. Is vortioxetine a good choice for patients with heart disease?

1813. Is vilazodone safe in patients with heart disease?

1814. What to do about the risk of QT prolongation with methadone. Part one

1815. What to do about the risk of QT prolongation with methadone. Part two

1816. What to do about the risk of QT prolongation with methadone. Part three

1817. Is methylphenidate detected in urine drug screens?

1818. Does methylphenidate during pregnancy increase the risk of congenital malformations?

1819. Should we recommend wearable bright light therapy devices?

1820. Do wearable bright light therapy devices work?

1821. Which SPECIFIC wearable bright light therapy devices? Part one

1822. Which SPECIFIC wearable bright light therapy devices? Part two

1823. Which SPECIFIC wearable bright light therapy devices? Part three

1824. How to identify subclinical hypothyroidism

1825. Next steps after subclinical hypothyroidism is identified

1826. What risks of subclinical hypothyroidism should we look for?

1827. When does subclinical hypothyroidism need to be treated?

1828. We prescribe “off-label” more often than we think

1829. Do we have to disclose that a treatment is off-label?

1830. What should be in the informed consent for off-label use?

1831. In off-label prescribing, adding scientific articles or references may backfire!

1832. In whom can antidepressants increase the risk of suicidality?

1833. What can we do about suicidality associated with antidepressants? Part one

1834. What can we do about suicidality associated with antidepressants? Part two

1835. What can we do about suicidality associated with antidepressants? Part three

1836. Does ginger work for nausea?

1837. How to dose ginger to treat nausea

1838. Which ways of taking ginger are and are not OK?

1839. What are the potential side effects of ginger?

1840. Can bupropion cause hyponatremia? Part one

1841. Can bupropion cause hyponatremia? Part two

1842. Bupropion after hyponatremia due to serotonergic antidepressants?

1843. True or False? (Quiz no. 49)

1844. *Prophylactic* bromocriptine with risperidone?

1845. A resource for looking up hepatotoxicity with a medication, herb, or supplement

1846. Liver injury can occur with second-generation antipsychotics

1847. Increased liver enzymes: Stop antipsychotic? Rechallenge?

1848. What to do if liver injury occurs on an antipsychotic

1849. Basic tips about prior authorization for medications

1850. Advanced tips about prior authorization

1851. How much notice when “terminating” a patient?

1852. Termination letters need not be hurtful

1853. What a termination letter *should* include

1854. What the termination letter should *not* include

1855. Special issues in sending the termination letter

1856. “Informal” evaluation for involuntary movements is important and very useful

1857. “Masked” dyskinesia versus “withdrawal-emergent” dyskinesia

1858. How to do an AIMS examination via telepsychiatry

1859. Tips on diagnosing tardive dyskinesia

1860. How to ask about excessive daytime sleepiness

1861. What is causing the excessive daytime sleepiness?

1862. Use ICD-10 codes for side effects as well

1863. Why it is important to longitudinally chart serum creatinine and eGFR values

1864. Another way in which charting serum creatinine values can be helpful

1865. What is REM sleep behavior disorder?

1866. Don’t confuse REM sleep behavior disorder with these other conditions

1867. Why REM sleep behavior disorder is so important

1868. REM sleep behavior disorder is often an early manifestation of another serious disorder

1869. Screening and diagnosis of REM sleep behavior disorder

1870. Management of REM sleep behavior disorder. Part 1

1871. Management of REM sleep behavior disorder. Part 2

1872. Blue-light-blocking glasses for persons with bipolar disorder?

1873. Blue-light-blocking glasses for delayed sleep phase disorder?

1874. Which blue-light-blocking glasses to recommend. Part 1

1875. Which blue-light-blocking glasses to recommend. Part 2

1876. Which blue-light-blocking glasses to recommend. Part 3

1877. Is there such a thing as “depressed” affect?

1878. What are all the possible features that can indicate a depressed affect?

1879. What we do and do not know about lamotrigine rechallenge

1880. Should a lamotrigine rechallenge be tried in this patient?

1881. Reducing risk when rechallenging with lamotrigine. Part 1

1882. Reducing risk when rechallenging with lamotrigine. Part 2

1883. True or False? (Quiz no. 50)

1884. VMAT2 inhibitors can cause parkinsonism

1885. What do we know about parkinsonism induced by VMAT2 inhibitors?

1886. How should VMAT2-inhibitor-induced parkinsonism be managed?

1887. Why irritable bowel syndrome is important for us to know about

1888. Alarm features: It may not be irritable bowel syndrome

1889. How to diagnose irritable bowel syndrome

1890. A low FODMAP diet is recommended for irritable bowel syndrome

1891. How the low FODMAP diet is implemented

1892. Which prescription medications are used for irritable bowel syndrome?

1893. Please urge (almost) everyone to consume more soluble fiber

1894. Clinical recommendations about dietary fiber

1895. Does naltrexone alone work to produce weight loss?

1896. Can antidepressants impair sperm quality and male fertility? Part 1

1897. Can antidepressants impair sperm quality and male fertility? Part 2

1898. Mago’s rule no. 11

1899. Should we use droperidol, which is available again?

1900. How risky is droperidol really?

1901. Is droperidol more effective than other antipsychotics?

1902. What test should we order to screen for HIV?

1903. What tests should we order to screen for syphilis?

1904. How EXACTLY to screen for syphilis

1905. When do we need to worry about a low platelet count?

1906. How is samidorphan similar to and different from naltrexone? Part 1

1907. How is samidorphan similar to and different from naltrexone? Part 2

1908. Some antidepressants can reduce activation of important “prodrugs”

1909. Some antidepressants may increase the risk of recurrence of breast cancer

1910. Is the interaction between tamoxifen and some antidepressants a big deal?

1911. Which antidepressants to avoid if a woman is on tamoxifen

1912. Testing ourselves is important for effective learning! (Quiz no. 51)

1913. For those with excessive abdominal gas or bloating

1914. Diagnostic criteria for body dysmorphic disorder (BDD). Part 1

1915. Diagnostic criteria for body dysmorphic disorder (BDD). Part 2

1916. Why it is important to identify and treat body dysmorphic disorder (BDD)

1917. Are we misdiagnosing body dysmorphic disorder as something else?

1918. Tips on engaging patients with BDD in treatment

1919. Tips on treating antipsychotic-induced parkinsonism. Part 1

1920. Tips on treating antipsychotic-induced parkinsonism. Part 2

1921. For how long should anticholinergics be given (Part 1)

1922. For how long should anticholinergics be given (Part 2)

1923. Differences between the available anticholinergic medications (Part 1)

1924. Differences between the available anticholinergic medications (Part 2)

1925. What exactly is affective or mood instability?

1926. In persons reporting “mood swings”, consider these diagnoses

1927. Affective instability in borderline personality disorder

1928. Affective instability is different in bipolar disorder and borderline personality disorder (part 1)

1929. Affective instability is different in bipolar disorder and borderline personality disorder (part 2)

1930. Rapid, ultra-rapid, and ultra-ultra rapid cycling

1931. Mixed features are not the same as affective instability

1932. What exactly is affective or mood instability? Diagnostic recommendations in a patient with “mood swings” (part 1)

1933. Diagnostic recommendations in a patient with “mood swings” (part 2)

1934. Three key points about “psychodynamic psychopharmacology”

1935. Clinical recommendations regarding psychodynamic psychopharmacology

1936. Psychological factors in treatment resistance (part 1)

1937. Psychological factors in treatment resistance (part 2)

1938. Tips on reducing non-adherence to medications

1939. Use the patient’s relational style in prescribing medications

1940. Tell patients about another option: Half-caffeinated coffee

1941. Ready-made half-caffeinated coffee is widely available

1942. What to do about valproate in a patient on a ketogenic diet

1943. Possible problems with valproate plus a ketogenic diet

1944. Just 3 quick questions! (Quiz no. 52)

1945. What to do about contraception in women on carbamazepine or oxcarbazepine

1946. Rumination is a common and important (but neglected) symptom

1947. Why I say that rumination is an important symptom

1948. How is rumination different from an obsession?

1949. It is important to measure the amount of wine

1950. Do psychostimulant medications cause clinically-significant increases in blood pressure?

1951. Is THIS patient at higher risk of stimulant-induced hypertension?

1952. How exactly should blood pressure be monitored in persons on stimulants

1953. How long to peak plasma concentrations of different stimulant preparations?

1954. What level of blood pressure is unacceptable in patients on stimulants?

1955. How to manage stimulant-induced hypertension (part 1)

1956. How to manage stimulant-induced hypertension (part 2)

1957. How to manage stimulant-induced hypertension (part 3)

1958. Stimulant medications can sometimes cause somnolence or sedation

1959. More on somnolence caused by ADHD medications

1960. Conclusions and Clinical recommendations about stimulant-induced somnolence/ sedation

1961. Two case vignettes about neuropsychiatric consequences of traumatic brain injury

1962. When do we say a patient had a “traumatic brain injury (TBI)”?

1963. Some key facts about traumatic brain injury (TBI)

1964. Post-TBI neuropsychiatric syndromes and symptoms

1965. Looking at motor activity helps predict impending aggressive behavior

1966. Overview of strategies for agitation/aggressiveness

1967. Systemic measures to improve safety from agitation/aggressive behavior

1968. Before going to see an agitated/aggressive patient

1969. How to physically locate ourselves and a patient who is agitated/ aggressive

1970. Verbal de-escalation of agitation/ aggressiveness: What NOT to do (Part 1)

1971. Verbal de-escalation of agitation/ aggressiveness: What NOT to do (Part 2)

1972. Verbal de-escalation of agitation/ aggressiveness: What NOT to do (Part 3)

1973. Tips on the PROCESS of talking to an agitated/ aggressive patient

1974. What might help to verbally calm an angry patient down

1975. Verbal de-escalation: Three ways to agree with a patient

1976. Two tips for speaking to a patient who is making threats

1977. ICD-10-CM diagnostic codes to use when a diagnosis has not been made yet

1978. Why should mental health clinicians care about acne?

1979. Can lamotrigine cause acne?

1980. Clinical recommendations on lamotrigine and acne

1981. Pancreatitis for mental health clinicians

1982. Serum lipase is the key test, not serum amylase

1983. Can antidepressants cause pancreatitis?

1984. Don’t skip this quiz! (Quiz no. 53)

1985. Should we consider N-acetylcysteine (NAC) for OCD?

1986. Conclusions and Clinical recommendations on NAC for OCD

1987. Which SSRIs are more sedating or more activating? Part 1

1988. Which SSRIs are more sedating or more activating? Part 2

1989. Which SSRIs are more sedating or more activating? Part 3

1990. What exactly is emotional blunting/ flattening?

1991. Emotional blunting/ flattening can have *many* different causes

1992. Why emotional blunting/ flattening can be a big deal

1993. How to differentiate between emotional blunting/ flattening and depression

1994. Clinical recommendations for screening and evaluation of emotional blunting/ flattening

1995. How to manage antidepressant-induced emotional blunting/ flattening (Part 1)

1996. How to manage antidepressant-induced emotional blunting/ flattening (Part 2)

1997. Which antidepressants come in liquid forms?

1998. Why we must do better in diagnosing and treating depression in HIV/ AIDS

1999. Which antidepressants for persons with HIV/ AIDS?

2000. Consider psychostimulants and modafinil/ armodafinil in HIV/ AIDS

2001. How to match the patient with the right Z-drug

2002. Let’s explicitly identify patients with “treatment-resistant” schizophrenia

2003. PsychopharMYTH: “Vortioxetine does not cause sexual dysfunction”

2004. We should know about a drug interaction checker for HIV medications

2005. How exactly to use the HIV Drug Interaction checker

2006. Clinical case: Esomeprazole (Nexium®) for a patient on citalopram?

2007. Clinical case: A patient on escitalopram and daily ibuprofen

2008. Which antipsychotics are more likely to cause pancreatitis?

2009. What can we do about antipsychotic-related pancreatitis?

2010. Avoid these two SSRIs in patients with HIV/ AIDS (if possible)

2011. Poor man’s vortioxetine

2012. Why and how to monitor and evaluate for suicide risk after bariatric surgery

2013. Why, who, and how to monitor for increased alcohol use after bariatric surgery (Part 1)

2014. Why, who, and how to monitor for increased alcohol use after bariatric surgery (Part 2)

2015. True or False? (Quiz no. 54)

2016. Biotin can interfere with many laboratory tests—and lead to serious misdiagnosis

2017. Clinical recommendations regarding biotin interfering with many laboratory tests

2018. Details about what to expect from serotonin reuptake inhibitors in body dysmorphic disorder

2019. Which serotonin reuptake inhibitors for body dysmorphic disorder?

2020. How high do we need to go with serotonin reuptake inhibitors for body dysmorphic disorder?

2021. More on (off-label) using high doses of serotonin reuptake inhibitors

2022. How long should a serotonin reuptake inhibitor trial for body dysmorphic disorder be?

2023. What if a trial of a serotonin reuptake inhibitor doesn’t work for body dysmorphic disorder?

2024. Antipsychotic augmentation in body dysmorphic disorder

2025. What other (off-label) augmentation strategies could be tried in body dysmorphic disorder?

2026. Augmentation and switching in treating body dysmorphic disorder

2027. When prescribing an amphetamine, warn patients about anti-acid medications

2028. Clinical recommendations about amphetamines and anti-acid medications

2029. Why we must identify and assess cognitive symptoms in patients with POTS

2030. Diagnosing and treating cognitive impairments in postural tachycardia syndrome (POTS)

2031. In suicidal patients, avoid 90-day prescriptions of these medications

2032. Which psychiatric medications are particularly lethal in overdose?

2033. Clinical recommendations regarding lethality in overdose

2034. Methotrexate may be the cause of many psychiatric symptoms

2035. Watch for these neuropsychiatric side effects in patients on methotrexate

2036. Is lumateperone (Caplyta®) really different from other atypical antipsychotics? Part 1

2037. Is lumateperone (Caplyta®) really different from other atypical antipsychotics? Part 2

2038. Putting it all together: Why lumateperone is expected to have fewer motor side effects

2039. Is lumateperone really less likely to cause extrapyramidal symptoms?

2040. Is lumateperone (Caplyta®) weight-neutral? Part 1

2041. Is lumateperone (Caplyta®) weight-neutral? Part 2

2042. Why would lumateperone be weight-neutral? Does it make sense?

2043. Which antipsychotics have a low risk of increasing serum prolactin levels? Part 1

2044. Which antipsychotics have a low risk of increasing serum prolactin levels? Part 2

2045. Which antipsychotics have a low risk of increasing serum prolactin levels? Part 3

2046. Does lurasidone (Latuda®) really have a low risk of increasing serum prolactin?

2047. Does olanzapine (Zyprexa®) really have a low risk of increasing serum prolactin?

2048. Does ziprasidone (Geodon®) really have a low risk of increasing serum prolactin?

2049. Think of antipsychotics as having 4 levels of risk of hyperprolactinemia

2050. For effective learning, you *MUST* test yourself! (Quiz no. 55)

2051. Recommend xylitol-containing products to prevent dental cavities (caries)

2052. Essential instructions about how xylitol must be used

2053. Potential side effects of xylitol (and an important warning)

2054. XyliMelts® Dry Mouth delivers xylitol for several hours—even while sleeping

2055. Are the metabolic side effects of second-generation (atypical) antipsychotics dose-related?

2056. Does vitamin D supplementation increase the risk of kidney stones? Part 1

2057. Does vitamin D supplementation increase the risk of kidney stones? Part 2

2058. Does vitamin D supplementation increase the risk of kidney stones? Part 3

2059. Why clinicians are excited about semaglutide injection (Wegovy™)

2060. FDA indications for semaglutide injection (Wegovy™)

2061. A simple primer on what GLP-1 agonists are

2062. Overview of GLP-1 agonists (part 1)

2063. Overview of GLP-1 agonists (part 2)

2064. Won’t semaglutide cause hypoglycemia?

2065. Relatively common side effects of semaglutide injection (Wegovy™)

2066. What about the boxed warning about thyroid C-cell tumors with semaglutide injection (Wegovy™)?

2067. Ten “Warnings and Precautions” about semaglutide injection (Wegovy™): Part 1

2068. Ten “Warnings and Precautions” about semaglutide injection (Wegovy™): Part 2

2069. Why we MUST know about fentanyl and fentanyl analogs

2070. Special tests are needed to identify fentanyl in the urine

2071. Higher doses of naloxone are needed for opioid overdoses involving fentanyl

2072. More naloxone administrations are needed for overdoses involving fentanyl

2073. Special points about managing fentanyl opioid use disorder (part 1)

2074. Buprenorphine initiation might *precipitate* withdrawal symptoms in fentanyl users

2075. Option 1 for reducing the risk of buprenorphine precipitating opioid withdrawal

2076. Buprenorphine initiation by “microdosing” or “ultrarapid microdosing”

2077. Where can I find someone who prescribes clozapine?

2078. Are psychostimulant medications contraindicated in persons with PTSD? (Part 1)

2079. Are psychostimulant medications contraindicated in persons with PTSD? (Part 2)

2080. Are psychostimulant medications contraindicated in persons with PTSD?

2081. Why we must refer more patients for clozapine treatment (part 1)

2082. Why we must refer more patients for clozapine treatment (part 2)

2083. What can we do about the underutilization of clozapine and delays in starting it? Part 1

2084. What can we do about the underutilization of clozapine and delays in starting it? Part 2

2085. What can we do about the underutilization of clozapine and delays in starting it? Part 3

2086. How *NOT* to offer long-acting injectable (LAI) antipsychotics to patients

2087. Tips on how to more effectively offer LAI antipsychotics to patients

2088. Are the terms “obesity” and “morbid obesity” obsolete?

2089. What terminology would *patients* prefer for overweight or obese?

2090. How to approach overweight and obesity

2091. Speaking to *patients* about overweight and obesity

2092. “Simple and Practical” patient education about lithium (part 1)

2093. “Simple and Practical” patient education about lithium (part 2)

2094. “Simple and Practical” patient education about lithium (part 3)

2095. “Simple and Practical” patient education about lithium (part 4)

2096. “Simple and Practical” patient education about lithium (part 5)

2097. “Simple and Practical” patient education about lithium (part 6)

2098. Do not skip this very brief quiz! (Quiz no. 56)

2099. Does folate/ L-methylfolate supplementation DECREASE or INCREASE the risk of breast cancer? Part 1

2100. Does folate/ L-methylfolate DECREASE or INCREASE the risk of breast cancer? Part 2

2101. Does folate/ L-methylfolate DECREASE or INCREASE the risk of breast cancer? Part 3

2102. When should we order a FREE valproic acid level?

2103. Six situations in which we should order a FREE valproic acid level

2104. Are free valproic acid levels important in real-world clinical practice?

2105. What upper limit should we use for free valproic acid levels?

2106. Basic facts about biotin—and why we care

2107. Situations in which we should think of possible biotin deficiency

2108. What would cause a false positive for fentanyl on a urine drug screen?

2109. Fentanyl analogs and why they are so important

2110. Why fentanyl test strips are extremely important

2111. Exactly how to use fentanyl test strips (part 1)

2112. Exactly how to use fentanyl test strips (part 2)

2113. Does dextromethorphan-bupropion (Auvelity™) have abuse potential?

2114. Key facts about dextromethorphan abuse or dependence

2115. Clinical features of dextromethorphan intoxication, toxicity, and withdrawal

2116. “Dextromethorpion” for (non-treatment-resistant) major depressive disorder

2117. A key clinical trial of “dextromethorpion” (part 1)

2118. A key clinical trial of “dextromethorpion” (part 2)

2119. Early improvement: A key clinical trial of “dextromethorpion” (part 3)

2120. “Response”: A key clinical trial of “dextromethorpion” (part 4)

2121. “Remission”: A key clinical trial of “dextromethorpion” (part 5)

2122. 12 things to look for in a clinical trial

2123. What causes false positive elevated serum potassium (pseudohyperkalemia)?

2124. When should we suspect pseudohyperkalemia?

2125. Clinical case: Is hyperkalemia a contraindication to haloperidol? (Part 1)

2126. Clinical case: Is hyperkalemia a contraindication to haloperidol? (Part 2)

2127. Methamphetamine use: What, Who, How, and Why (part 1)

2128. Methamphetamine use: What, Who, How, and Why (part 2)

2129. This is what acute methamphetamine intoxication looks like

2130. Methamphetamine use can have very serious cardiovascular effects

2131. What harms can long-term use of methamphetamine cause?

2132. Three scenarios in which psychosis can occur in a methamphetamine user

2133. This is a more effective way to learn (Quiz no. 57)

2134. There are three different types of intermittent fasting

2135. Who should NOT do intermittent fasting?

2136. How well does intermittent fasting work for overweight and obesity?

2137. How exactly to do time-restricted eating (part 1)

2138. How exactly to do time-restricted eating (part 2)

2139. What side effects can occur with intermittent fasting?

2140. Where might intermittent fasting be particularly useful?

2141. Where might intermittent fasting be particularly useful?

2142. How to reduce lamotrigine when an inducer is stopped

2143. Should we recommend taking a multivitamin?

2144. Do’s and don’ts for taking a multivitamin

2145. Which vitamin supplements should we be cautious about recommending?

2146. What to do about methadone-related QTc prolongation

2147. Which serotonin reuptake inhibitors may be preferred with methadone?

2148. Clinical recommendations regarding methadone and serotonin reuptake inhibitors

2149. What next after antidepressant-induced hyponatremia? Part 1

2150. What next after antidepressant-induced hyponatremia? Part 2

2151. What next after antidepressant-induced hyponatremia? Part 3

2152. How exactly to do fluid restriction

2153. Antipsychotics and QT prolongation: Which ones have lower risk?

2154. When to get an ECG when prescribing an antipsychotic

2155. Can a psychedelic be taken along with lithium?

2156. How exactly to use topical minoxidil foam

2157. How can vortioxetine-induced nausea be treated? Part 1

2158. How can vortioxetine-induced nausea be treated? Part 2

2159. Considerable beneficial effects are reported by psilocybin users

2160. What side effects can occur with psilocybin

2161. Is psilocybin addictive?

2162. Can psilocybin lead to suicide or other self-harm?

2163. Can psilocybin lead to suicide or other self-harm: Part 2?

2164. What is Hallucinogen Persisting Perception Disorder? Part 1 

2165. What is Hallucinogen Persisting Perception Disorder? Part 2 

2166. Clinical recommendations for hallucinogen persisting perception disorder

2167. Can you give me just one minute of your time? (Quiz no. 58)

2168. What is the orexin system and why is it so important? Part 1

2169. What is the orexin system and why is it so important? Part 2

2170. DORAs: FDA-indications and efficacy

2171. Potential side effects of dual orexin receptor antagonists (DORAs). Part 1

2172. Potential side effects of dual orexin receptor antagonists (DORAs). Part 2

2173. Potential side effects of dual orexin receptor antagonists (DORAs). Part 3

2174. Do DORAs have a low risk of abuse or dependence?

2175. Are dual orexin receptor antagonists (DORAs) safe in obstructive sleep apnea?

2176. Why mental health clinicians should care about dry eyes

2177. How to evaluate and manage dry eyes due to psychiatric medications

2178. Which type of artificial tears for persons with dry eyes?

2179. Omega-3 fatty acids for dry eyes?

2180. Does N-acetylcysteine (NAC) work for autism spectrum disorder?

2181. Why OROS tablets are such a big deal

2182. Which generics of Concerta® (methylphenidate extended-release) to recommend

2183. Do stimulant medications increase the risk of congenital malformations? Part 1

2184. Do stimulant medications increase the risk of congenital malformations? Part 2

2185. Clinical recommendations: Stimulant medications and the risk of congenital malformations (Part 1)

2186. Clinical recommendations: Stimulant medications and the risk of congenital malformations (Part 2)

2187. In suspected kidney disease, check the urine albumin-creatinine ratio

2188. Interpretation and importance of the urine albumin-creatinine ratio

2189. Tips on getting people off sleep pills (Part 1)

2190. Tips on getting people off sleep pills (Part 2)

2191. “Dizziness”: First, which of these 3 is it?

2192. Presyncope, vertigo, or disequilibrium? What to ask and look for

2193. How to approach a patient with vertigo

2194. Tips on evaluating and managing driving safety in the elderly

2195. Tips on evaluating driving safety in the elderly

2196. Advice to elderly drivers for improving driving safety

2197. Recommend these resources to elderly drivers

2198. Testing ourselves is one of the most effective ways of learning (Quiz no. 59)

2199. What tests should we order if Wilson disease is suspected? Part 1

2200. What tests should we order if Wilson disease is suspected? Part 2

2201. Can divalproex (Depakote ER®) affect sperm or cause infertility?

2202. Important! Will valproate’s effects on sperm go away if it is stopped?

2203. Should we routinely prescribe an anticholinergic with an antipsychotic?

2204. After a few months, try to reduce/ stop anticholinergic medication

2205. Urine ethyl glucuronide (EtG): An important test for recent alcohol use

2206. Tips on using serum gamma-glutamyl transferase (GGT) for alcohol use

2207. Measuring carbohydrate-deficient transferrin (CDT) to identify heavy alcohol use (part 1)

2208. Measuring carbohydrate-deficient transferrin (CDT) to identify heavy alcohol use (part 2)

2209. Which topical antiperspirants when something strong is needed?

2210. Specific antiperspirants with *maximum* strength aluminum zirconium

2211. Specific antiperspirants with *maximum* strength aluminum sesquichlorohydrate

2212. Specific antiperspirants with aluminum chloride, the strongest active ingredient

2213. Little-known but important instructions for correctly using a topical antiperspirant

2214. Are YOU liable if the patient doesn’t get essential blood tests done?

2215. Here’s what we could do if a patient refuses to get essential laboratory tests

2216. What are non-REM (NREM) sleep arousal disorders?

2217. Sleepwalking: Common and more than just walking

2218. Sleepwalking: how do we know that they’re asleep?

2219. Practical tips on the evaluation of sleepwalking

2220. Safety measures to recommend to patients with sleepwalking

2221. Practical tips on the management of sleepwalking

2222. Getting off a benzodiazepine: Factors affecting the rate of taper

2223. At what rate should we taper benzodiazepines taken at usual therapeutic doses?

2224. Rate of taper if on a very high dose and for a long time

2225. How to find a detoxification (detox) center

2226. Which nutritional supplement for weight loss and loss of appetite?

2227. Other nutritional supplements for weight loss and loss of appetite

2228. Useful, new resource: Prescriber’s guide to classic MAO inhibitors for treatment-resistant depression

2229. “Treatment-resistant” depression: Can a classic MAO inhibitor be safely augmented with an antipsychotic?

2230. NEVER prescribe any of these medications with a classic MAO inhibitor

2231. Can you not spare 2 minutes? (Quiz no. 60)

2232. A checklist for history-taking in eating disorders

2233. What to look for in the physical examination of patients with eating disorders (Part 1)

2234. What to look for in the physical examination of patients with eating disorders (Part 2)

2235. Which laboratory tests for which patients with eating disorders?

2236. How to reduce serious damage to the teeth from repeated vomiting (Part 1)

2237. How to reduce serious damage to the teeth from repeated vomiting (Part 2)

2238. What negative symptoms are and why they are important

2239. Specifically look for negative symptoms in patients with psychotic disorders

2240. It is important to identify *secondary* negative symptoms

2241. Treatment options for negative symptoms of schizophrenia

2242. Is cariprazine (Vraylar®) more effective than other antipsychotics for primary negative symptoms of schizophrenia?

2243. When to consider clozapine in a patient with significant negative symptoms

2244. More treatment options for primary negative symptoms of schizophrenia

2245. Why we need to specify which urine drug screen (UDS) panel we want done

2246. A specific example of a urine drug screen (UDS) for general psychiatric use

2247. Discuss risky driving behaviors with patients who have ADHD

2248. Tips on improving driving safety in persons with ADHD (part 1)

2249. Tips on improving driving safety in persons with ADHD (part 2)

2250. Tips on differentiating between antipsychotic-induced parkinsonism and Parkinson’s disease

2251. Is bupropion sustained-release OK to use after bariatric surgery?

2252. Specific guidance on prescribing bupropion after bariatric surgery

2253. What are the medication options for treating binge-eating disorder? (Part 1)

2254. What are the medication options for treating binge-eating disorder? (Part 2)

2255. What are the medication options for treating binge-eating disorder? (Part 3)

2256. Which second-generation antipsychotics have a lower or higher risk of causing akathisia? (Part 1)

2257. Which second-generation antipsychotics have a lower or higher risk of causing akathisia? (Part 2)

2258. What to do if we lose a patient to suicide (Part 1)

2259. What to do if we lose a patient to suicide (Part 2)

2260. Resources for support after a patient suicide

2261. Managing malpractice risks after a patient suicide (Part 1)

2262. Managing malpractice risks after a patient suicide (Part 2)

2263. Tips on going on after a patient suicide

2264. How to protect sensitive patient information from being disclosed (Part 1)

2265. How to protect sensitive patient information from being disclosed (Part 2)

2266. Testing ourselves is one the most effective ways of learning! (Quiz no. 61)

2267. Recommend these specific pill cutters

2268. Should we continue or stop antidepressant medications during ECT?

2269. Tips on what to do about benzodiazepines if ECT is needed

2270. What to do about anticonvulsants in a patient who is starting ECT

2271. Should lithium be stopped before ECT is given?

2272. Can generic dextromethorphan and bupropion be used instead of the brand name combination? (Part 1)

2273. Can generic dextromethorphan and bupropion be used instead of the brand name combination? (Part 2)

2274. Do you advise patients to consume more high-protein foods?

2275. How exactly to increase dietary protein intake (Part 1)

2276. How to increase protein intake *without* increasing calories

2277. We need tips on evaluating the risk of suicide in the near future

2278. What to ask about a suicide attempt

2279. More on what is particularly important to ask during suicide risk assessment

2280. A way of thinking about risk/ protective factors during suicide risk assessment

2281. Why we must recognize and treat sleep disorders during pregnancy

2282. Is it safe to recommend an antihistamine for insomnia during pregnancy? (Part 1)

2283. Is it safe to recommend an antihistamine for insomnia during pregnancy? (Part 2)

2284. Are the Z-drugs (zolpidem and others) safe to take during pregnancy?

2285. Conclusions about the potential risks of benzodiazepines during pregnancy (Part 1)

2286. Conclusions about the potential risks of benzodiazepines during pregnancy (Part 2)

2287. What is ashwagandha used for?

2288. Should we recommend ashwagandha for anxiety disorders or anxiety symptoms?

2289. What side effects (common or serious) can occur with ashwagandha?

2290. Should we recommend Costplusdrugs.com for lowering the cost of medications?

2291. Are prices on Costplusdrugs.com lower than on Goodrx.com?

2292. How exactly does Costplusdrugs.com work?

2293. E-prescribing has so many advantages!

2294. Great optional benefits that some e-prescribing platforms provide

2295. If serum lithium levels vary unexpectedly, consider these possible causes

2296. How are hypnagogic/hypnopompic “hallucinations” different?

2297. What causes should we consider for hypnagogic/ hypnogogic “hallucinations”?

2298. Are these 3 statements True or False? (Quiz no. 62)

2299. What exactly is sleep paralysis?

2300. Why it is important for us to look out for sleep paralysis

2301. How and why is bupropion sometimes used to “get high”?

2302. Why use bupropion to get high (and why that’s not a good idea)?

2303. Clinical recommendations regarding bupropion being used to “get high”

2304. We must identify ADHD in persons with substance use disorders

2305. Can stimulant medications be used along with buprenorphine or methadone? (Part 1)

2306. Can stimulant medications be used along with buprenorphine or methadone? (Part 2)

2307. Tips on how to treat ADHD in persons with substance use disorders

2308. Should we be checking testosterone levels in older men?

2309. Should we check testosterone levels in men with “treatment-resistant” depression?

2310. What can we do about the shortage of stimulant medications? Part one

2311. What can we do about the shortage of stimulant medications? Part two

2312. What can we do about the shortage of stimulant medications? Part three

2313. Can patchy hair loss be due to an antidepressant?

2314. Does any antidepressant have a lower or higher risk of causing hair loss?

2315. What blood pressure target for patients with hypertension? Part 1

2316. What blood pressure target for patients with hypertension? Part 2

2317. Beware of fake papers!

2318. For medications that must be taken “with food,” how recent does the eating have to be?

2319. How much better is olanzapine-samidorphan (Lybalvi®) than olanzapine alone? Part 1

2320. How much better is olanzapine-samidorphan (Lybalvi®) than olanzapine alone? Part 2

2321. How much better is olanzapine-samidorphan (Lybalvi®) than olanzapine alone? Part 3

2322. How much better is olanzapine-samidorphan (Lybalvi®) than olanzapine alone? Part 4

2323. What nutritional deficiencies can occur with a vegetarian or vegan diet?

2324. All vegans and many vegetarians should take vitamin B12 in a supplement

2325. Iron, zinc, and calcium supplementation for vegetarians and vegans?

2326. Is methylphenidate safe to take during lactation (breastfeeding)?

2327.  Conclusions and clinical recommendations regarding methylphenidate and breastfeeding

2328. We should know what viloxazine extended-release (Qelbree®) is

2329. Should we prescribe viloxazine extended-release (Qelbree®)?

2330. Many patients are on low-dose TCAs. Can other antidepressants be added? (Part 1)

2331. Many patients are on low-dose TCAs. Can other antidepressants be added? (Part 2)

2332. Many patients are on low-dose TCAs. Can other antidepressants be added? (Part 3)

2333. Many patients are on low-dose TCAs. Can other antidepressants be added? (Part 4)

2334. Why we should routinely ask and counsel patients about driving after cannabis use

2335. What exactly to ask and tell about THC-containing cannabis and driving

2336. What to do about excessive sweating in this patient with OCD (Part 1)

2337. What to do about excessive sweating in this patient with OCD (Part 2)

2338. Possible risks of using lurasidone (Latuda®) during pregnancy (Part 1)

2339. Possible risks of using lurasidone (Latuda®) during pregnancy (Part 2)

2340. Refer every pregnant patient with a mental disorder to this pregnancy registry

2341. Do we need to worry about stimulant medications as our patients become older adults?

2342. Clinical recommendations: What to do about stimulant medications in older adults

2343. Can stimulant and antipsychotic medications be used together?

2344. Won’t antipsychotic and stimulant medications oppose each other’s effects?

2345. Three quick questions to answer in just 60 seconds! (Quiz no. 63)

2346. What should we recommend about lamotrigine and breastfeeding?

2347. Clinical recommendations about lamotrigine and breastfeeding

2348. Lamotrigine dose usually needs to be changed during AND after pregnancy

2349. Clinical recommendations on changing lamotrigine dose during and after pregnancy

2350. How to store medications to protect them from temperature, humidity, air, and light (Part 1)

2351. How to store medications to protect them from temperature, humidity, air, and light (Part 2)

2352. Questions that can help in diagnosing akathisia

2353. Do you ask patients on naltrexone to wear a medical alert and carry a medical card?

2354. What information should the wallet/ pocket card for naltrexone provide?

2355. Where to get a medical alert bracelet and wallet/pocket card for naltrexone

2356. Tell patients why they should follow a Mediterranean diet (MedDiet)

2357. Mediterranean diet (MedDiet): A “Simple and Practical” guide

2358. Essential details for following the Mediterranean diet (MedDiet)

2359. Give patients these additional reasons to follow MedDiet

2360. We need to separate out questions about whether to combine two antipsychotics

2361. Should we *ADD* another second-generation antipsychotic?

2362. When is it appropriate to combine two antipsychotics?

2363. When is an oral antipsychotic needed ALONG WITH a long-acting injectable (LAI) antipsychotic?

2364. How to differentiate substance/medication-induced bipolar disorder from bipolar I or II disorder

2365. A Member’s case of substance/medication-induced bipolar disorder

2366. Which medications can cause manic symptoms?

2367. Does coenzyme Q10 (CoQ10) interact with psychiatric medications?

2368. Medication, CBT, or combination treatment for OCD? (Part 1)

2369. Medication, CBT, or combination treatment for OCD? (Part 2)

2370. Which causes more weight gain—venlafaxine or duloxetine?

2371. Clinical recommendations: Switch between duloxetine and venlafaxine due to weight gain?

2372. Does naltrexone cause insomnia OR does it cause sleepiness?

2373. Recommendations about what to tell patients about naltrexone and sleep problems

2374. Recommend these books to caregivers of persons with dementia

2375. Do we need to specifically tell persons with alcoholism to avoid drinking kombucha?

2376. Let’s be clear about these fundamental concepts about catatonia

2377. What’s the difference between “catalepsy”, “waxy flexibility”, and “posturing”?

2378. What’s the difference between “mannerisms”, “stereotypies”, and “perseveration”?

2379. Commonly misunderstood terms: “Stupor”, “mutism”, and “agitation” in catatonia

2380. How to examine for and correctly identify negativism

2381. Echo phenomena (echolalia, echopraxia) in catatonia

2382. How to systematically examine patients for catatonia (Part 1)

2383. How to systematically examine patients for catatonia (Part 2)

2384. Why we should learn about nicotine vaping addiction

2385. Should we prescribe the same medications for cessation of nicotine vaping as for smoking cessation?

2386. How often does each contraceptive method fail?

2387. Clinical recommendations on guiding patients regarding contraception effectiveness

2388. What to do in patients who had only a single episode of mania

2389. What to ask about a breastfed newborn whose mother is taking an SSRI

2390. Are you recommending this to all your patients with insomnia?

2391. Relaxation practice: Who benefits most and who may be harmed?

2392. Instructions for Relaxation practice (Part 1)

2393. Instructions for Relaxation practice (Part 2)

2394. 3-minute quiz to strengthen your learning (Quiz no. 64)

2395. Common mistakes in planning cognitive testing in outpatients

2396. Avoid these common mistakes regarding family members and cognitive testing

2397. Avoid these mistakes when STARTING cognitive testing

2398. Avoid making these mistakes when the patient makes mistakes

2399. Advanced tips on the most important single test for evaluating cognitive functioning

2400. Tips on choosing our words wisely (for the immediate and delayed recall test)

2401. Tips on carrying out the immediate and delayed recall test

2402. Next steps if the delayed recall test is not conclusive

2403. Final steps for when providing a hint does or does not work

2404. In what situations do we oppose OR may consider nicotine-containing e-cigarettes/ vape pens?

2405. Are nicotine-containing e-cigarettes/ vape pens safer than tobacco cigarettes?

2406. Watch out for these mistakes in interpreting what is said about e-cigarettes

2407. Conclusions about whether nicotine-containing e-cigarettes/ vape pens safer than tobacco cigarettes

2408. Should we consider ORAL ketamine for clinical depression/ suicidality?

2409. Should we ever prescribe methamphetamine (Desoxyn®)?

2410. Can zolpidem be used by a woman who is breastfeeding her baby? (Part 1)

2411. Can zolpidem be used by a woman who is breastfeeding her baby? (Part 2)

2412. Non-medication interventions that we should recommend for constipation (Part 1)

2413. Non-medication interventions that we should recommend for constipation (Part 2)

2414. Non-medication interventions that we should recommend for constipation (Part 3)

2415. How to choose and use a fiber supplement

2416. Polyethylene glycol (PEG 3350; MiraLAX®)

2417. Patient instructions for the next step over-the-counter treatment for constipation — a stimulant laxative

2418. Check for these “alarm” symptoms/ signs in patients with constipation

2419. Don’t recommend docusate (Colace®) for constipation

2420. Clinical case: Recurrence of depression after abruptly stopping phentermine (Part 1)

2421. Clinical case: Recurrence of depression after abruptly stopping phentermine (Part 2)

2422. What could be causing prominent shakiness and tremors in this patient?

2423. Valproate toxicity despite a valproic acid level in the usual therapeutic range

2424. Clinical recommendations regarding checking free valproic acid levels

2425. Take just one minute to answer True or False (Quiz no. 65)

2426. The lipid panel measures 3 things and calculates 2 more

2427. When should we order a lipid panel (and why not just check serum total cholesterol first)?

2428. How exactly to order the lipid panel

2429. Check for these causes if triglycerides are high

2430. For moderate hypertriglyceridemia, implement lifestyle interventions

2431. Recommend these lifestyle interventions for moderately elevated triglycerides

2432. Tips for interviewing patients with dementia

2433. Change lamotrigine dose in transgender women starting hormonal therapy?

2434. We should guide patients toward “healthier eating”

2435. Healthier eating at lower cost: Where to shop and What kinds of food items?

2436. Warn patients about these potential problems with canned food

2437. Suggest these specific healthier but affordable food items

2438. Should we look at serum FREE testosterone or TOTAL testosterone?

2439. Exactly which test should we order to measure free testosterone? (Part 1)

2440. Exactly which test should we order to measure free testosterone? (Part 2)

2441. Important instructions before checking serum testosterone

2442. What is “easy” bruising and what could be causing it?

2443. Why we need to know about von Willebrand disease

2444. You probably have patients with undiagnosed von Willebrand disease

2445. When to suspect von Willebrand disease

2446. A patient with antidepressant-associated bruising and von Willebrand disease (Part 1)

2447. A patient with antidepressant-associated bruising and von Willebrand disease (Part 2)

2448. Real-life examples: How to identify recent alcohol use in urine and blood tests

2449. Do you agree with my interpretation of urine and blood test results for Patient A?

2450. CDT and GGT, together, can help identify recent, heavy alcohol use

2451. Heavy alcohol use recently but the urine is negative for ethyl glucuronide?

2452. Why our patients (and we) usually don’t know their THC dose

2453. THC concentration has increased a LOT for all types of cannabis products

2454. Do patients who use cannabis understand the label?

2455. What do “Total THC”, “THCA”, and “THC” on the product label mean?

2456. What to ask and tell patients about their THC consumption

2457. Familiarizing ourselves with oral cannabis products our patients may be using

2458. Six ways to reduce risk if using oral cannabis products

2459. Many medications contain ingredients that are derived from animals

2460. Where to look up whether a pill contains animal ingredients

2461. Where would you look up inactive ingredients in GENERIC medications?

2462. Magnesium stearate in tablets and capsules is also usually derived from animals

2463. Religious beliefs and medications: Other factors to consider

2464. How to find medications that DON’T have certain inactive ingredients

2465. Key principles for managing bipolar disorder with rapid cycling (Part 1)

2466. Key principles for managing bipolar disorder with rapid cycling (Part 2)

2467. Key principles for managing bipolar disorder with rapid cycling (Part 3)

2468. General tips about mood charting in bipolar disorders

2469. Minimum, most important information to capture in a mood chart

2470. One way to be an ACTIVE learner is to test ourselves periodically (Quiz no. 66)

2471. Do you consider a full range of accommodations for students with ADHD? (Part 1)

2472. Do you consider a full range of accommodations for students with ADHD? (Part 2)

2473. Do you consider a full range of accommodations for students with ADHD? (Part 3)

2474. Plan BOTH short and long term accommodations/ interventions for students with ADHD

2475. Watch out! Many students with ADHD don’t ask for, get, or use accommodations/ support

2476. Should students with ADHD get accommodations even if adequately treated?

2477. Tips to help patients with ADHD who struggle in the morning (Part 1)

2478. Tips to help patients with ADHD who struggle in the morning (Part 2)

2479. Tips to help patients with ADHD who struggle in the morning (Part 3)

2480. Start here to learn about ADHD and executive dysfunction

2481. How much selenium to recommend for valproate-induced hair loss (Part 1)

2482. How much selenium to recommend for valproate-induced hair loss (Part 2)

2483. Which brands of selenium should we recommend?

2484. For how long should naltrexone be continued in alcohol use disorder? (Part 1)

2485. For how long should naltrexone be continued in alcohol use disorder? (Part 2)

2486. Continue addiction medications for one full cycle of birthdays, anniversaries, and holidays

2487. Useful tip about the next step when eGFR is low

2488. New “disease-modifying treatments” for Alzheimer’s disease

2489. Why amyloid-β and amyloid plaques are so important

2490. Untangling exactly whom lecanemab (Leqembi®) is FDA-approved for

2491. How well does lecanemab (Leqembi®) work?

2492. Lecanemab (Leqembi®) carries an important boxed warning

2493. Bottom line: Should we recommend treatment with lecanemab (Leqembi®)?

2494. Don’t fail to document this crucial part of informed consent

2495. Do you document these key facts as part of informed consent?

2496. When to ask for an MRI of the brain WITH or WITHOUT contrast (Part 1)

2497. When to ask for an MRI of the brain WITH or WITHOUT contrast (Part 2)

2498. What about the FDA’s warning about gadolinium retention in the body/ brain?

2499. Clinical example: Why we should ALWAYS do a quick drug interaction search

2500. Actively recommend vaginal lubricants to women who need them

2501. Specific advice on which vaginal lubricants to recommend

2502. Tips on avoiding problems related to vaginal lubricants

2503. Executive functions: A simple and practical introduction

2504. Emotional dysregulation is a HUGE problem in ADHD

2505. Evaluating patients with ADHD for executive function deficits

2506. It’s not just procrastination; it’s *paralysis*

2507. Why and how to look for impulsivity when evaluating for possible ADHD (Part 1)

2508. Why and how to look for impulsivity when evaluating for possible ADHD (Part 2)

2509. Tips on history-taking when evaluating an adult for possible ADHD

2510. Don’t miss ADHD in persons with high intelligence

2511. Look for external “scaffolding” that may hide ADHD symptoms

2512. Compensation, adaptation, and avoidance ARE evidence of impairment

2513. It is still *illegal* under Federal law to market marijuana, THC, and CBD

2514. Hy’s law: When liver enzyme elevation may be *extremely* serious

2515. Clinical recommendations for identifying severe liver injury

2516. We MUST test ourselves because it improves learning (Quiz no. 67)

2517. Tinnitus, auditory hallucinations, or both?

2518. Clinical case: OCD resistant to three trials of SSRIs (Part 1)

2519. Clinical case: OCD resistant to three trials of SSRIs (Part 2)

2520. Clinical case: OCD resistant to three trials of SSRIs (Part 3)

2521. Clinical case: OCD resistant to three trials of SSRIs (Part 4)

2522. What side effects can cannabidiol (CBD) cause in our patients?

2523. What to tell patients about the risks of long-term benzodiazepines (Part 1)

2524. What to tell patients about the risks of long-term benzodiazepines (Part 2)

2525. Wrongly assuming that only a “low dose” is needed (Part 1)

2526. Wrongly assuming that only a “low dose” is needed (Part 2)

2527. Risky to add aripiprazole for antipsychotic-induced hyperprolactinemia? (Part 1)

2528. Risky to add aripiprazole for antipsychotic-induced hyperprolactinemia? (Part 2)

2529. Risky to add aripiprazole for antipsychotic-induced hyperprolactinemia? Part 3

2530. How to adjust psychostimulant treatment if another medication affects urine pH (Part 1)

2531. How to adjust psychostimulant treatment if another medication affects urine pH (Part 2)

2532. Know the principles AND use drug interaction search tools

2533. Screening questionnaires SCREEN, not DIAGNOSE (Part 1)

2534. Screening questionnaires SCREEN, not DIAGNOSE (Part 2)

2535. Whom to screen for *possible* ADHD and how

2536. How to score and interpret the ASRS

2537. EXTREMELY important tip for reducing false positives on the ASRS

2538. A primer on the Paleolithic (“Paleo”) diet

2539. The Paleo diet is NOT recommended

2540. What if patients report seeing intact pills in their stools?

2541. Which psychiatric medications may patients sometimes see in their stools?

2542. Clinical recommendations: If patients report seeing intact pills in their stools

2543. Tips on diagnosing and treating ADHD in patients with thyroid disease

2544. DSM-5-TR® diagnostic criteria for prolonged grief disorder

2545. What is Prolonged Grief Treatment (PGT)?

2546. How are hydroxyzine pamoate (Vistaril®) and hydroxyzine hydrochloride (Atarax®) different?

2547. In liver disease, when should we NOT give naltrexone?

2548. Can thrombocytopenia be due to alcohol use?

2549. In ADHD and autism spectrum disorder, specifically look for the other

2550. Clonidine should NOT be stopped abruptly!

2551. How to reduce the risk and seriousness of clonidine withdrawal

2552. Look for about “social camouflaging” when autism spectrum disorder is a possibility

2553. Don’t miss autism spectrum disorder in female patients! (Part 1)

2554. Don’t miss autism spectrum disorder in female patients! (Part 2)

2555. Testing yourself with DOUBLE your learning! (Quiz no. 68)

2556. Resources on autism spectrum disorder for patients and families

2557. Can we diagnose ADHD without a history of ADHD in childhood? Yes and No

2558. Jet lag disorder is a real clinical condition

2559. We need to actively prevent/ manage jet lag in our patients

2560. Prevention of jet lag when traveling EASTward

2561. How exactly to use melatonin or melatonin receptor agonists for jet lag

2562. Should we get an ECG before prescribing a stimulant or other ADHD medication?

2563. Look for these cardiovascular risk factors relevant to many psychiatric medications

2564. Abbreviations for controlled-release formulations are out of control!

2565. A patient with normal ferritin and iron levels but low iron saturation

2566. Interpreting serum ferritin and iron saturation together

2567. In breastfeeding, consider the “milk/ plasma ratio” and the “relative infant dose”

2568. A brief summary about relative infant dose, relevant to medication safety during breastfeeding

2569. Don’t change the stimulant medication without first asking about this

2570. Basic facts about magnesium for mental health clinicians

2571. Does the patient have “true” hallucinations or pseudohallucinations?

2572. Clinical recommendations regarding pseudohallucinations

2573. Prioritize side effects more likely to lead to discontinuation of SSRIs

2574. Why might some adverse effects be more likely to lead to discontinuation?

2575. GLP-1 agonists may reduce alcohol craving/ use

2576. Clinical recommendations: GLP-1 receptor agonists for alcohol use disorder?

2577. Which psychiatric medications can cause sinus tachycardia?

2578. GLP-1 receptor agonists in patients on antipsychotic medications?

2579. Tirzepatide (Zepbound™): Whom is it for and how exactly does it work?

2580. Potential harms of tirzepatide (Zepbound™)

2581. Can acetaminophen (Tylenol®) be taken by patients with liver disease?

2582. Interpreting combinations of methylmalonic acid and homocysteine level results

2583. What happened with my patient when she couldn’t swallow pills

2584. Commonly used medications that can cause magnesium deficiency

2585. Could a medication be causing your patient’s nightmares?

2586. Just think “True” or “False” and check to see if you are right (Quiz no. 69)

2587. High-yield tips for success with bright light therapy (Part 1)

2588. High-yield tips for success with bright light therapy (Part 2)

2589. Clinical skills CANNOT be replaced by forms, checklists, scales, and questionnaires

2590. Tips on obtaining the psychiatric medication history (Part 1)

2591. Tips on obtaining the psychiatric medication history (Part 2)

2592. Tips on obtaining the psychiatric medication history (Part 3)

2593. Tips on obtaining the psychiatric medication history (Part 4)

2594. Tips on obtaining the psychiatric medication history (Part 5)

2595. Clinical case: Add as-needed quetiapine to a full dose of aripiprazole? (Part 1)

2596. Clinical case: Add as-needed quetiapine to a full dose of aripiprazole? (Part 2)

2597. What to advise patients about saturated and unsaturated fats (Part 1)

2598. What to advise patients about saturated and unsaturated fats (Part 2)

2599. What exactly is “prediabetes”?

2600. The diagnosis of prediabetes should be a wake-up call

2601. What to do if a patient’s delusion involves the treating clinician (Part 1)

2602. What to do if a patient’s delusion involves the treating clinician (Part 2)

2603. A primer on making the diagnosis of delayed ejaculation (Part 1)

2604. A primer on making the diagnosis of delayed ejaculation (Part 2)

2605. Can gabapentin cause sexual side effects?

2606. Do we still need to tell patients to stop biotin supplements for 3 days before getting laboratory tests?

2607. Why prescribers of antipsychotic medications should know about acute dystonia

2608. When does acute dystonia occur and how does it present?

2609. What increases or decreases the risk of medication-induced acute dystonia?

2610. Recommendations for reducing the risk of antipsychotic-induced acute dystonia

2611. What should be first-, second-, and third-line treatments for acute dystonia?

2612. Recommendations for treating antipsychotic-induced acute dystonia

2613. What to do AFTER the acute dystonia resolves

2614. Drug interactions in patients taking PEG 3350 (MiraLAX(R) and generics)

2615. What to do about stimulant medications for surgery or other procedures under anesthesia

2616. Methylphenidate on the day of surgery/ procedure under general anesthesia?

2617. Amphetamines on the day of surgery/ procedure under general anesthesia?

2618. What is our role in patients with hyperprolactinemia? (Part 1)

2619. What is our role in patients with hyperprolactinemia? (Part 2)

2620. What to ask and say to patients who “hear voices”

2621. Just think “True” or “False” and check to see if you are right (Quiz no. 70)

2622. For how long can fentanyl be detected in the urine?

2623. Tips on increasing informal exposure to sunlight

2624. Let’s stop using the CAGE questionnaire

2625. AUDIT-C: A practical guide

2626. “Agitation associated with dementia” now has an operational definition

2627. Brexpiprazole (Rexulti®) for “agitation associated with dementia due to Alzheimer’s disease” (Part 1)

2628. Brexpiprazole (Rexulti®) for “agitation associated with dementia due to Alzheimer’s disease” (Part 2)

2629. Apple Watch can identify deficits in deep sleep and response to interventions

2630. Recommended free app for evaluating sleep duration and quality

2631. Are GLP-1 receptor agonists associated with an increased risk of suicidal ideation/ behavior?

2632. Why do *some* GLP-1 receptor agonists carry a warning about depression/suicidality?

2633. Dyslipidemia is a huge contributor to disease and death—but often undiagnosed and untreated

2634. How to monitor for dyslipidemia in patients treated with an antipsychotic

2635. Mistakes when monitoring for dyslipidemia associated with second-generation antipsychotics

2636. Elevated LDL cholesterol or triglycerides must be brought down without much delay

2637. Why we need head-to-head clinical trials but typically don’t get them

2638. Does tirzepatide (Zepbound™) produce *even more* weight loss than semaglutide (Wegovy®)? (Part 1)

2639. Does tirzepatide (Zepbound™) produce *even more* weight loss than semaglutide (Wegovy®)? (Part 2)

2640. Timing of blood draw for a serum lamotrigine level

2641. How many days to wait before measuring the blood level of any medication

2642. How many days to wait before checking a steady-state lamotrigine level

2643. Should lithium be temporarily stopped before a colonoscopy?

2644. Can patients with ADHD develop tolerance to stimulant medications? (Part 1)

2645. Can patients with ADHD develop a tolerance to stimulant medications? (Part 2)

2646. Encourage pregnant women on an antiepileptic drug to enroll in these registries

2647. When should mental health clinicians prescribe a proton pump inhibitor?

2648. How to choose among the proton pump inhibitors (Part 1)

2649. How to choose among the proton pump inhibitors (Part 2)

2650. Wearing earplugs can reduce insomnia and improve sleep quality

2651. Instructions and precautions for using earplugs while sleeping

2652. To improve sleep, consider recommending a white noise smartphone app

2653. Testing ourselves is one of the most effective ways of learning! (Quiz no. 71)

2654. Use and recommend an FDA-cleared over-the-counter fentanyl urine test

2655. How to use and interpret the Alltest Fentanyl Urine Test Cassette

2656. Consider the many possible benefits of treating ADHD with stimulant medications

2657. When patients with bipolar disorders worry about losing their creativity (Part 1)

2658. When patients with bipolar disorders worry about losing their creativity (Part 2)

2659. How are drowsiness, excessive sleepiness, somnolence, hypersomnolence, and hypersomnia different?

2660. Right questions to ask about a patient with depression and excessive sleepiness

2661. Is lamotrigine a problem in patients on cancer chemotherapy that includes leucovorin?

2662. What to do if a patient develops thrombocytopenia during treatment with valproate (Part 1)

2663. What to do if a patient develops thrombocytopenia during treatment with valproate (Part 2)

2664. Can patients on lurasidone take nirmatrelvir + ritonavir (Paxlovid®)? (Part 1)

2665. Can patients on lurasidone take nirmatrelvir + ritonavir (Paxlovid®)? (Part 2)

2666. Why we should specifically look for remaining or residual symptoms in our patients

2667.  Tips on evaluating patients for remaining or residual symptoms

2668. HOW to ask about remaining or residual symptoms

2669. Common myths about IV ketamine for depressive disorders (Part 1)

2670. Common myths about IV ketamine for depressive disorders (Part 2)

2671. What to do about concomitant medications during ketamine or esketamine treatment (Part 1)

2672. What to do about concomitant medications during ketamine or esketamine treatment (Part 2)

2673. What to do about concomitant medications during ketamine or esketamine treatment (Part 3)

2674. Do stimulants need to be titrated up again after an interruption?

2675. What are “white coat hypertension” and “white coat effect”?

2676. Clinical recommendations regarding evaluation and follow-up of white coat hypertension

2677. Instructions to patients for measuring blood pressure and pulse rate at home (Part 1)

2678. Instructions to patients for measuring blood pressure and pulse rate at home (Part 2)

2679. Helpful ICD-10 codes for non-psychiatric, comorbid medical conditions

2680. Which thyroid hormone to use if one is needed for lithium-induced hypothyroidism

2681. Tips on laboratory testing to guide levothyroxine treatment of hypothyroidism

2682. Informal “bladder training” can help many of our patients

2683. Do you agree that answering questions is essential for effective learning? (Quiz no. 72)

2684. What are our options for generic, long-acting methylphenidate/ dexmethylphenidate preparations?

2685. How to choose between generic, long-acting methylphenidate/ dexmethylphenidate preparations

2686. What are the closest alternatives when forced to switch a stimulant? (Part 1)

2687. Closest alternative to methylphenidate tablet extended-release (Concerta®)?

2688. Is an ECG needed when prescribing low-dose doxepin?

2689. Encourage patients without early improvement to continue with TMS

2690. Tell patients this to reduce the risk of prematurely stopping the antidepressant

2691. A primer on tobacco-free oral nicotine pouches (Part 1)

2692. A primer on tobacco-free oral nicotine pouches (Part 2)

2693. GLP-1 receptor agonists for binge eating?

2694. GLP-1 receptor agonists may worsen eating disorders or precipitate disordered eating

2695. What do the terms complementary, alternative, integrative, and functional medicine mean? (Part 1)

2696. What do the terms complementary, alternative, integrative, and functional medicine mean? (Part 2)

2697. What do the terms complementary, alternative, integrative, and functional medicine mean? (Part 3)

2698. Which nutraceuticals or phytoceuticals do experts definitely recommend for psychiatric disorders?

2699. Will patients regain weight after GLP-1 receptor agonists are stopped? (Part 1)

2700. Will patients regain weight after GLP-1 receptor agonists are stopped? (Part 2)

2701. Which psychiatric medications need to be stopped before a DaT scan? (Part 1)

2702. Which psychiatric medications need to be stopped before a DaT scan? (Part 2)

2703. What drug interactions can occur with melatonin?

2704. What are myelodysplastic syndromes?

2705. Lithium in patients with neutropenia or thrombocytopenia?

2706. Which antidepressants are least likely to cause neutropenia/ agranulocytosis? (Part 1)

2707. Which antidepressants are least likely to cause neutropenia/ agranulocytosis? (Part 2)

2708. Does your patient have “insulin resistance”?

2709. Insulin resistance is associated with a *wide range* of *serious* consequences

2710. What dietary interventions should we recommend for metabolic health?

2711. What should we recommend regarding exercise for metabolic health?

2712. How much exercise per day or per week should we recommend?

2713. Consider prescribing metformin for conditions involving insulin resistance

2714. Three quick questions for you (Quiz no. 73)

2715. Non-alcoholic or alcohol-free beer in patients with past alcohol use disorder? (Part 1)

2716. Non-alcoholic or alcohol-free beer in patients with past alcohol use disorder? (Part 2)

2717. What are “non-alcoholic,” “alcohol-free,” “low alcohol,” and “reduced alcohol” beverages?

2718. Will non-alcoholic beer show up in breath or urine tests?

2719. Extending the action of melatonin: extended/time/sustained-release or bi-layer/dual spectrum

2720. Always keep in mind the possibility of a future pregnancy

2721. Tips on how to avoid alcohol in social settings (Part 1)

2722. Tips on how to avoid alcohol in social settings (Part 2)

2723. How zolpidem dosing differs between women and men (Part 1)

2724. How zolpidem dosing differs between women and men (Part 2)

2725. Which type of TMS device should we ask patients to look for? (Part 1)

2726. Which type of TMS device should we ask patients to look for? (Part 2)

2727. Do’s and don’ts regarding mixing medication with food or beverages (Part 1)

2728. Do’s and don’ts regarding mixing medication with food or beverages (Part 2)

2729. Instructions to patients regarding mixing medications with food/ beverages

2730. Why does Abilify Maintena® have an FDA-indication for bipolar disorder but Aristada® does not?

2731. Abilify Asimtufii® has two BIG advantages over Abilify Maintena®

2732. Must-know facts about aripiprazole LAI (Abilify Asimtufii®)

2733. Which injections can only be given in the gluteal muscle—and why?

2734. How to choose between injecting into the deltoid or gluteal muscles (Part 1)

2735. How to choose between injecting into the deltoid or gluteal muscles (Part 2)

2736. Don’t access/send patient information over unsecured public Wi-Fi

2737. A simple solution to unsecure Wi-Fi networks

2738. Which VPN services are highly-recommended?

2739. Can stimulant medications either “cause” psychosis or make it worse?

2740. How to reduce the risk of stimulants in patients with a past history of psychosis

2741. Patient handouts can have potential advantages AND disadvantages

2742. Tips on choosing or preparing effective patient handouts

2743. Tips on using patient handouts effectively

2744. Patient handouts for the management of constipation

2745. Answering quizzes is one of the BEST ways to learn psychopharmacology! (Quiz no. 74)

2746. Use an e-fax service instead of a traditional fax machine

2747. A primer on Doximity’s free e-fax service

2748. What risk factors to look for in patients with a history of priapism

2749. Which antipsychotics may have a higher risk of priapism?

2750. How and why to compare antipsychotics’ affinity for alpha-1 receptors

2751. Clinical recommendations regarding antipsychotics and priapism

2752. What to say to patients about osteoporosis and antidepressant use (Part 1)

2753. What to say to patients about osteoporosis and antidepressant use (Part 2)

2754. What are ICD-10-CM Z codes?

2755. Could documenting Z codes be useful clinically, in research, and in reimbursement?

2756. Tamsulosin (Flomax®) and psychiatric medications: What to watch for

2757. Factors, including drug interactions, that increase tamsulosin levels

2758. Which topical antiperspirants can be used on the face, neck, and body?

2759. Topical anticholinergics for localized hyperhidrosis

2760. Drysol®: A topical antiperspirant available only by prescription

2761. Over-the-counter antiperspirants that can be used on the face, neck, and body

2762. Magnesium supplement for suspected alcohol/ medication-induced deficiency? (Part 1)

2763. Magnesium supplement for suspected alcohol/ medication-induced deficiency? (Part 2)

2764. Which type of magnesium supplement to recommend

2765. Which CAM products can cause or contribute to insomnia?

2766. Great options for “alcohol-removed” red, white, rosé, or sparkling wines

2767. Four kinds of atypical responses to stimulant medications (Part 1)

2768. Four kinds of atypical responses to stimulant medications (Part 2)

2769. Four kinds of atypical responses to stimulant medications (Part 3)

2770. My favorite YouTube channel for tips related to physical therapy

2771. How to get advice if extra medication is taken by mistake

2772. How to get advice if extra medication is taken by mistake

2773. Check patients’ phones for how well their CPAP is working

2774. Stimulant medications for cancer-related fatigue? (Part 1)

2775. Stimulant medications for cancer-related fatigue? (Part 2)

2776. Clinical recommendations: Using stimulant medications for cancer-related fatigue

2777. Three quick true or false questions (Quiz no. 75)

2778. A primer on blepharospasm for mental health clinicians (Part 1)

2779. A primer on blepharospasm for mental health clinicians (Part 2)

2780. Were the patient’s experiences really panic attacks (in the medical sense)?

2781. How I remember the symptoms that can occur in panic attacks

2782. When to NOT diagnose panic disorder in a person with panic attacks

2783. Consider non-psychiatric medical conditions as the cause of panic attacks (Part 1)

2784. Consider non-psychiatric medical conditions as the cause of panic attacks (Part 2)

2785. Clinical recommendations about non-psychiatric medical conditions causing panic attacks

2786. What can we do about this important preventable cause of deaths on inpatient psychiatric units?

2787. When should we worry that our patient is taking too much magnesium? (Part 1)

2788. When should we worry that our patient is taking too much magnesium? (Part 2)

2789. List all relevant diagnosis codes to help plan comprehensive treatment

2790. An outpatient visit note organized by a list of diagnoses

2791. What laboratory tests to order to fully evaluate for possible vitamin B12 deficiency

2792. Why does this patient have elevated homocysteine and C-reactive protein?

2793. Can varenicline (Chantix®) be stopped abruptly or should it be tapered off?

2794. Catatonia: What next after benzodiazepines and ECT?

2795. Which psychiatric medications should be stopped before skin prick allergy testing?

2796. Are we missing cyclothymic disorder by putting it into bipolar disorder NOS?

2797. Do’s and Don’ts for providing referrals when the care of a patient is terminated

2798. What is low-dose naltrexone (LDN) and should it be used for anything? (Part 1)

2799. What is low-dose naltrexone (LDN) and should it be used for anything? (Part 2)

2800. Why and how to ask about nocturnal panic attacks

2801. Does N-acetylcysteine (NAC) reduce cravings in substance use disorders?

2802. How is narcolepsy diagnosed—clinically and in the sleep lab? (Part 1)

2803. How is narcolepsy diagnosed—clinically and in the sleep lab? (Part 2)

2804. Should we check blood levels for oxcarbazepine (Trileptal®)?

2805. Which ADHD medications if significant heart disease is present?

2806. Should we consider doxazosin an alternative to prazosin for PTSD?

2807. Make sure you know the answers to these clinically-relevant questions (Quiz no. 76)

2808. Why they are a particularly worrisome way of smoking cannabis

2809. What are cannabis joints and spliffs or mulled cigarettes?

2810. Cannabis “bongs” and pipes

2811. Why using cannabis concentrates in vapes or by “dabbing” is dangerous

2812. Don’t miss bruxism in patients with ADHD—it can cause significant problems

2813. How to manage bruxism associated with ADHD medications

2814. When to give up on ECT in “treatment-resistant” major depressive disorder (Part 1)

2815. When to give up on ECT in “treatment-resistant” major depressive disorder (Part 2)

2816. Why it matters that quetiapine’s metabolite is a *norepinephrine* reuptake inhibitor

2817. My best tip for reducing (or stopping) benzodiazepines and hypnotics

2818. How to treat ADHD symptoms in autism spectrum disorder

2819. Clinical recommendations for treating ADHD symptoms in autism spectrum disorder

2820. Which psychiatric medications (other than clozapine) can cause hypersalivation (sialorrhea)?

2821. How should we approach medications that were recently approved by the FDA?

2822. A brief review of gepirone extended-release (Exxua®)(Part 1)

2823. A brief review of gepirone extended-release (Exxua®)(Part 2)

2824. What is benzgalantamine (Zunveyl®) and how is it different?

2825. A brief review of donanemab (Kisunla®) for Alzheimer’s disease

2826. Does serdexmethylphenidate+dexmethylphenidate (Azstarys®) have significant advantages? (Part 1)

2827. Does serdexmethylphenidate+dexmethylphenidate (Azstarys®) have significant advantages? (Part 2)

2828. What is the procedure for obtaining an early medication refill?

2829. Instructions for patients to avoid common problems in telepsychiatry sessions

2830. Tips on prescribing for patients at risk of medication overdose (Part 1)

2831. Tips on prescribing for patients at risk of medication overdose (Part 2)

2832. Which antidepressants are most likely to be fatal in overdose?

2833. Warnings and tips regarding patient rated scales/questionnaires (Part 1)

2834. Warnings and tips regarding patient rated scales/questionnaires (Part 2)

2835. Some patients with ADHD need quiet; others need background music or noise

2836. Clinical recommendations: Quiet or background music or noise for patients with ADHD?

2837. How to distinguish between stimulant preparations *without* using brand names (Part 1)

2838. How to distinguish between stimulant preparations *without* using brand names (Part 2)

2839. True or False? (Quiz no. 77)

2840. What is “word-finding difficulty” and what could be causing it?

2841. Can antidepressants cause word-finding difficulty?

2842. We must differentiate between misophonia and hyperacusis

2843. If misophonia is present, which clinical conditions should we look for?

2844. What to do first in a patient with misophonia

2845. Specific strategies for the management of misophonia

2846. Misophonia: Find a clinician or support group

2847. What does the respiratory event index (REI) on a home sleep study mean?

2848. Which symptoms of ADHD is guanfacine effective for?

2849. Was my patient’s liver injury due to alcohol or a statin? (Part 1)

2850. Was my patient’s liver injury due to alcohol or a statin? (Part 2)

2851. Why I screen for hyperglycemia using hemoglobin A1c (HbA1c)

2852. What can cause a falsely elevated or low hemoglobin A1c (HbA1c)? (Part 1)

2853. What can cause a falsely elevated or low hemoglobin A1c (HbA1c)? (Part 2)

2854. What to tell patients about the risks of using a sauna or hot tub

2855. Awake bruxism is common and harmful, but typically undiagnosed and untreated

2856. Why mental health clinicians should screen for awake bruxism

2857. How to screen for possible bruxism

2858. Any reassuring facts about weight gain with antidepressants?

2859. Check weight after one month on an antidepressant; take action if…

2860. Myth or Fact? Our verdict on common beliefs about antidepressants and weight gain

2861. Why would you need to find a compounding pharmacy?

2862. How to find a compounding pharmacy (Part 1)

2863. How to find a compounding pharmacy (Part 2)

2864. Should we routinely use cystatin C to evaluate kidney function? (Part 1)

2865. Should we routinely use cystatin C to evaluate kidney function? (Part 2)

2866. Automatic calculators for eGFR using creatinine, cystatin C, or both (Part 1)

2867. Automatic calculators for eGFR using creatinine, cystatin C, or both (Part 2)

2868. Recommended app for calculating eGFR in adults and youth

2869. What dose equivalence to use when changing between Z-drugs

2870. Testing yourself is a great way to solidify your knowledge (Quiz no. 78)

2871. How to unlock a PDF article so that you can highlight text in it

2872. Comparing treatment options: Efficacy before side effects

2873. Three REVEALING questions to ask patients about their therapists

2874. How to help patients get more out of their therapy (Part 1)

2875. How to help patients get more out of their therapy (Part 2)

2876. How to help patients get more out of their therapy (Part 3)

2877. Is the cyproheptadine interfering with the effect of the SSRI? (Part 1)

2878. Is the cyproheptadine interfering with the effect of the SSRI? (Part 2)

2879. Red yeast rice for dyslipidemia? (Part 1)

2880. Red yeast rice for dyslipidemia? (Part 2)

2881. Specific dietary changes that we should recommend for elevated LDL cholesterol

2882. Recommendations for dietary fats in a healthy diet

2883. Eat MORE to lose excess weight

2884. What are adverse events, adverse effects, side effects, and adverse drug reactions? (Part 1)

2885. What are adverse events, adverse effects, side effects, and adverse drug reactions? (Part 2)

2886. Discussion of a clinical case of antidepressant-induced hyponatremia (Part 1)

2887. Discussion of a clinical case of antidepressant-induced hyponatremia (Part 2)

2888. How reliable is the labeled THC content at cannabis dispensaries?

2889. The rationale for xanomeline+trospium (Cobenfy™), approved for the treatment of schizophrenia

2890. Efficacy of xanomeline+trospium (Cobenfy™) and comparison with second-generation antipsychotics

2891. Xanomeline+trospium (Cobenfy™): Side effects

2892. Macrocytosis: A brief summary for mental health clinicians

2893. What should we do about valproate-induced macrocytosis?

2894. What to do about “baseline” laboratory tests

2895. Which of the many screening tests for thyroid dysfunction should we order? (Part 1)

2896. Which of the many screening tests for thyroid dysfunction should we order? (Part 2)

2897. What to tell patients with alcohol use disorder about taking acetaminophen (paracetamol)

2898. Is it true that mirtazapine does not cause hyponatremia?

2899. Medication-induced hyponatremia: Stop or change other medications that increase the risk

2900. Just say “True” or “False” (Quiz no. 79)

2901. Why and how to calculate the FIB-4 score in asymptomatic alcohol-associated liver disease (Part 1)

2902. Why and how to calculate the FIB-4 score in asymptomatic alcohol-associated liver disease (Part 2)

2903. Case study: Conclusions of the paper are not consistent with the statistical significance (Part 1)

2904. Case study: Conclusions of the paper are not consistent with the statistical significance (Part 2)

2905. Should we start metformin at the same time as an antipsychotic?

2906. Consider starting metformin, if it is needed, in inpatients on an antipsychotic

2907. Why does my patient drink such excessive amounts of fluids?

2908. Psychogenic polydipsia: Clinical features and complications

2909. How to diagnose psychogenic polydipsia (Part 1)

2910. How to diagnose psychogenic polydipsia (Part 2)

2911. Options for managing psychogenic polydipsia (Part 1)

2912. Options for managing psychogenic polydipsia (Part 2)

2913. Most important points to know about tardive dyskinesia (Part 1)

2914. Most important points to know about tardive dyskinesia (Part 2)

2915. Options for steady, full-day coverage with just one pill of stimulant medication

2916. What doses to use when converting to or from serdexmethylphenidate–dexmethylphenidate (Aztarys®)

2917. Phosphatidylethanol (PEth) testing to identify recent alcohol use

2918. How do PEth and CDT tests compare for identifying recent alcohol use? (Part 1)

2919. How do PEth and CDT tests compare for identifying recent alcohol use? (Part 2)

2920. Tips for reducing or managing nausea/ vomiting associated with GLP-1 agonists (Part 1)

2921. Tips for reducing or managing nausea/ vomiting associated with GLP-1 agonists (Part 2)

2922. Tips for reducing or managing nausea/ vomiting associated with GLP-1 agonists (Part 3)

2923. Does your patient have *positional* (supine) obstructive sleep apnea?

2924. How I helped my patient with positional obstructive sleep apnea

2925. Buying and using a positional therapy device for positional obstructive sleep apnea

2926. Why clonidine isn’t usually recommended for ADHD in *adults*

2927. Tips on diagnosing “delirium superimposed on dementia”

2928. Arrange for close follow-up after delirium with OR without pre-existing dementia

2929. Important questions to consider before we start “deprescribing”

2930. How quickly and in what order should we deprescribe medications?

2931. Why and how patients should maintain an updated medication list

2932. Significantly boost your learning by taking this 3 question quiz (Quiz no. 80)

2933. Tips on examining patients for parkinsonism: Muscle rigidity (Part 1)

2934. Tips on examining patients for parkinsonism: Muscle rigidity (Part 2)

2935. Tips on examining patients for parkinsonism: Muscle rigidity (Part 3)

2936. Can lamotrigine cause memory impairment? (Part 1)

2937. Can lamotrigine cause memory impairment? (Part 2)

2938. Can lamotrigine cause memory impairment? (Part 3)

2939. Telepsychiatry: What billing codes and “modifiers” to use (Part 1)

2940. Telepsychiatry: What billing codes and “modifiers” to use (Part 2)

2941. What changes (updates) have been made to the Prescribing Information?

2942. Where to find the latest, most up-to-date version of the Prescribing Information (Part 1)

2943. Where to find the latest, most up-to-date version of the Prescribing Information (Part 2)

2944. Are bupropion SR and bupropion ER the same thing?

2945. Checking urine albumin/creatinine ratio and serum cystatin allowed lithium to continue (Part 1)

2946. Checking urine albumin/creatinine ratio and serum cystatin allowed lithium to continue (Part 2)

2947. We sometimes have to prescribe differently based on the Child-Pugh score or class

2948. How to calculate the Child-Pugh score and determine the severity of hepatic impairment

2949. Let’s not say that the diagnosis is “Depression” or “Anxiety”

2950. Understanding the diagnosis of Persistent Depressive Disorder (DSM-5-TR®)

2951. A common misunderstanding about dysthymia and why it makes a big difference

2952. Do you recommend Meetup.com to your patients?

2953. How to check for possible tampering of urine samples for drug testing (Part 1)

2954. How to check for possible tampering of urine samples for drug testing (Part 2)

2955. Monitor carefully even AFTER substance/medication-induced psychosis subsides

2956. How can we know that a patient’s psychotic symptoms may be substance- or medication-induced?

2957. Why and how to keep separate “psychotherapy notes” for a patient

2958. Can SSRIs and SNRIs be combined? (Part 1)

2959. Can SSRIs and SNRIs be combined? (Part 2)

2960. Can SSRIs and SNRIs be combined? (Part 3)

2961. Can SSRIs and SNRIs be combined? (Part 4)

2962. Have you found that answering quizzes is one of the BEST ways to learn? (Quiz No. 81)

2963. Which SSRIs can be considered or should be avoided in children and adolescents? (Part 1)

2964. Which SSRIs can be considered or should be avoided in children and adolescents? (Part 2)

2965. How is “Complex PTSD” different from PTSD?

2966. Should patients with panic attacks rebreathe the same air by using a paper bag?

2967. Tips on offering disulfiram for alcohol use disorder

2968. Principles to help patients on disulfiram avoid hidden sources of alcohol

2969. Specific tips to give to patients about how to avoid “hidden” alcohol in food and beverages

2970. Recommend these alcohol-free mouthwash options to patients on disulfiram or with a dry mouth

2971. Patients on disulfiram may appreciate being told about these alcohol-free options for fragrances

2972. In what situations should we STOP cholinesterase inhibitors in patients with dementia? (Part 1)

2973. In what situations should we STOP cholinesterase inhibitors in patients with dementia? (Part 2)

2974. How much of each nutrient should I consume each day to be healthy?

2975. A second nutrition metric that everyone should understand—Daily Values

2976. An example of using Recommended Dietary Allowance (RDA) and % Daily Value

2977. Identify the person’s stage of change to know what interventions to use (Part 1)

2978. Identify the person’s stage of change to know what interventions to use (Part 2)

2979. Identify the person’s stage of change to know what interventions to use (Part 3)

2980. What strategies and techniques to use in the precontemplation stage

2981. What strategies and techniques to use in the contemplation stage

2982. What strategies and techniques to use in the preparation stage

2983. What strategies and techniques to use in the Action and Maintenance phases

2984. Which psychiatric medications can cause painful ejaculation?

2985. What could we do about painful ejaculation due to psychiatric medications?

2986. What could a high or low albumin-globulin ratio mean?

2987. Ways of using the person’s name, and of others in their life, to build rapport (Part 1)

2988. Ways of using the person’s name, and of others in their life, to build rapport (Part 2)

2989. Give all these instructions while prescribing zolpidem

2990. Can you figure out this “puzzling” case of oxycodone overdose with a negative UDS?

2991. Teach “box breathing” to patients with anxiety, panic, insomnia, or high stress levels (Part 1)

2992. Teach “box breathing” to patients with anxiety, panic, insomnia, or high stress levels (Part 2)

2993. Can “additive effects” increase the risk of Stevens-Johnson Syndrome (SJS) with lamotrigine?

2994. True or False? (Quiz No. 82)

2995. What to do about a couple’s mismatched circadian sleep-wake rhythm (Part 1)

2996. What to do about a couple’s mismatched circadian sleep-wake rhythm (Part 2)

2997. Which medication(s) for anxiety/ depression symptoms in patients with ADHD? (Part 1)

2998. Which medication(s) for anxiety/ depression symptoms in patients with ADHD? (Part 2)

2999. Which medication(s) for anxiety/ depression symptoms in patients with ADHD? (Part 3)

3000. Which medication(s) for anxiety/ depression symptoms in patients with ADHD? (Part 4)

3001. Which diagnosis codes to use when ordering a vitamin B12 level (Part 1)

3002. Which diagnosis codes to use when ordering a vitamin B12 level (Part 2)

3003. Which diagnosis codes to use when ordering a vitamin B12 level (Part 3)

3004. Patient instructions for getting iron studies done

3005. Which products for extremely dry hands due to repeated hand washing?

3006. Post-SSRI sexual dysfunction (PSSD). (Part 1)

3007. Post-SSRI sexual dysfunction (PSSD). (Part 2)

3008. Post-SSRI sexual dysfunction (PSSD). (Part 3)

3009. Is your desktop or laptop computer HIPAA-compliant? (Part 1)

3010. Is your desktop or laptop computer HIPAA-compliant? (Part 2)

3011. Is your desktop or laptop computer HIPAA-compliant? (Part 3)

3012. How to re-titrate stimulant medications after an interruption (Part 1)

3013. How to re-titrate stimulant medications after an interruption (Part 2)

3014. Do we need to avoid hydroxyzine in older adults?

3015. Why we must plan for managing ADHD during pregnancy and breastfeeding

3016. Tips on planning for pregnancy and breastfeeding in women with ADHD (Part 1)

3017. Tips on planning for pregnancy and breastfeeding in women with ADHD (Part 2)

3018. Can a woman taking a prescription amphetamine breastfeed her infant? (Part 1)

3019. Can a woman taking a prescription amphetamine breastfeed her infant? (Part 2)

3020. Is it safer during breastfeeding to take methylphenidate or an amphetamine?

3021. What to do if fish oil supplements cause nausea, burping, or a fishy aftertaste (Part 1)

3022. What to do if fish oil supplements cause nausea, burping, or a fishy aftertaste (Part 2)

3023. What to do if fish oil supplements cause nausea, burping, or a fishy aftertaste (Part 3)

3024. Three quick questions that are not too difficult (Quiz No. 83)

3025. When patients tell us that a test result or their blood pressure was “normal”

3026. Could the GLP-1 receptor agonist be causing your patient’s insomnia?

3027. What does this study tell us about the renal safety of immediate- versus prolonged-release lithium? (Part 1)

3028. What does this study tell us about the renal safety of immediate- versus prolonged-release lithium? (Part 2)

3029. What to do about psychiatric medications during the month of Ramadan (Part 1)

3030. What to do about psychiatric medications during the month of Ramadan (Part 2)

3031. What to do about psychiatric medications during the month of Ramadan (Part 3)

3032. What patients taking a stimulant medication must know before visiting Japan (Part 1)

3033. What patients taking a stimulant medication must know before visiting Japan (Part 2)

3034. When is it particularly important to screen adults for autism spectrum disorder?

3035. What to tell patients after a single (“first”) episode of mania

3036. GABA “supplements”: Do they work and what are their side effects?

3037. GABA “supplements”: Potential side effects

3038. Which TYPE of GABA supplement should we recommend?

3039. Does melatonin need to be gradually tapered off when stopping it?

3040. Tips on motivating and helping patients to drink more fluids (Part 1)

3041. Tips on motivating and helping patients to drink more fluids (Part 2)

3042. Your thoughts on the high rates of adverse effects in this study? (Part 1)

3043. Your thoughts on the high rates of adverse effects in this study? (Part 2)

3044. Your thoughts on the high rates of adverse effects in this study? (Part 3)

3045. Differentiating antidepressant discontinuation (withdrawal) from worsening of the illness (Part 1)

3046. Differentiating antidepressant discontinuation (withdrawal) from worsening of the illness (Part 2)

3047. Differentiating antidepressant discontinuation (withdrawal) from worsening of the illness (Part 3)

3048. When tapering off a medication, it is important to use “hyperbolic tapering”

3049. An example to show how to do hyperbolic tapering when discontinuing a medication (Part 1)

3050. An example to show how to do hyperbolic tapering when discontinuing a medication (Part 2)

3051. How to use oral syringes for giving small amounts of liquid medicines

3052. Are you sure you know which foods are “red meat”? (Part 1)

3053. Are you sure you know which foods are “red meat”? (Part 2)

3054. Clinical Recommendations regarding reducing red meat consumption

3055. Three quick ‘True or False’ questions (Quiz no. 84)

3056. Urinalysis: A “simple and practical” guide for mental health clinicians (Part 1)

3057. Urinalysis: A “simple and practical” guide for mental health clinicians (Part 2)

3058. Urinalysis: A “simple and practical” guide for mental health clinicians (Part 3)

3059. Urinalysis: A “simple and practical” guide for mental health clinicians (Part 4)

3060. Relevance of increased or decreased urine pH in psychiatry

3061. Some psychiatric medications can cause ‘dry orgasms’

3062. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 1)

3063. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 2)

3064. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 3)

3065. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 4)

3066. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 5)

3067. Referring patients for esketamine (Spravato®) treatment: Who, Where, and How? (Part 6)

3068. Coffee consumption is associated with an increased risk of lung cancer

3069. Do antidepressant medications “increase the risk” of sudden cardiac death?

3070. How to convert from oral paliperidone or risperidone to paliperidone palmitate 1-month LAI (Part 1)

3071. How to convert from oral paliperidone or risperidone to paliperidone palmitate 1- month LAI (Part 2)

3072. How to convert from oral paliperidone or risperidone to paliperidone palmitate 1- month LAI (Part 3)

3073. A brief primer about vitamin K2

3074. Only the minimum about cannabigerol (CBG)

3075. Does your patient have essential tremor, the most common cause of tremors?

3076. How to correctly start, titrate, and optimize venlafaxine for panic disorder (Part 1)

3077. How to correctly start, titrate, and optimize venlafaxine for panic disorder (Part 2)

3078. How to correctly start, titrate, and optimize venlafaxine for panic disorder (Part 3)

3079. Power Hour: An Effective Way to Get Many Small Tasks Done

3080. Don’t miss nicotine as a cause of increase in pulse rate or blood pressure

3081. Monitor pulse rate and blood-pressure when bupropion and nicotine are combined

3082. How to become a specialized expert even without any subspecialty degree or training

3083. Are you a dash-shaped, I-shaped, T-shaped, or pi-shaped clinician?

3084. Which psychiatric conditions and treatments are NOT within your expertise?

3085. Three quick ‘True or False’ questions (Quiz no. 85)

3086. When should we diagnose pica as a DSM-5-TR™ Feeding and Eating Disorder?

3087. Which comorbid conditions and complications should be looked for in patients with pica?

3088. Do medications have any role in the management of pica? (Part 1)

3089. Do medications have any role in the management of pica? (Part 2)

3090. A patient with elevated WBC, absolute neutrophil, and platelet counts (Part 1)

3091. A patient with elevated WBC, absolute neutrophil, and platelet counts (Part 2)

3092. Do you tell patients that they should eat fruit regularly?

3093. Which fruits have fewer calories and less sugar?

3094. Any interactions between oral contraceptives and antidepressants? (Part 1)

3095. Any interactions between oral contraceptives and antidepressants? (Part 2)

3096. Tirzepatide (Zepbound®) for obstructive sleep apnea (Part 1)

3097. Tirzepatide (Zepbound®) for obstructive sleep apnea (Part 2)

3098. Tirzepatide (Zepbound®) for obstructive sleep apnea (Part 3)

3099. What is “accelerated rTMS” and does it work? (Part 1)

3100. What is “accelerated rTMS” and does it work? (Part 2)

3101. How to think about rare but serious side effects

3102. Can sertraline cause QT prolongation? (Part 1)

3103. Can sertraline cause QT prolongation? (Part 2)

3104. A systematic approach to risk factors for QT prolongation

3105. First FDA-cleared blood testing device to aid in diagnosing Alzheimer’s disease

3106. Expert opinion on the Lumipulse G pTau217/ß-Amyloid 1-42 blood test

3107. How well does the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio blood test work?

3108. Who is being tested changes the positive/ negative predictive values of a test (Part 1)

3109. Who is being tested changes the positive/ negative predictive values of a test (Part 2)

3110. Who is being tested changes the positive/ negative predictive values of a test (Part 3)

3111. How to identify specific medications for possible deprescribing in older adults at risk of falls (Part 1)

3112. How to identify specific medications for possible deprescribing in older adults at risk of falls (Part 2)

3113. How to identify specific medications for possible deprescribing in older adults at risk of falls (Part 3)

3114. Why and how to manage the “therapeutic illusion” (Part 1)

3115. Why and how to manage the “therapeutic illusion” (Part 2)

3116. Why and how to manage the “therapeutic illusion” (Part 3)

3117. Psychopharmacology Quiz (Quiz No. 86)

3118. Which antipsychotics are more often associated with urinary incontinence/enuresis (bedwetting)? (Part 1)

3119. Which antipsychotics are more often associated with urinary incontinence/enuresis (bedwetting)? (Part 2)

3120. Which antipsychotics are more or less often associated with urinary incontinence or enuresis? (Part 3)

3121. What diagnoses should we use for patients with Overweight or Obesity? (Part 1)

3122. What diagnoses should we use for patients with Overweight or Obesity? (Part 2)

3123. What diagnoses should we use for patients with Overweight or Obesity? (Part 3)

3124. Multiple specific dietary recommendations to give to patients with elevated LDL cholesterol (Part 1)

3125. Multiple specific dietary recommendations to give to patients with elevated LDL cholesterol (Part 2)

3126. Multiple specific dietary recommendations to give to patients with elevated LDL cholesterol (Part 3)

3127. Unnecessary (and potentially harmful medications) in over-the-counter “sleeping pills” (Part 1)

3128. Unnecessary (and potentially harmful medications) in over-the-counter “sleeping pills” (Part 2)

3129. Who is at higher risk for vitamin D deficiency?

3130. Do this before checking vitamin D levels or recommending supplementation

3131. “Objective” tests for diagnosing ADHD and evaluating treatment response? (Part 1)

3132. “Objective” tests for diagnosing ADHD and evaluating treatment response? (Part 2)

3133. “Objective” tests for diagnosing ADHD and evaluating treatment response? (Part 3)

3134. A brief primer on lipoprotein(a)

3135. Clinical implications of measuring serum lipoprotein(a)

3136. What is apolipoprotein B (apoB), and why is checking its level so important?

3137. Don’t prematurely offer a box of tissues to a patient who is crying

3138. Can valproate use by men increase the risk of infertility or neurodevelopmental disorders? (Part 1)

3139. Can valproate use by men increase the risk of infertility or neurodevelopmental disorders? (Part 2)

3140. Should we ask former or current smokers if they have been screened for lung cancer? (Part 1)

3141. Should we ask former or current smokers if they have been screened for lung cancer? (Part 2)

3142. Tips for better concentration and retention while reading

3143. A clinical trial comparing treatment options for major depression after a failed SSRI trial (Part 1)

3144. A clinical trial comparing treatment options for major depression after a failed SSRI trial (Part 2)

3145. A clinical trial comparing treatment options for major depression after a failed SSRI trial (Part 3)

3146. A clinical trial comparing treatment options for major depression after a failed SSRI trial (Part 4)

3147. Reviewing what we have learned is very important! (Quiz no. 87)

3148. Caveats about using medications in borderline personality disorder

3149. Borderline personality disorder: Should we disclose, discuss, and document the diagnosis? (Part 1)

31450. Borderline personality disorder: Should we disclose, discuss, and document the diagnosis? (Part 2)

3151. Can folinic acid (leucovorin) be used instead of L-methylfolate?

3152. Beware of possible cognitive biases during diagnostic evaluations (Part 1)

3153. Beware of possible cognitive biases during diagnostic evaluations (Part 2)

3154. Beware of possible cognitive biases during diagnostic evaluations (Part 3)

3155. Strategies for cognitive debiasing related to diagnosis (Part 1)

3156. Strategies for cognitive debiasing related to diagnosis (Part 2)

3157. Why we must learn about delta-8-tetrahydrocannabinol (delta-8-THC)

3158. Potential harms of delta-8-THC

3159. How to look up and think about drug interactions with nirmatrelvir+ritonavir (Paxlovid™) (Part 1)

3160. How to look up and think about drug interactions with nirmatrelvir+ritonavir (Paxlovid™) (Part 2)

3161. How to look up and think about drug interactions with nirmatrelvir+ritonavir (Paxlovid™) (Part 3)


What should be next? What clinically important question do you want Simple and Practical Medical Education to answer? Post it at the bottom of this page under “Leave a Reply.”


***Read why your colleagues are raving about our service**


***Click here to become a Member!***


Copyright © 2016 to 2025, Simple and Practical Medical Education, LLC. All rights reserved. The content on this website may not be reproduced in any form without express written permission.

Disclaimer: The material on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified healthcare professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.

Share this:

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email

Comments

  1. Ava Smith says

    July 13, 2022 at 8:22 pm

    This question is from Ava Smith, PA. After the recent daily emails on screening tools: the take away is use tools with very high sensitivity and high negative predictive value. What is a good site or source to find out the sensitivity and neg predictive value–I see same screening tools studied many times with multiple and different conclusions on above percentages.

    Reply
  2. Jessica Lee says

    May 13, 2019 at 10:50 am

    I love the daily emails. They are a joy to read thank you so much for this

    Reply
    • Rajnish Mago, MD says

      May 13, 2019 at 4:46 pm

      Thanks, Jessica, for your kind words!
      Raj

      Reply
  3. Elise Wise says

    September 13, 2018 at 10:56 am

    Hello Dr. Mago. I have found the subscription to your services so very helpful. I am wondering if you could address the following question on one of your daily emails. I am concerned about the use of valproic acid in patients diagnosed with Non-alcoholic Fatty Liver Disease. My specific example: a patient who has been in remission from very severe bipolar disorder on the combination of olanzapine and valproic acid for a number of years with normal LFTs. In the last month, AST and ALT elevated slightly. No symptoms of GI problems. His PCP sent him for US which showed NAFLD. What is the safety/liability to the patient (relative) to staying on valproic acid in light of this finding with the liver. The patient has other risk factors for NAFLD: obesity, DM, sedentary lifestyle etc.

    If you could comment on this in a broad sense it would be most helpful. I am sure that psych providers will be seeing more and more of this syndrome (?) being diagnosed.

    Thank you Dr. Mago. Your emails and website are invaluable to my practice!
    Elise Wise, Psychiatric Nurse Practitioner, Phoenix, AZ

    Reply
  4. Peter Pinto says

    August 13, 2018 at 7:20 pm

    Thank you for offering this fantastic service as I look forward to reading my daily email. I was hoping you could start a new mini-series on pearls for private practice. I know you covered your recommendation for Lumello as an electronic medical record already but please comment on other facets such as how do you screen your patients? What is your procedure for dismissing patients if they have had repeat no-shows? Etc ….

    Reply
  5. SABA MANSOOR says

    April 11, 2018 at 10:41 am

    Any comments on recent NY times article on difficulty patients have when trying to stop antidepressants? I have never had this difficulty so wanting to hear your opinion on this. Thanks

    Reply
  6. Randall Sexton says

    November 24, 2017 at 9:39 am

    Can you discuss SSRIs as REM sleep suppressants in hypersomnia and narcolepsy? Are their effects really significant?

    Reply
  7. Richard Dickes says

    November 12, 2017 at 4:12 pm

    It would be useful to have a discussion about when the chronic use of benzodiazepines is helpful. Some uses that come to mind include REM behavior disorder, persistent myoclonus especially if nocturnal, persistent intractible anxiety not blocked by SSRI treatment, difficult to manage AM anxiety that may be relieved by a long acting hs benzo, patients with persistent anxiety who do not tolerate SSRIs and patients who arrive with a long history of taking benzos

    Reply
    • Rajnish Mago, MD says

      November 23, 2017 at 10:40 am

      Thanks for your commment. You bring up a situation that we often face in clinical practice. You have listed some situations in which long-term use of benzodiazepines may be helpful. With regard to the last one — patients who arrrive with a long history of taking benzos — I think that we should always reassess whether they really need to continue to take the medication or, more commonly, can they reduce the dose very gradually.

      Reply
  8. ,richard Rosse says

    July 5, 2017 at 3:31 pm

    Is there a way to get CME credit?

    Reply
    • Rajnish Mago, MD says

      July 5, 2017 at 4:45 pm

      At this time, we are unable to offer CME credit. The process for being able to give CME credit is tedious and expensive. You may say that we provide CME, but without the “credit”!

      Reply
  9. Sharon Katz PMHNP says

    June 3, 2017 at 9:27 am

    Regarding Gabapentin: In my primary care and rheumatology patient population I have been using Gabapentin for the co-occuring pain, anxiety, and insomnia. Often they have cycles of moods which are kindled by the inflammatory process. Use has been effective in enabling patients to return to work and lifestyles, managing their moods as well as inflammatory pain.

    Reply
    • Rajnish Mago, MD says

      June 24, 2017 at 9:09 pm

      Thank you for your comment! It makes sense to use a medication that can address several of the problems a patient has.

      Reply
  10. DrCotner says

    April 1, 2017 at 1:42 pm

    Simple and Practical is so informative and fun to read every day! I too look forward to reading Dr. Mago’s email every morning. His daily mentorship provides necessary guidelines that build clinical confidence and keeps the art of psychopharmacology exciting! Both the physician and patient benefit from our staying truly informed, safe, and effective in practice. Thank you, Dr. Mago!

    Reply
    • Rajnish Mago, MD says

      April 2, 2017 at 12:52 pm

      Thank you so much, Dr. Cotner, for your kind comment! You made my day!

      Reply
  11. SABA MANSOOR says

    March 15, 2017 at 12:22 pm

    VERY HELPFUL! I CAN BRUSH UP ON MANY TOPICS THAT I HAVE FORGOTTEN.

    Reply
  12. aghoury says

    February 10, 2017 at 6:38 am

    This service is amazing Dr. Mago. I am looking forward for it everyday, and read it immediately. It is on my starred inbox emails. Thanks

    Reply

Leave a Reply:Cancel reply

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter

Copyright 2016 to 2025: Simple and Practical Medical Education, LLC. All rights reserved.